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 i 
Abstract 
Colorectal cancer (CRC) recurrence after curable resection is still high. This fact strongly 
suggests that the dissemination of circulating tumour cells (CTC) occurs early in the 
disease process. The first clinical results obtained suggest that CTC detection and 
enumeration can be used to estimate prognosis and may serve as an early marker to 
assess anti-tumour activity of a treatment.  
Telomerase is an RNA-dependant DNA polymerase that synthesises telomeric DNA 
sequences on the tip of chromosomes and is widely considered to be one of the most 
abundant and common tumour markers.  Telomerase consists of two components; one is 
the functional RNA (hTR), which acts as a template for telomeric DNA synthesis.  The 
second component is human telomerase reverse transcriptase (hTERT), the catalytic 
subunit of telomerase, which is concomitantly associated with telomerase activation 
during carcinogenesis. Its expression in tumours has been very commonly described 
using reverse transcriptase-polymerase chain reaction (RT-PCR). Furthermore hTERT 
peptides were found to be immunogenic both in vitro and in vivo and hence may be a 
suitable target for novel cancer immunotherapy.  
The aim of this study was to detect circulating tumour cells (CTC) in the peripheral blood 
of CRC patients using telomerase as a tumour marker. Telomerase presence and activity 
were measured using a combination of approaches including; ELISPOT assay to detect 
viable CTL that can recognise hTERT peptides in 30 patients with CRC. The results 
showed that 71% of pre-operative samples and 54% post-operative samples had CTL 
reaction towards hTERT peptides. The second approach was to study the enzyme activity 
using TeloTAGGG Telomerase TRAP assay. In this study 97 patients were recruited, and 
telomerase activity was positive in 11% of patients. Finally the RT-PCR approach used in 
this thesis failed to detect hTERT mRNA in serum samples as a result of long duration of 
samples storage. In conclusion: CTC detection in the peripheral blood is a rare event 
especially in none metastatic disease, There is an urgent need for standardised isolation 
and analysis techniques to be adopted thus allowing large-scale, appropriately controlled, 
multicenter trials to be undertaken on the most promising candidate marker. 
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CHAPTER 1 
 
INTRODUCTION 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 2 
1.1 Colorectal Cancer (CRC) 
1.1.1 Incidence 
 
CRC is a common cancer worldwide with higher incidence rates in Western Europe and 
North America compared with Asia, Africa and South America, whereas intermediate 
rates prevail in Eastern Europe. Figure 1.1 shows the worldwide incidence of CRC. 
 
Figure 2.1 Incidence of CRC (Cancer Research UK 2007 website) 
 
CRC is the most common malignancy in the UK after breast and lung. Around 100 new 
cases of CRC are diagnosed each day in the UK. In 2004 there were 36,109 new cases of 
large bowel cancer registered in the UK. It is the second most common cancer in women 
after breast cancer, accounting for 12% of all cancers and the third most common cancer 
in men after prostate and lung cancer accounting for 14% of all cancers. The incidence 
trends for men and women differ. Since the late 1970s male CRC incidence rates have 
increased by nearly 21% to almost 57 per 100,000 in 2000. Female rates have remained 
stable since the late 1970s at around 36 per 100,000 and mortality is declining at similar 
 3 
rates for both genders (Coleman et al. 2004). CRC is more common in Scotland and 
Northern Ireland than in England and Wales (Cancer Research UK 2004). 
1.1.2 Distribution  
 
There are more cases of colon cancer than rectal cancer; around two-thirds (22,349) in 
the colon and one-third (13,760) in the rectum (Cancer Statistics registrations 2004). Half 
of colon cancer grows in the rectosigmoid colon, 25% in the right colon and 25% in the 
transverse colon, splenic flexure, descending colon and in the hepatic flexure (Fig 1.2).   
 
Figure 1.2 CRC distribution (Cancer Research UK website) 
 
1.1.3 Mortality  
 
In 2005 there were 16,092 deaths from CRC in the UK, comprising 10,308 from colon 
and 5,784 from rectal cancer (Office for National Statistics 2006) and the mortality rates 
were higher in men than women. Around 8,500 men and 7,600 women died of the 
disease. There have been significant improvements in 5-year survival over the last 30 
years. For colon cancer the five year survival rate has increased from 22% to 47% for 
men and from 23% to 48% in women. Similarly, there have been improvements in the 
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five year survival rate of rectal cancer. For men 5-year survival increased from 25% to 
47%, and for women, 27% to 51%. (Aaltonen et al. 1994). 
1.1.4 Pathology 
 
The vast majority (98%) of colorectal tumours are adenocarcinoma, the remainder being 
squamous cell carcinoma and carcinoids. Tumours of mesenchymal origin are relatively 
rare (Kumar 1994).  The macroscopic appearances of CRC are classified into 4 types:  
1) Ulcer: the ulcerative cancer which presents as a typical malignant ulcer with 
raised rolled edges, often with a necrotic base. 
2) Polypoid cancer:  a proliferative type of lesion which protrudes into the bowel 
lumen.  
3) Annular or stenotic cancer: a circumferential lesion. 
4) Diffuse infiltrative cancer: an extensive lesion infiltrating the bowel wall often 
for at least 5-8 cm. 
1.1.5 Grading 
 
Colorectal carcinoma varies in the degree of differentiation not only from tumour to 
tumour but also from area to area within the same tumour as they tend to be 
heterogeneous in their morphology. In 1999 the World Health Organisation (WHO) has 
classified the tumour grade into: 
1) Grade I: poorly differentiated.  
2) Grade II: moderately differentiated. 
3) Grade III: well differentiated. 
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Approximately 60% of CRCs are moderately differentiated and the rest are equally 
divided into well and poorly differentiated. 
1.1.6 Staging 
 
The pathologic staging of CRC is based upon the extent of invasion of the tumour 
through the bowel wall, the involvement of regional lymph nodes and the presence of 
distant metastases.  The Dukes’ system was described in the early 1930s, originally solely 
for rectal tumours, and divides CRC into three groups as shown in Table 1.1  A more 
recent modification is the Astler-Coller system which was itself modified to include 
distant metastases (Table 1.2).  Finally, the TNM (Tumour-Node-Metastasis) 
classification is a universal staging system which was adapted for a number of tumour 
types and is probably the most commonly used worldwide (Table 1.3).  Table 1.4 enables 
equivalent stages in each system to be compared. 
 
Table 1.1: Dukes’ stage (Dukes 1932) 
Dukes’ Stage Description 
A The tumour is confined to the bowel wall with no involvement of lymph nodes 
B The tumour extends through the bowel wall but with no involvement of lymph nodes 
C There is involvement of lymph nodes 
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Table 1.2: Astler-Coller staging (Astler and Coller 1954) 
Astler-Coller Description 
A Tumour limited to the bowel mucosa 
B1 Tumour extends into the muscularis propria but not through it; 
nodes uninvolved 
B2 Tumour penetrates through the muscularis mucosa; nodes 
uninvolved 
C1 Tumour extends into the muscularis propria but not through it; 
with involved nodes  
C2 Tumour penetrates through the muscularis mucosa; with 
involved nodes  
D Distant metastases 
 
Table 1.3: TNM staging 
T Tumour size 
Tx Primary tumour cannot be assessed  
T0 No evidence of primary tumour 
Tis Carcinoma insitu; intraepithelial or invasion of lamina propria 
T1 Tumour invades submucosa 
T2 Tumour invades muscularis propriety 
T3 
Tumour invades through muscularis propria into subserosa or into non-peritonealized 
pericolic or perirectal tissue 
T4 Tumour perforates the visceral peritoneum and/or directly invading other organs or tissues  
N Lymph node involvement 
Nx  Regional nodes cannot be assessed 
N0  No regional lymph nodes metastasis 
N1 Metastasis in 1-3 regional lymph nodes 
N2 Metastasis in 4 regional lymph nodes 
N3 Involvement of any lymph node along named vascular trunk 
M Metastases 
Mx Distant metastasis cannot be assessed  
M0 No distant metastasis 
M1 Distant metastasis present 
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Table 1.4: Comparison of TNM group staging and Dukes’/modified Astler-Coller  
equivalents modified (Fleming et al. 1997) 
 
1.2 Aetiology  
 
The aetiology of CRC is multifactorial. And it is widely accepted that both environmental 
and genetic factors have a role in colorectal carcinogenesis. 
1.2.1 Environmental factors 
 
The international differences, migrants’ data and recent rapid changes in incidence rates 
in Italy and Japan show that CRC is sensitive to environmental changes, e.g. Diet, 
medication, activity, etc. Dietary intake has been thought to play a role in the 
carcinogenesis of the colon and the rectum. In 1971 Burkitt was the first to popularize the 
theory that a high fibre diet reduces the intestinal transit time and thus decreases the 
exposure to potential carcinogens. Also that bulky stool has a dilution effect on the 
secondary bile acids which have a proliferative effect on the intestinal mucosa (Burkitt 
1971). Other studies have subsequently suggested that CRC is at lower risk with higher 
intake of high fibre diet (Singh and Fraser 1998), and a high intake of vegetables and fruit 
decreased the risk of  developing adenomatous polyps in men (Giovannucci et al. 1992). 
TNM grouping                    TNM stage            Dukes’ stage                       modified Astler-Coller 
stage 
Tis, N0 M0                                0                            None                                            None 
T1,N0, M0                                 I                              A                                                   A 
T2, N0, M0                                                                A                                                  B1 
T3, N0, M0                               II                              B                                                  B2 
T4, N0, M0                                                                B                                                  B3 
Any T, N1, M0                         III                             C                                                  C1 
Any T, N2, M0                                                          C                                                  C2 
Any T, N3, M0                                                          C                                                  C3 
Any T, any N, M1                    IV                           None                                               D 
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However another study showed that there is no relation between high fibre diet and the 
risk of CRC in women (Fuchs et al. 1999).  
Another dietary factor is Calcium and Vitamin D3, where calcium and vitamin D3 
decrease the risk of CRC by binding to the secondary bile acids and fatty acids forming 
insoluble soaps therefore inhibiting their proliferative effect on intestinal mucosa 
(Newmark et al. 1984) (McMichael and Potter 1985). Folic acid depletion has been 
reported to  play a role in colorectal carcinogenesis, a study undertaken by Freudenheim 
(428 colon and 372 rectal cancer cases) (Freudenheim et al. 1991) showed that increased 
folate intake is associated with lower risk of CRC. A second cohort study undertaken by 
Giovannucci  assessed dietary intake for a 1-year period for a cohort of 47,931 U.S. 
males (Giovannucci et al. 1995) showed an increase risk of CRC with low folate and 
methionine intakes. Also the same study showed an increased risk of CRC with high 
alcohol intake. Other studies have shown that non-steroidal-anti-inflammatory-drugs 
(NSAIDS) such as aspirin have a protective role in CRC by suppressing Cyclooxygenase 
(COX) and regulating colon carcinoma-induced angiogenesis by two mechanisms: COX-
2 can modulate production of angiogenic factors by colon cancer cells, while COX-1 
regulates angiogenesis in endothelial cells. Inhibition of COX-2 produces effects on the 
proliferation and apoptosis (Barnes et al. 1998) and angiogenesis (Tsujii et al. 1998) of 
intestinal mucosa.   
Other studies showed that hormonal factors have a protective role against CRC. A meta-
analysis was performed on 18 epidemiologic studies of postmenopausal hormone therapy 
and CRC and found a 20% reduction [RR = 0.80, 95% confidence interval (CI), 0.74 to 
0.86] in risk of colon cancer and a 19% decrease (RR = 0.81, 95% CI, 0.72 to 0.92) in the 
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risk of rectal cancer for postmenopausal women who had ever taken hormone therapy 
compared with women who never used hormones (Grodstein et al. 1999), however the 
relation of CRC with use of menopausal hormones was evaluated in the United States 
among 40,464 postmenopausal women, 41 to 80 years of age, who were followed for an 
average of 7.7 years. Long term use of menopausal hormones was not associated with 
risk of total CRCs or cancers of the colon or rectum. Recent hormone users, however, had 
a small but insignificant reduction in risk of CRC (RR = 0.78, CI = 0.55-1.1) (Troisi et al. 
1997). Table 1.5 summarises the main findings regarding environmental factors with the 
molecular mechanisms by which they are thought to act (Potter 1999). 
Table 1.5: Epidemiology and biology of CRC (Potter, JD) (Potter 1999) 
Population risk factors                                  molecules 
 
Family history     FAP  APC 
      HNPCCmicrosatellite instability pathway 
      ? Others 
Meat and smoking    Nitrosamines and  
       Heterocyclic amines 
        ? APC mutation 
       ? K-ras mutation 
Alcohol      acetaldehyde DNA damage 
      Effects via reduced folate 
Vegetables     Antioxidants reduced DNA damage 
      Folate DNA integrity 
      Fibre SCFAs apoptosis 
Physical activity/low              Reduced growth stimulus 
 Body mass               Reduced transit time 
NSAIDS               COX-2 inhibit 
HRT                ? Prevention of ER hypermethylation 
 
SCFAs: short chain fatty acids 
FAP: Familial Adenomatous Polyposis 
APC: adenomatous Polyposis Coli 
HRT: Hormonal Replacement Therapy 
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1.2.2 Familial and genetic factors 
 
Family history is strongly associated with increased risk of CRC, 12-15% of colon cancer 
have a family history of colon cancer in a first degree relative (Potter et al. 1993), (Kerber 
et al. 1998). In 1976 Lovett was first to describe the association between the incidence of 
CRC and family history (Lovett 1976). 
Studies have shown that proximal colon cancer is more associated with family history 
than distal colon (Lynch et al. 1993). Slattery (Slattery et al. 2003) collected data from 
two population-based case control studies of colon and rectal cancer: Cases were first 
primary colon cancer diagnosed between 1991 and 1994 (n = 1308 cases and 1544 
controls) or rectal cancer diagnosed between 1997 and 2001 (n = 952 cases and 1205 
controls). The results showed that family history of CRC was associated with the greatest 
risk among those diagnosed at age 50 or younger (OR: 2.09 95% CI: 0.94-4.65 for rectal 
tumours; OR: 3.00 95% CI: 0.98-9.20 for distal colon tumours; and OR: 7.88 95% CI: 
2.62-23.7 for proximal colon tumours), while the effect of family history on rectal cancer 
was less significant (OR: 1.37 95% CI: 1.02-1.85). Table 1.6 represents the risk of having 
a family history of CRC. 
Table 1.6: Degree of risk of developing CRC according to number of family 
members with the disease (Lovett 1976) 
 
1 first degree relative                                                                1/17          
1 first degree relative, 1  second  degree relative                     1/12  
1 first degree relative < 45 years old                                        1/10  
2 parents                                                                                   1/8.5 
2 first degree relatives                                                              1/6  
3 first degree relatives                                                              1/2    
  
 
 
 11 
1.2.3 Familial Adenomatous Polyposis (FAP) 
 
FAP is an autosomal dominant genetic disorder first described by Lockhart-Mummery in 
1925. It affects approximately 2 in 8,000 people (Bisgaard et al. 1994) and is associated 
with hundreds to thousands of adenomatous polyps in the colon and the rectum, usually 
manifested in the teens/early twenties, which  inevitably develop into malignant polyps if 
not treated. FAP is caused by germline mutations in the adenomatous polyposis coli 
(APC) gene which was first identified in 1991 (Nishisho et al. 1991) and mapped to 
chromosome 5q (Groden et al. 1991). Somatic mutations of this gene are associated with 
tumourgenesis in 80% of colorectal tumours. APC encodes a large protein with multiple 
cellular functions and interactions, including roles in signal transduction, mediation of the 
intercellular adhesion, stabilization of the cytoskeleton and possibly of the regulation of 
the cell cycle and apoptosis (Fearnhead et al. 2001). However APC mutations are not 
solely responsible for all cases of FAP as intense screening for APC gene mutations were 
not found in 30% of classical FAP patients. In 2003 a biallelic germline mutation of the 
base –excision repair gene MYH was first reported (Lipton et al. 2003) (Sieber et al. 
2003) which was found in the APC negative FAP patients. The germline MYH mutations 
predispose people to a recessive phenotype, multiple adenomas, or polyposis coli. For 
patients with about 15 or more colorectal adenomas especially if no germ-line APC 
mutation has been identified and the family history is compatible with recessive 
inheritance genetic testing of MYH is indicated for diagnosis and calculation of the level 
of risk in relatives. 
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1.2.4 Hereditary Non-Polyposis Colon Cancer (HNPCC) 
 
HNPCC is an autosomal dominant syndrome (Lynch et al. 1985) , which accounts for 
approximately 2% of all CRC (Aaltonen et al. 1994) (Lynch et al. 1989). It is 
characterized by predominantly affecting the right side of the colon, with a tendency to 
arise in the younger age groups and possessing a strong hereditary trend. It also involves 
other cancer such as those of the endometrium, urinary tract, the biliary system and the 
small intestine (Lynch et al. 1989). The Amsterdam Criteria were set out to diagnose 
HNPCC (Vasen et al. 1991).  However, extracolonic tumours were not taken into account 
and in order to improve sensitivity and specificity, newer, more detailed criteria were 
defined, namely the Amsterdam Criteria II (Vasen et al. 1999), the Bethesda (Rodriguez-
Bigas et al. 1997) and the most recently Modified Bethesda Guidelines (Umar et al. 
2004). These criteria are the basis upon which genetic counselling screening is offered to 
affected individuals and their families to determine the level of risk and offer appropriate 
family-screening. The latest criteria are shown in Table 1.7. 
The clinical diagnosis can be confirmed by testing for germline mutations in a family of 
genes that are involved in DNA mismatch repair (MMR) (Liu et al. 1995) (Herman et al. 
1998). The MMR system identifies and repairs errors that result from the activity of DNA 
polymerase during replication. The MMR system recognizes the mismatch, excises it and 
facilitates the resynthesis of the correct sequence (Kolodner et al. 1995). 
Five mismatch repair genes  have been known to be involved in HNPCC susceptibility ( 
hMSH2, hMLH1, hPMS1, hPMS2 and hMSH6/GTBM) (Akiyama et al. 1997) (Miyaki et 
al. 1997) (Fishel et al. 1993). hMSH2 and hMLH1 germline mutations were found to be 
responsible for more than 90% of HNPCC families. (Lipton et al. 2004).  
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*Hereditary nonpolyposis CRC (HNPCC)-related tumours include 
Colorectal, endometrial, stomach, ovarian, pancreas, ureter and renal pelvis, 
biliary tract, and brain (usually glioblastoma as seen in Turcot syndrome) 
tumours, sebaceous gland adenomas and keratoacanthomas in Muir–Torre syndrome, 
and carcinoma of the small bowel. 
†MSI-H _ microsatellite instability–high in tumours refers to changes in two 
or more of the five National Cancer Institute-recommended panels of microsatellite 
markers. 
‡Presence of tumour infiltrating lymphocytes, Crohn’s-like lymphocytic reaction, 
mucinous/signet-ring differentiation or medullary growth pattern. 
§There was no consensus among the Workshop participants on whether to 
include the age criteria in guideline 3 above; participants voted to keep less than 
60 years of age in the guidelines. 
 
1.3 Genetics of CRC 
 
The evidence suggests that there are few pathways for a normal colonic cell to transform 
into a cancerous one.  The adenoma –carcinoma sequence, was first described by Morson 
(Morson 1974).  
APC is a tumour suppressor gene whose mutation usually occurs early in the adenoma-
carcinoma sequence, germline mutations of APC being responsible for FAP. APC 
Table 1.7: The Revised Bethesda Guidelines for testing colorectal tumours for 
microsatellite instability (MSI) (Umar et al. 2004) 
Tumours from individuals should be tested for MSI in the following situations: 
1) Colorectal cancer diagnosed in a patient who is less than 50 years of 
     age. 
2) Presence of synchronous, metachronous colorectal, or other HNPCC associated 
tumours,* regardless of age.  
3) Colorectal cancer with the MSI-H† histology‡ diagnosed in a patient 
who is less than 60 years of age.§ 
4)  Colorectal cancer diagnosed in one or more first-degree relatives with 
           an HNPCC-related tumour, with one of the cancers being diagnosed  
          under age 50 years. 
5) Colorectal cancer diagnosed in two or more first- or second-degree 
     relatives with HNPCC-related tumours, regardless of age. 
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mutations or allelic losses of 5q are seen in 40-80% of CRC and adenomas (Korinek et al. 
1997). APC binds to a protein called β-catenin, and stimulates its phosphorylation. In 
cells with an APC mutation, this phosphorylation does not take place and β-catenin is 
activated. The intracellular location of β-catenin changes upon APC mutation; it migrates 
to the nucleus, interacts with transcription factors, and induces the expression of genes 
that stimulate cell growth.  
Mutations in the APC or β-catenin genes results in failure of proper adhesion-migration 
of cells and transcription of proliferating signal (Polakis 1997) (Korinek et al. 1997) and 
are sufficient to initiate the growth of a small benign tumour but are not sufficient to 
make such tumours progress to more advanced forms. Several other pathways participate 
in this progression. One of these pathways involves transforming growth factor β 
(TGFβ), a small polypeptide hormone that negatively controls colon cell growth through 
regulation of transcription factors like SMAD4 (Kinzler and Vogelstein 1996).  
K-ras is an oncogene whose mutation is also thought to occur early in the adenoma-
carcinoma sequence. It encodes a protein involved in signal transduction within pathways 
critical for normal proliferation and differentiation. K-ras mutations occur in 35-42% of 
CRC and a similar proportion of large adenomas, but are less common in smaller 
adenomas, perhaps suggesting that K-ras mutation is not directly involved in initiating 
cancerous change but does facilitate subsequent growth. 
The other pathway in CRC development is via the dysplasia- carcinoma sequence. In 
ulcerative colitis, patients have a 20 fold higher risk of developing CRC than normal 
individuals. It was found that most patients with ulcerative colitis have a mutation in the 
p53 gene resulting in dysplasia and carcinoma (Brentnall et al. 1994). The p53 gene is 
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found on chromosome 17p and either p53 mutation or 17p allelic loss or immuno-
histochemical evidence of p53 overexpression has been found in 4-26% of adenomas, 
50% of invasive foci within adenomas and 50-75% of CRC. P53 is inactivated not only in 
CRC but also in most other cancer types. Activation of the normal p53 gene inhibits cell 
growth by blocking the cell cycle and by stimulating cellular suicide (apoptosis). 
Kinzler’s group has discovered several of the genes that mediate these effects. The 
p21
Waf1
 and 14-3-3σ genes control cell birth by regulating passage through various phases 
of the cell cycle. The PUMA gene is a powerful stimulator of apoptosis that is located in 
mitochondria and binds to homologous proteins, like BAX, that control cell death 
(Kinzler and Vogelstein 1996). Figure 1.3 demonstrates the key steps in the adenoma 
carcinoma sequence. 
 
Figure 1.3 adenoma-carcinoma sequence 
 
The final pathway involves mutations or hypermethylation of the MMR genes. (Kane et 
al. 1997) (Herman et al. 1998). This mutation results in microsatellite instability. 
Microsatellites are repetitive genetic loci which are relatively stable, when these loci 
become unstable as a result of insertion or deletion of repeated units, they become prone 
Cancer  Small 
adenoma 
Large 
adenoma 
Normal 
cell 
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to form small loop in DNA strand during DNA replication. These are normally repaired, 
but in the absence or mutated form of MMR genes, these loops become permanent and 
alleles will be formed in the next round of replication which lead to loss of growth and 
apoptosis control. Furthermore the mutation of MMR genes results in the inhibition of 
TGF receptor on the colonic epithelial cells (Markowitz et al. 1995) and BAX gene 
(Rampino et al.) which leads to loss of growth and apoptosis control. This hypothesis is 
supported by the fact that this tumour suppressor gene is absent in 90% of CRC with 
microsatellite instability and 10% of sporadic CRC (Grady et al. 1997). 
1.4 Telomeres and telomerase 
1.4.1 The end replication problem 
 
Replication of chromosomes poses a special problem for cells. Watson and Olovnikov 
independently hypothesised that DNA should be progressively lost from the ends of 
chromosomes each time the cell divides (Olovnikov 1996). 
 The reason is that the traditional DNA polymerase cannot fully replicate the 3’ end of the 
lagging strand of a linear molecule (Figure 1.4). 
DNA consists of two strands of nucleic acid subunits.  The "direction" of a strand of 
DNA is determined by how these nucleic acid subunits are attached and the two strands 
run antiparallel to one another.  This means that one strand runs 5’-3’ while the 
complimentary strand runs 3’-5’. During replication the DNA helix seperates into two 
strands. DNA polymerase synthesises the complementary leading and lagging strands of 
new DNA that combine with the parent strands to form two daughter copies of the DNA. 
DNA polymerase can only make DNA in a 5’-3’ direction and it needs RNA primers 
which attach to the DNA strand thus giving the DNA polymerase a place to start. Thus 
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the result is one strand that is synthesised as a continuous piece of DNA (leading strand) 
and another that is synthesized in small, discontinuous pieces (lagging strand). This 
leaves a gap at the 3’ end of the lagging strand which cannot be replicated and results in 
the telomere becoming shorter, by ~50-200 base pairs (bp), with each successive cell 
division. This would mean the loss of the genetic material each time the cell divides and 
hence loss of function and eventually cell death. But this does not happen; the reason is 
the presence of telomeres.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig.1.4 End replication problem (www.uic.edu/.../ReplicationFork.gif) 
 
1.4.2 Telomeres 
 
Telomeres are the terminal ends of each chromosome and consist of repetitive tandems of 
the sequence TTAGGG (Fig 1.5). Telomeres do not carry any genetic information; they 
function as a ―cap‖ that protects the DNA chromosome from loss, therefore preserving 
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the genetic integrity of the chromosomes, preventing its degradation and end to end 
fusion. 
 The end of the telomere terminates with a single stranded 3’ overhang of variable length. 
(Wright et al. 1997) (McElligott and Wellinger 1997) (Makarov et al. 1997). In addition 
to these repeated sequences, a number of proteins are attached to telomere DNA strands. 
These are telomeric repeat factors 1 (TRF1) and 2 (TRF2), which help to maintain the 
telomeric stability and regulate telomere length. They are known to specifically recognise 
the TTAGGG repeat sequence (Broccoli et al. 1997) (Bilaud et al. 1997). TRF1 regulates 
telomere length by inhibiting telomere elongation once telomeres reach a critical size by 
inhibiting the action of telomerase at the ends of individual telomeres (van Steensel and 
de Lange 1997). While TRF2 suppresses end to end fusion between chromosomes by 
maintaining the correct structure at telomere termini and hence serves to stabilize 
chromosome ends (van Steensel et al. 1998).  
As a result of the end replication problem mentioned earlier, telomeric sequence of the 
lagging strand becomes shorter with each time the DNA replicates. Consistent with this 
hypothesis, telomere shortening was observed with progressive cell divisions in vitro and 
with increasing age in vivo (Harley et al. 1990) (Hastie et al. 1990) (Lindsey et al. 1991) 
(de Lange et al. 1990). 
Telomere shortening occurs in different types of human tissues and organs including; 
dermal fibroblasts (Allsopp et al. 1995), mucosal keratinocytes (Kang et al. 2002), 
peripheral blood cells (Cawthon et al. 2003), gastrointestinal epithelial cells (Furugori et 
al. 2000), adrenocortical cells (Yang et al. 2001), renal cortex (Melk et al. 2000), liver 
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(Takubo et al. 2000) and spleen (Takubo et al. 2002). Most of these cells are mitotically 
active and hence indicate the effect of cell division on telomere length during ageing. 
Conversely it was also found that telomeres length is stable in tissues that do not have 
mitotic activity such as the heart and the brain tissues (Takubo et al. 2002). 
Telomeres shorten during each cell division by 5-200 bp. Telomere length in human is 5-
10 kbp and hence the proliferative capacity of primary human cells in tissue cultures is 
limited to 50-70 population doublings (Harley et al. 1990).  
Telomeres shorten to a point where further division lead to cell senescence, this phase is 
known as phase 1 or M1 (Hara et al. 1991) (Wright et al. 1989). It is a process in which 
the cell is viable, but loses the ability to replicate; this phase can be bypassed by the 
mutation of certain tumour suppressor genes such as p53, p16 and rb genes. (Shay et al. 
1991). Further shortening of the telomere length leads to the M2 crises phase. (Counter 
1996) (Shay and Wright 1989), where further shortening leads to apoptosis and cell 
death. Rarely some cells manage to overcome these crises by the activation of the 
telomerase enzyme, in this case the cell becomes immortal or transforms into a cancerous 
cell.  
 
Fig. 1.5 Human telomere 
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1.4.3 Telomeres and ageing 
 
While telomere shortening has been linked to the ageing process, it is not yet known 
whether shorter telomeres are just a sign of ageing or actually contribute to ageing. 
Richard Cawthon and colleagues found shorter telomeres are associated with shorter lives 
(Cawthon et al. 2003). Among 143 unrelated individuals older than 60, those with shorter 
telomeres were three times more likely to die from heart disease and eight times more 
likely to die from infectious diseases. Also Cawthon found that when people are divided 
into two groups based on telomere lengths, the group with longer telomeres live an 
average of five years more than those with shorter telomeres.  
1.4.4 Telomerase 
 
Telomerase is an RNA-dependant DNA polymerase that syntheses telomeric DNA 
sequences and almost universally provides the molecular basis for unlimited cellular 
proliferation. Telomerase is present in germline cells at a level which allows constant 
maintenance of the telomere length. It is absent in most normal somatic cells, but present 
in low levels in  basal layer of the skin (Harle-Bachor and Boukamp 1996), peripheral 
blood mononuclear cells (PMNC) (Counter et al. 1995), activated lymphocytes (Weng et 
al. 1996) and intestinal crypts (Hiyama et al. 1996). The high turnover of these tissues 
implies the need for maintenance of telomere length to allow continues proliferation.   
Telomerase was first discovered in Tetrahymena thermophila in 1985 (Greider and 
Blackburn 1985). Telomerase consists of two components; one is the functional human 
telomerase RNA (hTR), which acts as a template for telomeric DNA synthesis (Feng et 
al. 1995). hTR is expressed in all tissues regardless of telomerase activity with cancer 
cells having a  five-fold higher expression than normal cells (Kilian et al. 1997) (Lingner 
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et al. 1997). hTR is transcribed by RNA polymerase II and is processed at the 3’ end to 
produce a mature transcripts of 451 nucleotides (Feng et al. 1995).  
The second component of telomerase is the human telomerase reverse transcriptase 
molecule (hTERT), which is the catalytic subunit of telomerase (Yi et al. 1999), it is 
concomitantly associated with telomerase activation during cellular immortalization and 
carcinogenesis (Nakamura et al. 1997) (Meyerson et al. 1997) (Harrington et al. 1997). 
The mode of action of telomerase was first described by Greider and Blackburn (Greider 
and Blackburn 1989) who observed that telomerase recognizes the G-rich strand of an 
existing telomere repeat sequence and elongates it in the 5’ to 3’ direction by adding  
single stranded TTAGGG repeats to the end of the chromosome. The telomerase complex 
is a RNA-dependant enzyme that uses the 3’ nucleotide overhang as a template for 
telomerase mediated elongation of the telomere (Zakian 1996).  The 3’ end of the 
template region of the hTR anneals to the 3’overhang of the telomeric DNA then adds 
one DNA nucleotide at a time until full telomeric subunit is formed (Miller and Collins 
2002). When the subunit is complete, the enzyme slides to a new end and starts the same 
process again (Figure 1.6). 
 
Figure 1.6 Telomerase structure (www.uic.edu/.../bios100/f05pm/telomerase.jpg) 
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1.5 Telomerase regulation 
 
Telomerase regulation occurs at different levels including; hTERT transcription, hTERT 
splicing, epigenetic regulation and post-translational. Of all components of the telomerase 
complex hTERT plays the most important role in regulation. 
1.5.1 Transcriptional regulation of hTERT 
 
hTERT expression has been found to be up regulated in most  precancerous lesions and 
human cancers studied including gastric (Jong et al. 1999), ovarian (Kyo et al. 1999), 
urinary bladder (Suzuki et al. 1999),  cervical (Wisman et al. 2000) and skin (Wu et al. 
1999) tumours, with expression being associated with telomerase activity (Weinrich et al. 
1997). hTERT is encoded by hTERT gene located on the short arm of chromosome 5 
(15p15.33) (Meyerson et al. 1997) (Bryce et al. 2000), it consists of 16 exons and 15 
introns and extends over 40 kB (Cong et al. 1999) (Wick et al. 1999).  
Transient transfection experiments showed that hTERT promoter is inactive in normal 
cells but active in immortal cells (Bryce et al. 2000) (Takakura et al. 1999). This 
promoter was found to be GC rich and lacking the TATA box. The proximal part of this 
promoter is responsible for the majority of transcriptional activity. This promoter has 
multiple binding sites such as E boxes and SP1 binding sites; some factors are involved 
in the activation of hTERT promoter by binding to these binding sites. One of these 
factors is c-myc, which  is an oncogene that promotes growth, proliferation and apoptosis 
(Grandori et al. 2000). It has been shown that the c-myc gene induces hTERT expression 
and telomerase activity by binding to the E box on the promoter site (Wu et al. 1999). 
SP1 is another protein that has a role in the regulation of hTERT transcription where it 
binds to its binding site inducing hTERT expression (Kyo et al. 2000). Furthermore SP1 
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co-operates with c-myc to activate hTERT transcription. However these two factors are 
not enough to explain cancer specific telomerase activation since some tumours were 
found to have telomerase activity  by up-regulation of hTERT transcription independent 
of c-myc and SP1 effect (Oh et al. 2001) (Gewin and Galloway 2001). 
Some hormones have also been found to have a role in the regulation of hTERT 
transcription, including the steroid sex hormones. It was found that sequence analysis of 
hTERT promoters revealed oestrogen response elements. This binding of oestrogen to 
these sites was shown to induce the transcription of hTERT expression (Kyo et al. 1999a) 
(Kyo et al. 1999b) (Misiti et al. 2000). Also it was found that hTERT expression can be 
induced indirectly by inducing c-myc expression in oestrogen receptor positive cells 
(Kyo et al. 1999b). 
Progesterone has a complex role in hTERT transcription, it initially activates 
transcription by inducing hTERT promoters (Wang et al. 2000), and later exhibits a 
negative effect by inducing p21 expression, the over-expression of p21 leads to 
repression of hTERT expression in progesterone positive cells (Mitchell et al. 1999a) 
(Mitchell et al. 1999b) (Belair et al. 1997). 
1.5.2 hTERT transcription repressors 
 
Telomerase repressors may exist in normal cells, which contribute to the silencing of 
telomerase activity. It was found that transfer of certain human chromosomes into cancer 
cells results in the repression of hTERT expression and down regulation of telomerase 
activity; i.e. the transfer of chromosome 3 into renal cancer and breast cancer cell lines 
resulted in hTERT mRNA repression and shortening of telomere length (Oshimura and 
Barrett 1997). 
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Few telomerase repressors have been clearly identified to date, one of these repressors is 
however the myeloid specific zinc finger protein 2 (MZF-2). This protein has an 
inhibitory effect on hTERT transcription through binding to its sites on hTERT promoter. 
Another repressor is the Wilms’ tumour 1 suppressor gene product (WT1). 
Its over-expression inhibits telomerase. However, WT1 gene is expressed in limited cell 
types such as the kidney spleen and gonads, which makes its potential role in hTERT 
regulation limited to these tissues.  
P53 over-expression also has a role in hTERT regulation. It interacts with SP1 and 
prevents it from binding to hTERT promoter in vitro hence inhibits hTERT expression 
(Xu et al. 2000). It was found that over-expression of p53 in head and neck squamous cell 
carcinoma was associated with inhibition of telomerase activity (Kanaya et al. 2000) 
(Fuxe et al. 2000) (Henderson et al. 2000). 
1.5.3 hTERT splicing 
 
Variant splicing forms several transcripts which are detected in human body (Ulaner et al. 
1998) (Ulaner et al. 2000). The function of these transcripts is still unknown and only the 
full-length transcripts function as the catalytic subunit of telomerase. 
These transcripts include  transcript, which lacks a small region at the beginning of 
exons 6,  transcript which lacks exons 7 and 8, and -  which lacks both areas.1.5.4  
1.5.4 Epigenetic regulation of hTERT transcription. 
 
DNA methylation is important for the development of mammals. Methylation of proto- 
oncogenes and tumour suppressor genes is associated with human cancer (Jones and 
Takai 2001).  
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It has been shown that treatment with DNA methylation inhibitor 5-azacytidine induces 
hTERT transcription in two telomerase-negative cell lines (Devereux et al. 1999) 
(Dessain et al. 2000). Also the degree of methylation in the hTERT promoter and 
telomerase activity in B-cell lymphocytic leukaemia has been shown to be inversely 
correlated (Bechter et al. 2002). 
Transcription is influenced by chromatin structure as well as post-transcriptional 
modification of histones, and has been implicated in the physiological control of 
chromatin structure (Stein and Schultz 2000). Histone acetylation is catalyzed by histone 
acetyl transferase (HAT) and deacetylase (HDAC). Several transcriptional factors such as 
Mad can repress transcription by recruiting HDAC to specific sites in certain promoters 
(Laherty et al. 1997) (Heinzel et al. 1997), also HDAC mediates transcriptional 
repression via the SP1 binding sites (Doetzlhofer et al. 1999). 
1.5.5 Post-translational regulation of hTERT 
 
Normal ovarian tissues and uterine leiomyoma cells have no telomerase activity despite 
the fact that both express hTR and hTERT mRNA (Ulaner et al. 2000). Also hTERT 
mRNA is present in T and B lymphocytes. This suggests that the expression of hTERT is 
not always sufficient to produce telomerase activity and that posttranslational 
modification of hTERT may play an important role in regulating telomerase activity. 
Data indicate that hTERT phosphorylation has a role in determining telomerase activity. 
It was found that PMNC telomerase activity is enhanced by protein kinase C (PKC) and 
the use of phosphatase 2A inhibits telomerase activity by inhibiting hTERT 
phosphorylation (Li et al. 1997). 
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Also interesting data  from Liu et al (Liu et al. 2001) showed that induction of telomerase 
activity during the activation of resting CD4 T cells was independent of hTERT protein 
increase. Instead, hTERT is phosphorylated and translocated from the cytoplasm to the 
nucleus, indicating that phosphorylation has an important role in the regulation of 
telomerase activity. 
1.6 Telomerase and cancer 
 
One of the most important differences between normal cells and tumour cells is that the 
former exhibit cellular senescence whereas tumour cells continue to proliferate 
indefinitely. 
 As mentioned earlier as the cell divides it reaches a stage where further cell division 
leads to critical shortening of telomere length, reaching the crisis phase (M2), at this point 
the cell either enters senescence or commences expression of telomerase and becomes a 
telomerase positive, immortal tumour cell. Telomerase maintains the telomere length 
allowing indefinite cell division and malignant transformation (Fossel 1998). It assures 
cancers cells immortality, which allows the accumulation of mutations required for cells 
to become malignant (Holt et al. 1996). 
Although telomerase has an important role in tumourgenesis, it has been established that 
ectopic expression of telomerase in normal human fibroblasts is sufficient for their 
immortalization but is not associated with malignant transformation (Morales et al. 
1999). This means that many cell types need hTERT plus other factors to produce 
immortality. It was found that inactivation of p53/p21 or pRb/p16 pathways play a role 
together with telomerase in tumourgenesis for some cell types, such as mammary 
epithelial cells and keratinocytes. hTERT have also been shown to collaborate with viral 
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oncoproteins, such as SV40LT (which inactivates p53 and pRb) or human papillomavirus 
16 (HPV16) E6 and E7 proteins which inactivate pRb, to escape from senescence 
(Morales et al. 1999).  
Most human cancers have shortened telomeres and express high levels of telomerase 
(Kim et al. 1994) (Shay et al. 1997).  Owing to the strong association between telomerase 
and cancers, telomerase and its two components; hTR and hTERT have been the focus of 
intensive studies in many tumours as potential diagnostic markers or therapeutic markers. 
Researchers in the last decade have been trying to use different ways to measure 
telomerase tumour cells in both tissue and blood samples. Various studies have evaluated 
telomerase and its subunits as a tumour marker in CRC; Yan and colleagues (Yan et al. 
1999) studied the correlation of telomerase activity and the expression of hTERT subunit 
in 25 adenocarcinoma tissue samples, 30 adenomas and 15 samples of normal mucosa. 
Telomerase activity and hTERT expression were measured using telomerase repeat 
amplification protocol (TRAP) assay and RT-PCR analysis, and it was found that hTERT 
mRNA was expressed in all cancer samples and, 12/13 telomerase-positive adenoma 
samples, but was never detected in the telomerase negative colorectal tissues. The authors 
concluded that hTERT expression correlates with telomerase activity. Another study used 
the same techniques to detect telomerase activity and hTERT mRNA in 140 cancer 
tissues, 140 normal adjacent mucosa and 20 adenomas. They found that the median value 
of hTERT expression and telomerase activity were higher in cancer tissues than 
adenomas and normal samples, and that hTERT expression significantly correlated with 
telomerase activity in cancer and adenoma samples (p= 0.031, p= 0.021) respectively 
(Niiyama et al. 2001).  
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Furthermore Gertler and colleagues assessed the correlation betwee hTERT mRNA and 
the disease histology by studying CRC samples from 57 patients utilizing real time RT-
PCR. They found that the expression of hTERT in cancer samples and corresponding 
adjacent mucosa was higher in advanced disease  (Gertler et al. 2002). 
Telomerase activity has been detected in different types of human cancers. In his review 
Shay et al has summarised data on telomerase activity in various types of human cancers 
(Shay and Bacchetti 1997).  
1.7 Circulating Tumour Cells (CTC) 
 
Treatment of solid tumours is still insufficient in a great majority of cases in part due to 
the development of metastases. Lymphatic and haematogenous pathways are the most 
important pathways for tumour spread. Even in localized diseases the relapse rate is still 
high, this suggests that undetected occult tumour cells and micrometastases in localized 
disease play a crucial role in the process of metastases. 
Metastases are an important factor that regulates the prognosis and cancer outcome. In 
the process of metastases, tumour cells shed from the primary tumour, spread through the 
blood stream, bind to the vascular endothelium, spread into the extracellular space, 
escape the host defence mechanisms and finally form a secondary tumour. 
In 1869 Ashworth, reported in Ghossein (Ghossein and Bhattacharya 2000) was the first 
to describe CTC when he discovered cells in the blood stream similar to those in the 
tumour at post mortem.  CTC are a potential cause of disease relapse particularly 
following surgery, therefore the presence or absence of CTC has been considered by 
some to be an important prognostic factor pre and/or post-operatively, and an indicator 
for the decision concerning adjuvant treatment and follow up (Hardingham et al. 1995).  
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However, this idea has been questioned as the majority of CTC shed from solid tumours 
do not survive in the blood and only approximately 1% live long enough to form distant 
metastases (Fidler 1970).  Also, the reliability of using CTC has been debated from a 
methodological perspective because it has been reported that cells are only shed 
intermittently and often circulate in clumps, both factors can make accurate detection 
problematic (Ghossein et al. 1995). 
1.8 CTC enrichment 
 
As mentioned above one of the main limitations in the detection of CTC is that the 
number in the circulation can be very low.  In order to solve this problem a variety of 
enrichment methods have been employed.  Immunomagnetic separation has been one of 
the most widely-used methods.  This technique has 3 main variations; MACS (magnetic 
affinity cell sorting) systems, magnetic beads and ferro fluid based system (Ring et al. 
2004).  The first two methods use specific antibodies linked to magnetic beads that bind 
tumour-expressed molecules and allow isolation by magnetism.  There are different ways 
these reagents can be used, either for positive selection, where the antibodies interact 
directly with circulating epithelial cells and allow their separation, e.g. CEA 125 and Ber-
EP4, or negative selection, where the beads remove all the unwanted cells from the 
mixture, leaving the desired cells in solution unmodified, e.g. CD45 beads with a pan-
leucocyte marker can be used to remove white blood cells from any tumour cells of 
epithelial origin in blood.  Figure 1.7 diagrammatically illustrates both positive and 
negative methods of isolation. 
The third variation, the ferro fluid based system, is simply a modification of that 
described above and uses epithelial cell adhesion molecules, rather than antibodies, 
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coupled to colloids of 1nm ferro fluid, which can bind to cells and be magnetically 
separated (Racila et al. 1998). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.7 Positive (A) and negative (B) isolation of desired cell populations 
 
1.9 CTC in blood and CRC  
 
The relatively poor overall survival rate of CRC strongly supports that dissemination of 
CTC is thought to be early in the disease process and emphasise the need of finding new 
tumour markers valuable in the early detection and as a marker of prognosis and response 
to treatment.   
The introduction of early lymphovascular ligation before manipulation of the tumour in 
surgery (non touch isolation) was first introduced by Barnes (Barnes 1952) as a way to 
reduce the incidence of tumour cell dissemination and metastasis development. It was 
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found that non touch isolation reduces the dissemination of CTC. In the study done by 
Hayasha 18/27 CRCs samples had mutations for K-ras and p53. Blood samples were then 
collected of the portal vein before, during, and after manipulation of tumours. Eleven out 
of  eighteen were operated on in a conventional resection technique and 7 were in the no-
touch isolation technique. In 8 /11 (73%) conventional resection technique cases the same 
genetic alteration of the primary tumour in the portal blood during operation were 
identified, whereas only 1 patient (14%) in the no-touch isolation technique group had a 
positive result. (Hayashi et al. 1999). Other studies has reinforced Hayashi results (Weitz 
et al. 1998) (Sales et al. 1999) but only one study showed that surgical manipulation has 
no role in CTC dissemination at the time of surgery, where sixteen patients underwent 
resection for primary CRC and two patients with irresectable tumours were studied, 
reverse transcriptase-polymerase chain reaction (RT-PCR) was used to detect  carcino 
embryonic antigen (CEA) in tumour biopsy specimens and blood samples obtained from 
the antecubital vein before and after surgery and from the main drainage vein of the 
tumour when the tumour had been excised; CEA was positive in all tissue samples. In 
two patients CEA was detected in antecubital vein blood before surgery and in one of 
them also after surgery. Only in one patient (Dukes C) CEA was detected from the main 
drainage vein of the tumour. (Garcia-Olmo et al. 1999).  
The major obstacle of using blood samples to detect CTC was the presence of activated 
lymphocytes, which normally express high levels of telomerase, so in order to escape this 
problem different studies have used immunomagnetic separation techniques to separate 
CTC from activated lymphocytes. BerEP4 monoclonal antibody that recognizes an 
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epitope on the protein moiety of glycopeptides (34 and 39 kDa) expressed at the surface 
of epithelial cells in normal and malignant tissues (Latza et al. 1990). 
Few studies have been done on colorectal and breast cancers. Loveday and colleagues did 
a study using BerEP4 antibody in immunomagnetic separation to separate tumour cells 
from pre and post-operative blood samples of 35 CRC patients, and tried to detect 
telomerase activity in CTC (Loveday et al. 2004). 
Another study tried to detect telomerase activity in portal and peripheral blood samples of 
CRC patients, they found that telomerase activity was higher in portal than in peripheral 
blood samples, and that telomerase activity is more expressed in patients with liver 
metastasis, which suggests that the presence of telomerase activity in portal blood 
samples reflects the existence of liver metastasis of CRC (Nozawa et al. 2003). 
Another study used immunomagnetic separation and TRAP-ELISA to detect telomerase 
activity in circulating tumour cells and non small cell carcinoma of the lung, this study 
found that 73% patients with stage IIIB or IV non small cell carcinoma of the lung had 
telomerase activity and in 72% of stage C or D colon cancer detected telomerase activity 
(Gauthier et al. 2001). This study did not look at the prognostic value of telomerase in 
circulating tumour cells since it was only looking at telomerase activity in pre-operative 
samples. 
 Also telomerase activity has been detected in CTC of breast cancer patients, where one 
study showed that 84% of patients with metastatic breast cancer have positive telomerase 
activity in their blood samples (Soria et al. 1999). 
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1.10 Methods of CTC detection 
 
Over the past twenty years numerous groups have attempted to detect CTC, both with 
and without enrichment, in patients with solid malignancies, and to establish their clinical 
significance using a wide range of different techniques.  The two main analysis 
techniques that have been commonly used are: cytometry and nucleic acid based assays, 
both of which have advantages and disadvantages. 
1.10.1 Cytometric methodology  
 
In both flow and immunocytochemical techniques monoclonal antibodies against various 
epithelial specific antigens are used to detect, and often enumerate, the tumour cells.  The 
monoclonal antibodies label the tumour cells that can be subsequently visualized (directly 
or indirectly) fluorescently or colorimetrically (Cote et al. 1999).  Both technologies are 
robust and have been demonstrated to work in model in vitro systems.  A diverse 
repertoire of antigens has been investigated; by far the most common of these being the 
intracellular cytokeratins (CK).  It is generally accepted that the detection limit for 
cytometric methodology is 1 specific tumour cell amongst 1,000,000 irrelevant cells 
when one or more different monoclonal antibodies against CKs have been used (Racila et 
al. 1998)
-
(Pantel et al. 1993).  However, there are two main disadvantages of using 
cytometric techniques; first, the sensitivity to detect micrometastases by these techniques 
has been questioned due to the limited amount of screened cells and secondly the lack of 
methodological standardization.  Together these problems are thought to be the reason for 
many discrepancies in the immunocytochemical data from different studies (Braun and 
Pantel 1999) (Muller and Schlimok 2000), with false positive rates ranging from below 
1% to over 80% having been reported. 
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1.10.2 Nucleic acid based methodology 
 
This method relies heavily on the polymerase chain reaction (PCR) for the detection and 
molecular characterization of CTC.  The use of nucleic acid based methodology gives at 
least a ten-fold improvement in the sensitivity of detecting CTC allowing the 
identification of 1 cell in a background of 10,000,000 unwanted cells (Pelkey et al. 1996)
-
(Castells et al. 1998).  Both DNA and RNA molecular markers have been used for the 
detection of CTC and these will be discussed individually.   The major disadvantage of 
circulating DNA material is that it can be released by dying tumour cells and remains in 
the circulation because of its relatively high stability in comparison to RNA.  Therefore, 
the presence of DNA markers does not necessarily indicate the presence of viable CTC 
but is indicative of a tumour burden (Zehentner 2002). 
1.10.3 DNA markers 
 
Genomic mutations in K-ras or p53, two of the commonest genetic abnormalities in CRC, 
have been reported to be useful for the detection of tumour cells circulating in the 
lymphatics of colorectal and non-small cell carcinoma of the lung (Hayashi et al. 1995) 
(Hashimoto et al. 2000).  A recent study done by Hsieh and colleagues (Hsieh et al. 2005) 
tried to identify the prognostic values of K-ras, p53 and adenomatous polyposis coli 
(APC) gene mutations in tumours and sera of 118 CRC patients using polymerase chain 
reaction-single strand conformation polymorphism (PCR-SSCP) analysis, followed by 
direct DNA sequencing of the amplified genomic DNA.  Subsequently, serum molecular 
markers were correlated to the patients' clinicopathological features and risk of 
metastases and recurrence.  This study showed that both serum APC and p53 presence 
closely correlated with lymph node metastasis and TNM stage (both P < 0.05).  
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Moreover, the presence of one or more serum markers was associated with depth of 
tumour invasion (P = 0.03), lymph node metastasis (P < 0.001), and TNM stage (P < 
0.001).  In addition, postoperative metastasis and recurrence rates were higher in patients 
positive for one or more serum markers, compared with those patients who were negative 
for all three (P < 0.001).  APC and K-ras markers were more frequently observed in 
patients with metastasis (both P < 0.05), while p53 was commonly detected in the cases 
of peritoneal metastasis (P = 0.004).  These recent findings, from a relatively large patient 
cohort, suggest that serum molecular markers are potentially useful markers for CRC 
prognosis. 
Also, Hibi et al (Hibi et al. 1998) characterised the genetic alterations in serum DNA 
obtained from 44 CRC patients using an oligonucleotide-mediated mismatch ligation 
assay.  Among the 16 cases with K-ras gene mutations in these tumours, the same 
mutation was detected in three paired serum samples simultaneously.  In the 10 tumours 
with a p53 mutation an identical mutation was detected in DNA from serum samples of 
seven.  Comparison of the molecular analysis with clinical diagnosis of these patients 
revealed that five of these seven patients had early stage tumours (P = 0.01).  Taken in 
combination, either a K-ras or p53 mutation was detected in serum from 40% of the 
patients (n=10) whose primary tumours contained a mutation, and in 23% of all the 44 
patients with CRC.  It was concluded that the frequent detection of p53 mutation in the 
serum of patients with early stage tumours suggests a possible use as a marker for CRC 
monitoring; however the relatively small cohort size requires further confirmatory work. 
Hardingham and colleagues also studied K-ras mutation and found that the presence of 
mutations on codon 12 of K-ras in CTC was predictive of decreased free survival and 
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increased the risk of relapse (Hardingham et al. 1995).  The study investigated the 
presence of tumour cells in perioperative peripheral blood samples in a cohort of twenty-
seven patients. Immunomagnetic beads, labelled with Ber- EP4, were used to harvest 
epithelial cells from blood and K-ras mutations were identified by PCR.  Circulating K-
ras mutant cells were detected in 9 of 27 patients; seven of whom died as a result of 
recurrent or metastatic disease after a median of 14 months, whereas mutant cells were 
not detected in 18 patients, and 16 of 18 remained disease free after a median follow-up 
of 16 months.  This study indicates that detection of circulating tumour cells 
perioperatively by immunobead-PCR can provide a sensitive prognostic marker for 
recurrent and metastatic CRC.  Additional, well-controlled, studies of this type are 
urgently needed to verify these encouraging findings. 
1.10.4 RNA markers 
 
The fact that the presence of circulating DNA cannot be used to definitely confirm the 
presence of viable cancer cells because of its relatively high stability, researchers have 
turned to mRNA as it has a shorter half-life once released from tumour cells (Zehentner 
2002).  The most common hypothesis for the presence of circulating mRNA is from cell 
lysis of circulating tumour cells, micrometastases shed by the tumour, the induction of 
tumour necrosis, apoptosis and active release (Anker et al. 1999). 
Initially there was a concern that mRNA would be too labile however, it was successfully 
detected in various malignancies.  Kopreski et al was the first to detect tyrosinase mRNA 
in the plasma of  malignant melanoma patients using reverse transcriptase –PCR (RT-
PCR) (Kopreski et al. 1999). Subsequently mRNA of various genes has been widely used 
to detect CTC in different types of solid tumours.  Table 1.8 shows all the studies on 
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tumours of gastrointestinal tract to date and compares these with the studies on breast 
cancer; the single most studied tumour type. 
 
 
Table 1.8: mRNA markers of breast and gastrointestinal tumours 
  BREAST   
mRNA marker Cohort size Method Positive results Ref 
Maspin 30 Nested RT-PCR 38% in post CT samples 
(Sabbatini et al. 2000) 
PTHRP 30 RT-PCR 30% 
(Wulf et al. 1997) 
MUC-1 122 
RT-PCR & southern 
blot 11% primary cancer 
(de Cremoux et al. 2000) 
   24% in mets  
hTERT 18 RT-PCR 25% 
(Chen et al. 2000) 
B-HCG 119 
RT-PCR & southern 
blot 8% 
(Hoon et al. 1996) 
hMAM 114 Nested RT-PCR 25% 
(Zach et al. 1999) 
hMAM 78 Nested RT-PCR 24% 
(Silva, A. L. et al. 2002) 
hMAM 98 Real time-PCR 11% 
(Suchy et al. 2000) 
hMAM 60 Nested RT-PCR 9% with no mets 
(Bossolasco et al. 2002) 
   24% with mets  
hMAM 33 RT-PCR 54% 
(Lin et al. 2003) 
HER2/neu 17 Semi nested RT-PCR 59% 
(Wasserman et al. 1999) 
MAG 16 RT-PCR & ECL 25% 
(Miyashiro et al. 2001) 
CK19 60 Nested RT-PCR 13% in primary cancer 
(Slade et al. 1999) 
   54% in mets  
CK19 78 RT-PCR 25% 
(Schoenfeld et al. 1997) 
 
For abbreviations see page 42 
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BREAST 
(continue)     
mRNA 
marker Cohort size Method Positive results Ref 
CK19 53 Nested RT-PCR 43% before CT 
(Manhani et al. 2001) 
   14% after CT  
CK19 34 Nested RT-PCR 21% 
(Datta et al. 1994) 
CK19 109 Nested RT-PCR 30% with no node disease 
(Kahn et al. 2000) 
   36% with node disease  
   71% with mets  
CK19  Real time-PCR 30% with no mets 
(Aerts et al. 2001) 
   > 70% with mets  
CK19 148 Nested RT-PCR 30% with no mets 
(Stathopoulou et al. 2002) 
   52% with mets  
CK19 161 Nested RT-PCR 27% after CT 
(Xenidis et al. 2003) 
CK19 77 with no mets Nested RT-PCR 31% in early before CT 
(Stathopoulou et al. 2003) 
 47 with mets  7% in early before CT  
   40% with mets before CT  
   20% with mets after CT  
CK19  RT-PCR 70% 
(Lopez-Guerrero et al. 1999) 
CEA   63%  
Maspin   22%  
CK19 45 RT-PCR 49% 
(Silva et al. 2001) 
hMAM   60%  
B-HCG 65 Nested RT-PCR 2% for 4 markers 
(Taback et al. 2001) 
C-MET   3% for 3 markers  
Mag-A3   15% for 2 markers  
alpha 4 Gnt   49% for 1 marker  
Maspin 29 Nested RT-PCR 20% with mets 
(Luppi et al. 1996) 
hMAM 133 invasive Nested RT-PCR 8% 
(Grunewald et al. 2000) 
CK19 cancer  48%  
EGFR   10%  
CK19 20 Nested RT-PCR & 90% 
(Gradilone et al. 2003) 
EGFR  southern blot 5%  
CK20   0%  
CK19 72 RT-PCR 10% 
(Hu and Chow 2001) 
CK20   3% 
 
B-HCG   13%  
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  OESOPHAGEAL & OROPHARYNGEAL   
mRNA 
marker Cohort size Method Positive results Ref 
CEA & 
CK20 28 Real time-PCR CEA 25% 
(Ito et al. 2004) 
   CK20 105  
SCCA 70 RT-PCR 33% 
(Kaganoi et al. 2004) 
CEA 54 RT-PCR 57% 
(Nakashima et al. 2003) 
CK19 40 NPC Nested RT-PCR 25% early stage 
(Lin et al. 2000) 
   40% advanced stage  
   75% distant mets  
  GASTRIC   
mRNA 
marker Cohort size Method Positive results Ref 
CK19, 
CK20 52 RT-PCR 10% 
(Majima et al. 2000) 
CK20 47 RT-PCR 43% 
(Zhang et al. 2003) 
CK19 64 MAH  
(Wu et al. 2006) 
hTERT     
CEA     
MUC1     
c-MET 52 RT-PCR 62% 
(Uen et al. 2006) 
MUC1   71%  
alpha 4 
Gnt 37  62% 
(Shimizu et al. 2003) 
CEA 59 Real time -PCR 46% 
(Ikeguchi and Kaibara 
2005) 
CEA 57 RT-PCR 37% 
(Miyazono et al. 2001) 
CEA 46 RT-PCR can identify risk of recurrence 
(Seo et al. 2005) 
CK20 70 RT-PCR 40% 
(Illert et al. 2005) 
CEA 36 RT-PCR 22% 
(Nishida et al. 2000) 
CK 34 RT-PCR 21% 
(Yeh et al. 1998) 
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  LIVER   
mRNA 
marker Cohort size Method Positive results Ref 
AFP 38 Real time-PCR 24% 
(Morimoto et al. 2005) 
AFP & MAG-1 65 Nested RT-PCR 42% for MAG-1 
(Yang et al. 2005) 
   54% for AFP  
IGF-II 111 RT-PCR 34% 
(Dong et al. 2005) 
AFP 50 RT-PCR 40% 
(Cillo et al. 2004) 
AFP 93 RT-PCR 53% 
(Liu et al. 1998) 
AFP 30 RT-PCR 95% 
(Jiang et al. 1997) 
ALB 62 RT-PCR 63% 
(Muller et al. 1997) 
AFP 64 RT-PCR 36% 
(Komeda et al. 1995) 
AFP 33 RT-PCR 52% 
(Matsumura et al. 
1994) 
ALB 27 RT-PCR 43% 
(Hillaire et al. 1994) 
  BILIARY & PANCREAS   
mRNA 
marker Cohort size Method Positive results Ref 
alpha 4 Gnt 55 Quantitative RT-PCR 76% 
(Ishizone et al. 2006) 
CEA 67 RT-PCR 48% 
(Uchikura et al. 2002) 
CEA 40 Nested RT-PCR 42% in bile duct cancer 
(Miyazono et al. 1999) 
   62% in pancreatic cancer  
 
RT-PCR, Reverse transcriptase polymerase chain reaction; ECL, 
Electrochemiluminescence; PTHrP, Parathyroid hormone related protein; hMAM, 
Human mamoglobulin; HER2/neu, human epidermal growth factor receptor 2; hTERT, 
Human telomerase reverse transcriptase; B-HCG, Beta-subunit of human chorionic 
gonadotropin; MUC-1, Membrane associated mucin 1; MAG-A3, Melanoma associated 
antigen; Alpha 4 Gnt, alpha 1,4 N-acetylglucosaminyltransferase; SCCA, Squamous cell 
carcinoma antigen; NPC, Nasopharyngeal cancer; CK, Cytokeratins; CEA, Carcino 
embryonic antigen; MAH, Membrane array hybridization; C-MET, Hepatocyte growth 
factor receptor; Mets, Metastases; AFP, Alpha-fetoprotein; MAG-1, Malignant antigen; 
IGF-II; Insulin like growth factor; ALB, Albumin.  
 
RT-PCR has been used to detect disseminated tumour cells in the peripheral blood, bone 
marrow, and peritoneal lavage of CRC patients by detecting the mRNA of various 
tumour and epithelial markers, and prognostic value has been reported (Schott et al. 
1998).  As said previously this technique has the ability to detect at best 1 cancer cell in 
10,000,000 unwanted cells (Castells et al. 1998) (Mori et al. 1996) (Nakamori et al. 
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1997).  Despite its wide use in detecting cancer cells RT-PCR has the disadvantage of not 
being able to quantify marker expression, it simply gives negative/positive 
discrimination.  This has led researchers to use real time PCR, which allows the 
quantification of low level background transcription and the definition of cut off values 
for marker expression, hence improving sensitivity (Bustin et al. 1999)
 
(Straub et al. 
2001).  Although an extremely powerful and reliable technique any PCR-based technique 
still has the disadvantage of potentially being over-sensitive, in that it can detect minimal 
amounts of mRNA expression in a non tissue specific manner (illegitimate transcription) 
meaning the technique is usually highly sensitive but insufficiently specific (Solmi et al. 
2004).  
The most commonly used RT-PCR targets in CRC studies are human telomerase reverse 
transcriptase (hTERT), cytokeratins (CK), carcino-embryonic antigen (CEA), epidermal 
growth factor receptor (EGFR), as well as a number of rare markers such as Dipeptidase I 
(DPEP I) Apolipoprotein AI (Apo-A1).  The merits and limitations of each of these 
markers will be considered in turn. 
1.10.5 hTERT mRNA 
 
hTERT expression is associated with telomerase activation during cellular 
immortalisation and carcinogenesis as discussed in section 1.4.4. Its expression has been 
detected in serum samples from 70/78 patients (90%) with hepatocellular carcinoma 
(Miura, N. et al. 2003) and in  four serum samples out of 16 patients (25%) with breast 
cancer (Chen et al. 2000) using RT-PCR. 
hTERT expression was also detected intracellularly in the peripheral blood of 18/65 
(46%) patients with gastric cancer using red blood cell (RBC) lysis followed by RT-PCR 
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(Shin et al. 2002), and detected in 29/55 (53%) patients with hepatocellular carcinoma 
using immunomagnetic separation technique to isolate CTC followed by RT-PCR 
(Waguri et al. 2003). 
hTERT mRNA has been detected in the plasma samples of CRC patients (Lledo et al. 
2004).  Peripheral blood samples of 50 patients were collected pre operatively and real 
time PCR was used to detect the expression of hTERT, it was found that 82% of CRC 
patients had hTERT mRNA expression values higher than the maximum values of 
normal control and the sensitivity and the specificity of the assay were 98% and 64% 
respectively.  The authors concluded however that, ―hTERT expression did not correlate 
with the disease stage nor with the serum levels of CEA‖.  The fact that plasma samples 
alone were used in this study, without an attempt to first isolate tumour cells by means of 
immunomagnetic separation, could explain the high level of detection of hTERT 
expression, as transcription of telomerase from non-tumour sources such as activated 
lymphocytes would have been possible. 
1.10.6 CK 
 
CK are intermediate filament keratins found in epithelial tissue.  There are two main 
types: the acidic type I CKs and the basic or neutral type II CKs.  These molecules are 
expressed by all epithelial cells and are part of the cell architecture; the most commonly 
used CKs for detection of CTC are CK19 and CK20 which are expressed in the 
gastrointestinal epithelium, urothelium, merkel cells and tumours derived from these 
tissues (Weitz et al. 1999). 
Various studies have managed successfully to detect CK markers intracellularly and 
extracellularly.  Vlems evaluated the use of CK 20 intracellularly in CRC patients using 
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RT-PCR on mononuclear cells collected from the peripheral blood and bone marrow and 
found that it was expressed in 9/30 blood and in 9/19 bone marrow samples (Vlems et al. 
2002); but was also found to be expressed in 10/47 of healthy, non cancer individuals.  
This study has been corroborated by a number of other studies (Bustin et al. 1999) 
(Champelovier et al. 1999).  A recent study done by Guo and co-workers (Guo et al. 
2005) detected CK20 mRNA intracellularly in 72.5-82.5% in CTC of 40 CRC patients 
using a combination of positive and negative immunomagnetic isolation and real time 
PCR.  They demonstrated that CK20 mRNA presence in CTC correlates significantly 
with the tumour size and lymphatic and hepatic invasion, but not the grade of 
differentiation.  A study by Wong and colleagues, (Wong et al. 2001) evaluated the use of 
CK19 expression in a cohort of 33 CRC patients and 26 normal controls, by separating 
PBMC containing any CTC and extracting RNA from the cells in a one step method.  A 
standard curve was made using different concentrations of PBMC spiked with the SK-
BR-3 cell line followed by a semi-quantitative RT- PCR and Southern blot analysis.  This 
study found that CK19 was expressed in 64% of CRC patients and 19% of controls and 
that the upper limit of CK mRNA among controls was exceeded by 14 patients, 12 of 
which (86%) developed metastases or recurrence.  It was concluded that CK19 
expression correlates with disease stage and CEA serum levels.  Other studies have 
explained the expression of CK19 in healthy, non cancer, patients by the fact that blood 
samples might have been contaminated by epidermal cells during venepuncture leading 
to the illegitimate transcription of CK19 in the epidermal cells (Dingemans et al. 1997) 
(Castells et al. 1998) (Krismann et al. 1995), such technical difficulties are hard to 
overcome. 
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Some studies have used both CK19 and CK20 expression in an attempt to increase the 
specificity of the prognostic markers.  Hardingham and colleagues (Hardingham et al. 
2000) used both markers to detect CTC from blood samples of 94 CRC patients and 64 
patients with adenomas and inflammatory bowel disease, using immunomagnetic 
separation and RT-PCR.  They found that 20% of CRC patients had CK19 and CK20 
expressed in CTC, whereas 10% of patients with benign adenoma had CTC expressing 
CK19 and CK20 and only 2% of patients with benign inflammatory bowel disease were 
positive.  It was concluded that the presence of CK19/CK20 positive CTC was associated 
with a reduction in the disease free survival period.   
Another study investigated the prognostic value of CK in CRC using a MACS system, 
followed by immunocytochemistry, to detect CTC expressing CK in the bone marrow.  
Of the 51 patients with CRC, 65% showed positive expression of CK and the presence of 
these cells correlated significantly with tumour stage, tumour extension and the clinically 
used tumour marker CA 19-9 (Weihrauch et al. 2002).  Conversely, in a small study of 
patients with CRC (n=12) Gradilone and colleagues (Gradilone et al. 2003), using RT-
PCR and Southern blot analysis for CK19 and CK20 in peripheral blood, claimed that 
both markers had no prognostic value after a follow up of 40 months.  It is difficult to 
explain such discrepancies, although the small size of the study cohorts is likely to be 
very influential, which are exemplified by many other studies. See Table 1.9 for a 
summary of all the work which has investigated the prognostic value of CK in CRC 
patients. The main limitation of using CK as a tumour marker, despite some encouraging 
results, is the fact that normal controls commonly give positive results, and so this has 
encouraged researchers to look for better markers. 
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Table 1.9: CK as a marker in the peripheral blood of CRC patients 
Cohort 
Size Marker Sample Method Positive results Correlation Ref. 
30 CK20 PBMC RT-PCR 9/30 in blood No 
(Vlems et al. 
2002) 
    9/19 in BM   
33 CK19 PBMC 
Semiquantitive     RT-
PCR 64% Yes 
(Wong et al. 
2001) 
   & Southern blot    
58 CK20 PBMC RT-PCR 78% in BM Yes 
(Miura, M. et 
al. 2003) 
    74% in portal vein   
    69% in peripheral blood   
40 CK20 PBMC IMS & real time PCR 73%-83% Yes 
(Guo et al. 
2005) 
27 CRC       
21 
Controls CK19+ ck20 PBMC RT-PCR 30% CK19 
GCC a 
good 
marker 
(Bustin et al. 
1999) 
 & GCC   100% ck20 
CK not a 
good 
marker  
    80% GCC   
94 CRC     Yes 
(Hardingham 
et al. 2000) 
64 
Benign CK19+CK20 Whole blood IMS+RT-PCR 20% in CRC   
    10% in adenoma   
    12% in IBD   
26 CK8+CK19 Whole blood IMS+ nested RT-PCR 12/23 patients No 
(Silva, J. M. 
et al. 2002) 
 CK20      
100 CK20 Whole blood RBC lysis + RT-PCR 34/100 Yes 
(Guller et al. 
2002) 
    16 with no mets   
53 CK19 Plasma Nested RT-PCR 74% Yes 
(Hampton et 
al. 2002) 
129 
CRC CK20 Serum Real time PCR 88% CRC No 
(Wharton et 
al. 1999) 
58 
Controls    84% controls   
12 CRC CK19+CK20 Serum  75% CK19 No 
(Gradilone et 
al. 2003) 
35 
Controls   
RT-PCR + southern 
blot 8% ck20   
       
CK, Cytokeratins; PBMC, Peripheral mononuclear cells; BM, bone marrow: IMS, 
Immunomagnetic separation; RT-PCR, reverse transcriptase-polymerase chain reaction; 
IC, intracellular; EC, extracellular; RBC, red blood cells. 
1.10.7 CEA 
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CEA is a glycoprotein involved in cell adhesion.  It was first identified in 1965 in human 
colon cancer tissue extracts, and it was later found that serum from individuals with CRC 
and other carcinomas had raised levels of CEA compared with healthy individuals.  CEA 
and related genes make up the CEA family which belong to the immunoglobulin 
superfamily.  In humans there are 29 genes, 18 of which are normally expressed by 
columnar epithelial cells and goblet cells of the colon, mucous neck cells and pyloric 
mucous cells of the stomach, as well as various specialised squamous and secretory 
epithelium (Hammarstrom 1999). 
Because of the observed over-expression of CEA protein in CRC, the mRNA has been 
used as a marker to detect CTC (Berinstein 2002).  In summary, most available data on 
CRC indicates that the presence of CTC detected by CEA mRNA correlates with the 
presence of distant metastases (Jonas et al. 1996) and hence, as expected, associated with 
poor prognosis (Mori et al. 1998).  However CEA mRNA was also detected in patients 
with inflammatory disease and in normal controls reducing its specificity as a tumour 
marker per sé in CRC.  A recent study (Douard et al. 2005) developed a new multiplex 
RT-PCR assay for CTC detection based on the expression of carcinoembryonic antigen-
related cell adhesion molecule 5 (CEACAM5; formerly CEA) and CEACAM7 (formerly 
CGM2) in 84 CRC patients, 32 non-CRC patients and 41 healthy individuals.  Positive 
immunomagnetic separation was applied to blood samples before RT-PCR.  RT-PCR 
assay was negative for all the 41 healthy individuals and the 32 non-CRC patients.  The 
test was positive in 53/84 (63%) of the CRC patients for CEACAM5 and/or CEACAM7, 
and 32/84 (38%) were positive for both markers.  When the CRC patients were sub-
divided in terms of stage, it was seen that 80% of stage III-IV cases (36/45) were positive 
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for one of the two markers, in contrast only to 44% of cases (17/39) for the early stage (I-
II) patients.  Further larger studies using a similar methodology, perhaps including 
additional markers, are eagerly awaited.  A full list of all the studies to date that have 
investigated CEA mRNA, in CRC is shown in Table 1.10 
In a very recent study Lloyd and her co-workers utilized multiple markers including CEA 
and CK20 to detect CTC in peripheral blood and peritoneal lavage using immuno-bead 
RT-PCR.  They reported that the presence of CTC in the peritoneal lavage, post bowel 
manipulation, correlated significantly with disease prognosis (P = 0.002), and suggested 
that lavage sampling is a more appropriate medium in which to detect CTC than 
peripheral blood (Lloyd et al. 2006). 
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Table 1.10: Carcinoembryonic antigen as a molecular marker in CRC 
Cohort Size Sample Method Positive results 
Correlate with 
Disease’s 
stage Ref. 
36 PBMC Real time PCR More in Duke’s D Yes 
(Miura, M. 
et al. 
2003) 
53 Plasma Nested RT-PCR 32% Yes 
(Silva, J. 
M. et al. 
2002) 
39 PBMC Real time PCR 6/39 in pre-op samples  
(Guller et 
al. 2002) 
   
10/39 in post-op 
samples   
95 CRC whole blood RT-PCR 41% in CRC Yes 
(Castells 
et al. 
1998) 
9 IBD   55.6% in IBD   
32 whole blood Real time PCR 16% No 
(Hampton 
et al. 
2002) 
51 CRC PBMC Nested RT-PCR 67% in CRC Yes 
(Guadagni 
et al. 
2001) 
8 benign polyps   
Negative in benign 
polyps   
100 whole blood RBC lysis + RT-PCR 48%  
(Wharton 
et al. 
1999) 
129 CRC Plasma Real time PCR 86% in CRC  
(Schuster 
et al. 
2004) 
58 controls   83.7% in controls   
33 CRC PBMC Semiquantitive RT- 88% in CRC  
(Wong et 
al. 2001) 
26 controls  PCR & southern blot 92% controls   
19 PBMC RT-PCR 21.1% in pre-op samples No 
(Noh et al. 
2001) 
   52.6% on follow up   
84 CRC PBMC 
IMS + RT-PCR for 
CEACAM5 + CEACAM7 CEACAM5 53/84   
32 BENIGN   CEACAM7 32/84  
(Douard 
et al. 
2005) 
41controls      
            
 
CRC, Colorectal cancer; IBD, inflammatory bowel disease; PBMC, Peripheral 
mononuclear cells; RT-PCR, Reverse transcriptase-polymerase chain reaction; 
CEACAM, carcinoembryonic antigen related cell adhesion molecule. 
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1.10.8 Epidermal growth factor receptor (EGFR) 
 
EGFR are receptors for the epidermal growth factor which plays an important role in the 
regulation of cell growth and proliferation.  The binding of EGF to its receptor causes 
activation of the intrinsic protein kinase activity that in turn stimulates DNA synthesis 
and cell proliferation (Carpenter and Cohen 1990).  Mutation involving EGFR can lead to 
its constant activation and result in the uncontrolled cell proliferation; a hallmark of 
cancer (Lynch et al. 2004).  As a tumour marker EGFR has the advantage of being 
expressed in a wide range of epithelial tumours (Khazaie et al. 1993), being rarely 
expressed by haemopoietic cells (Hildebrandt et al. 1997) and a number of high 
specificity antibodies are available, as these are being tested as potential targeted 
therapies (Baselga and Mendelsohn 1994) (Naruse et al. 2002) . 
EGFR is over-expressed in 50-70% of primary colon, breast and lung cancer tissue 
samples (Salomon et al. 1995).  EGFR has been detected in CTC in 22% of metastatic 
breast cancer patients (n=37), but not in localised disease or normal controls (Leitzel et 
al. 1998), and was found to be expressed in CTC in 74% of blood samples of bladder 
cancer patients  (n= 27, n=16 respectively), but not in healthy controls (Gazzaniga et al. 
2001a) (Gazzaniga et al. 2001b) 
EGFR expression has been found to be positive in 12.5%, 30%, 18% (n=16 , n=10 , 
n=11) of advanced CRC, non small cell lung cancer and pancreatic cancer respectively 
(Clarke et al. 2003).  In this study blood samples were collected from patients with 
advanced stage cancers and samples were mixed with red blood cell lysis buffer and then 
tumour markers were detected using real time PCR.  The integrity of the RNA was 
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confirmed using human beta2 microglobulin primers.  In a similar study De Luca (De 
Luca et al. 2000) examined the expression of EGFR in 91 patients with colon, breast and 
lung cancer.  They isolated CTC mixing peripheral blood sample with 5% (w/v) dextran 
saline and then EGFR was detected using reverse transcriptase and Southern blotting.  
EGFR was expressed in 17/30 (57%) of stage IV lung cancer, 11/23 (48%) of stage IV 
breast cancer and in 16/38 (59%) of Duke’s D colon cancer, it was found that 10.5% of 
healthy controls had a positive expression of EGFR as a result of illegitimate 
transcription of EGFR in leucocytes.  Also in this study EGFR sensitivity and specificity 
were compared with CEA and CK 19 mRNA; it was found that 5/11 (45%) and 3/11 
(27%) of patients expressed CEA mRNA and CK mRNA respectively and that 20% and 
10% of normal controls expressed CEA mRNA and CK mRNA respectively. 
The above studies have suggested that EGFR has a role in tumourigenesis, however, like 
that of hTERT, it is detected in the blood sample of patients with advanced disease and it 
could result in some false positive results, as a result of the illegitimate transcription. 
1.10.9 Dipeptidase I (DPEP I) 
 
DPEP I is a zinc dependent metallopeptidase that hydrolyses a variety of dipeptides and 
is involved in glutathione metabolism (Kozak and Tate 1982). DPEP I was identified as a 
tumour suppressor gene as a result of its decreased expression in Wilm’s tumour 
(Austruy et al. 1993), however, its exact role is still unknown.  One idea is that the 
enzyme is involved in the degradation of the extracellular matrix component that would 
facilitate the migration of tumour cells (McIver et al. 2004). 
Using immunomagnetic isolation CTC were separated and real time PCR for DPEP I 
showed that the molecules was over expressed by ≥ 2 fold in colon tumours, compared 
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with normal adjacent mucosa in 82% of patients, also it was detected in peritoneal lavage 
and blood samples of 15/38 (39%) patients with resectable CRC, but was absent in blood 
samples of healthy controls (McIver et al. 2004).  This study demonstrated some 
encouraging results showing that DPEP I was detectable in cancer patients, but not in 
normal controls.  Because the study was a small scale pilot, it needs to be reassessed with 
a larger group of patients; as this remains the only study to utilize DPEP I as a tumour 
marker.  Its applicability to other tumours also needs to be assessed. 
1.10.10 Apolipoprotein AI (Apo-A1) 
 
Apolipoprotein AI is the major protein moiety of high density lipoprotein (HDL); it is 
mainly produced in the liver and the intestines (Brewer et al. 1978), but is also produced 
in vitro by some differentiated cell lines established from human colorectal tumours 
(Reisher et al. 1993). 
Normanno and colleagues (Normanno et al. 1998) attempted to detect disseminated 
tumour cells in peripheral blood in 20 CRC patients using Apo-A1 mRNA.  Blood 
samples were collected pre- and immediately post-operatively and CTC were isolated by 
mixing the blood sample with 5% (w/v) dextran.  RNA was extracted and then northern 
blot and RT-PCR were used to detect expression of APO- A1m RNA.  No normal 
controls or patients with resected cancer were found to have APO-A1 expressed in 
peripheral blood, but two out of 10 patients with metastatic disease were positive. Despite 
the small numbers this study suggests that their RT-PCR technique is highly sensitive and 
specific, since they could detect up to 10 tumour cells in 5 ml of peripheral blood (one 
tumour cell in a background of 2.5 x 10
6
). 
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1.11 Telomerase and cancer Immunology  
1.11.1 The role of Cytotoxic T lymphocytes (CTL) 
 
In the last few decades efforts have been made to understand the role of immune 
surveillance mechanisms against cancer cells in order to develop effective anti tumour 
immunotherapy.  
The immune response against cancer cells is a complex one and involves the interaction 
of different cells and their products. However CTL play the major role in cancer 
immunity (Greenberg 1991) (Robins 1986). CTL are CD8
+ 
and therefore are class I 
Major Histocompatibility Complex (MHC) restricted in terms of cytotoxicity.  MHCI 
molecules are glycoproteins expressed on the surface of all nucleated cells; in human 
there are 3 principal forms of MHCI: HLA-A, HLA-B and HLA-C, these molecules are 
involved in antigen presentation to CTL. Antigen peptides bind to the α-chain of the 
MHC molecule to form a stable MHC-peptide complex which exits the rough 
endoplasmic reticulum (RER) to the surface of the Antigen Presenting Cell (APC) via 
Golgi apparatus which is then recognized by CD8
+ 
cells. Once CTL are activated they 
perform their cytolytic activity by releasing perforin and proteases. Perforin forms pores 
in the tumour cell membrane through which proteases enter the tumour cell stimulate 
apoptosis, and fragment the tumour DNA (Atkinson and Bleackley 1995). 
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An alternative way by which CTL respond against tumour cells is the Fas-FasL 
interaction. FasL is part of the tumour necrosis factor receptor family (TNF) that binds to 
Fas on the membrane of tumour cells inducing cell death (Ishiwatari-Hayasaka et al. 
1997). Some CTL also have Fas on their cell membranes which means potential self 
destruction of CTL as a tumour escape mechanism (O'Connell et al. 1996), also this 
interaction has been ―accused" of facilitating local tumour invasion by inducing apoptosis 
of hepatocytes adjacent to tumour margins (Yoong et al. 1999).  
1.11.2 Telomerase and tumour associated antigens (TAA) 
 
TAA are proteins aberrantly and overly expressed by tumour cells. TAA can be classified 
into humoral and cellular (CD4
+ 
and CD8
+
) responses according to the type of immune 
response they elicit. Many clinical studies have tried to identify one or more TAA that 
could have a role in future cancer immunotherapy but unfortunately most of those TAA 
described to date are restricted in expression to a few tumour types, therefore the concept 
of ―epitope deduction‖ was used, in which some gene products with selective tumour 
expression were deducted and then scanned for peptides that match MHC binding motifs 
(Schultze and Vonderheide 2001) (Vonderheide 2002), the above description was used in 
order to identify a universal TAA which desirably should possess the following features:  
1) Expressed by most human tumours but absent or rare in normal tissue. 
2) Plays a universal role in tumourgenesis. 
3) Includes peptide sequences that bind to MHC molecules. 
4) Be recognized by the T cell repertoire in an MHC restricted manner. 
5) Has the potential to be a major factor in future cancer immunotherapy. 
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Telomerase and its catalytic subunit have been proposed as a universal tumour antigen 
since it has all of the above features. Vonderheide and colleagues described the first 
immunogenic peptides from hTERT. This peptide designated as -I540 (ILAKFLHWL) - 
was found within the middle of the deduced amino acid sequence of hTERT, roughly 70 
amino acids to the amino terminus of the first reverse transcriptase motif. This peptide 
binds to CTL in a MHC class I (HLA-A2) restricted fashion (Vonderheide et al. 1999), 
and demonstrated that CTL were induced in 70% of individuals specific to I540 epitope 
in vitro. These CTL lines killed a wide range of tumour cell line and primary tumours in a 
peptide-specific MHC-restricted fashion. 
Using the same method Meniv et al. managed to identify another hTERT epitope -P865-  
(RLVDFLLV). In their experiments PMNC from prostate cancer patients and normal 
individuals were used. Positive HLA-A2 samples were pulsed with P540 and P 865 
hTERT peptides and their result showed that 9/10 blood samples from donors developed 
CTL activity for P540 with 7 having activity for P865 after in vitro immunization. 
Furthermore CTL had lytic activity in 3 out of 4 patients with prostate cancer, moreover 
in vivo immunization of HLA-A2 transgenic mice generated a specific CTL response 
against both hTERT peptides (Minev et al. 2000). 
Using the method of epitope deduction, Vonderheide groups screened HLA-A3-restricted 
peptide epitopes and identified K973 (KLFGVLRLK) which was subsequently tested for 
immunogenicity on human in vitro T-cell system. This epitope generated specific CTL 
from HLA-A3+ cancer patients and healthy individuals. These CTL lysed tumours from 
multiple histologies in an MHC-restricted fashion, suggesting that the epitope is naturally 
processed and presented by tumours. (Vonderheide et al. 2001). 
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Another study identified new hTERT-derived peptides carrying motifs for HLA-A24 
(Arai et al. 2001). Two of the 5 peptides tested, VYAETKHFL and VYGFVRACL, were 
capable of generating HLA-A24-restricted CTL and demonstrated cytotoxicity against 
leukemia cells.  
Cryptic epitopes that have a low affinity for HLA were also identified. Their affinity was 
increased using the P1Y heteroclitic peptide approach where peptides were mutated by 
tyrosine substitution at position one of the peptides in order to increase their affinity to 
bind to MHC. Two hTERT (hTERT 572 and hTERT 988)-derived low affinity peptides 
exhibited strong affinity for HLA-A2 and stimulated specific CTL from healthy donor 
PBMC. These CTL were able to lyse myeloma, melanoma and ovarian carcinoma cell 
lines. Also in vivo studies showed that HLA-A2 transgenic mice vaccinated with those 
two peptides generated CTL that specifically lysed antigen (Ag)-expressing tumour cells, 
thus recognizing the cognate endogenous Ag. This study suggests that low affinity 
epitopes could be used for cancer immunotherapy (Scardino et al. 2002). Another study 
confirmed that the low affinity peptide (P572) was  processed and presented by HLA -A2 
in tumour cells, and is recognized by specific CTL (Hernandez et al. 2002). 
Based on the above studies a few clinical experiments were done on colorectal and breast 
cancer patients. Titu et al studied the T-cell response against two HLA-A2-specific 
epitopes of hTERT (P540 and P865) in 37 CRC patients and 12 normal controls using an 
interferon gamma (IFN-γ) ELISPOT assay (Titu et al. 2004). CTL recognized P540 
HLA-A2 in 5 (13%) and P865 HLA-A2 in 4 (11%) of CRC patients. Two (5%) patients 
possessed T-cells that recognized both these peptides. No relationship between cancer 
stage and the presence of specific CTL against hTERT was observed although the 
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number of the patients was small. None of the normal controls possessed T-cells capable 
of recognizing the hTERT or the epitopes. The results of this study demonstrate that CTL 
active against hTERT are present in 20% of CRC patients, the authors suggested that this 
could be due to an error in protesome processing (Ayyoub et al. 2002), lack of co-
stimulatory molecules (Greenfield et al. 1998) or anergy and resistance to activation in 
ELISPOT assay (Hermans et al. 1998). 
In a similar manner Amaranath and colleagues investigated the specific CD8
+
 CTL 
response in a cohort of 45 primary breast cancer patients and 44 normal controls against 3 
hTERT peptides (I540, R865 and K973). In this study CTL recognized HLA-A2 P540 
and P865 epitopes in 13/17 (76%) and 8/17 (47%) respectively, CTL recognized both 
HLA-A2 epitopes in 8/17 (47%), CTL recognized HLA-A3 K973 epitope in 5/7 (71%) 
patients. In contrast, 38% of normal healthy female controls responded against a single 
peptide only (Amarnath et al. 2004).  
1.12 Aim of thesis 
 
Finally the aim of this thesis was to detect CTC in the peripheral blood of CRC patients 
using telomerase as a tumour marker and correlate the findings with clinicopathological 
status of the patients. Telomerase presence and activity was measured using a 
combination of approaches including; ELISPOT assay to detect CTL that can recognize 
hTERT epitopes, the TeloTAGGGTM Telomerase TRAP assay to study the enzyme 
activity, and finally RT-PCR to measure hTERT mRNA in serum.  
These techniques have increasing sensitivity, with the RT-PCR approach being expected 
to be the most sensitive.  
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CHAPTER 2 
METHODS AND MATERIALS 
In this chapter the general methods and materials for the following experiments 
conducted in this thesis will be described.  
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2.1 Study approval  
 
This study received ethical approval from the Hull and East Riding Local Research 
Ethics Committee (Ref: LREC/12/00/232) and NHS approval from the Hull and East 
Yorkshire NHS Hospitals Trust Research and Development department (Ref: ELSY 
2654). 
2.1.1 Patient recruitment 
 
Venous blood (30ml for PBMC and 10ml for CTC preparation) was initially taken from 
105 CRC patients. In addition healthy volunteers of similar age were recruited in this 
study as normal controls. Written informed consent form was obtained from all patients 
and normal controls.  
The blood samples were obtained by phlebotomy under aseptic technique. Venous blood 
was aspirated into a 60ml Luer-lock syringe pre-coated with 5000 I.U. (1ml) of sodium 
heparin, maintained at room temperature and then processed in the laboratory within a 
maximum of 2 hours. 
2.1.2 Aseptic technique 
 
All aseptic techniques were performed in a class II microbiological safety cabinet 
(Walker Safety Cabinets, Glossup, UK) fitted with a UV sterilizing lamp. All glassware 
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and heat-stable solutions were autoclaved prior to use at 121
o 
C for 15 minutes, whilst 
heat-labile solutions were sterilized by passage through a 0.2 Micron syringe filter 
(Sartorius AG, Goettingen, Germany). All disposable equipment and solutions were of 
sterile tissue culture grade, and all chemicals used were of molecular grade. 
2.1.3 Selection criteria 
 
Patients were selected according to the following criteria:
 
 Histological evidence of colonic or rectal adenocarcinoma. 
 Age > 18 years. 
 Patient able to provide written, informed, consent.  
 
Patients were excluded according to the following criteria: 
 Patients with other than benign or malignant tumours. 
 Underlying immunodeficiency disorder or immunodeficiency state. 
 Active autoimmune disorder.  
 Patients unwilling or unable to give written informed consent. 
 Concurrent chemotherapy or radiotherapy 
2.1.4 Study protocol 
 
Blood samples were obtained from CRC patients at multiple time points.  The initial 
sample was obtained pre-operatively at the time of recruitment.  Two further samples 
were then obtained in the post-operative period at between four and eight weeks 
following surgery. If the patient did not go on to receive post-operative, adjuvant therapy 
then their participation in the study finished at this point.  Those patients who received 
 60 
adjuvant treatment were requested to provide samples approximately every four weeks 
during the course of their treatment. A flow chart in figure 2.1 summarises the study 
protocol. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.1 Study protocol 
CTC: circulating tumour cells 
 
2.2 Labelling Dynabeads with BerEP4 
 
Pre-operative 40ml blood 
sample 
30ml for PBMC flowcytometry 
HLA-A2/A3 positive  
10ml for CTC and telomerase 
activity 
HLA-A2/A3 
negative 
 Chemotherapy No chemotherapy 
1 month interval 
blood sample  
Only one month post 
operative sample 
No 
chemotherapy 
Blood sample monthly interval 
Chemotherapy 
ELISPOT 
analysis 
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From the stock suspension 500µl (2 x 10
8
 beads) was removed and placed in a 1.5ml  
microcentrifuge tube.  This was then placed in a Dynal Magnetic Particle Concentrator 
(MPC) for 1 minute before pipetting off the supernatant.  The tube was removed from the 
MPC and the beads resuspended in 500µl PBS-0.1% BSA and the washing step repeated 
to ensure the removal of the azide preservative.  Following this 100µl (32µg) mouse 
monoclonal anti-human epithelial antigen clone Ber-EP4 antibody (Dako, Ely, UK) was 
added and the tube rotated at 4˚C for 30 minutes. 
2.3 Preparation of CTC 
 
The 10 ml of venous blood was mixed with an equal amount of phosphate buffered saline 
(PBS), pH 7.4, and then layered onto Ficoll-Hypaque (Histopaque, Sigma, Poole, UK). 
Blood/PBS mixture (20ml) was gently layered onto Histopaque (20ml) in a 50ml 
polypropylene tube (Greiner, Stonehouse, UK). The tube was subsequently centrifuged at 
400g for 30 minutes at 4
o
C. PBMC were isolated from the interface between Histopaque 
and plasma, and collected into a polypropylene tube.  
2.3.1 Immunomagnetic separation (IMS) and CTC preservation  
 
The isolated PBMC were then washed with an equal amount of PBS and centrifuged at 
400g for 5 minutes. After centrifugation the PBMC were resuspended in 500µl PBS-1% 
w/v bovine serum albumin (BSA) and 12µl of 5x10
6 
pre-washed immunomagnetic 
Dynabeads. 
The mixture was then incubated with rotation at 4
o
C for 30 minutes in the dark room. 
After this incubation the beads and the epithelial cells were harvested by placing the tube 
against a magnet (Dynal). Cells were washed 3 times in PBS-1% BSA, the supernatant 
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was discarded, and cells were resuspended at a concentration of 1-2x10
7
 cells/ml in heat 
inactivated foetal calf serum (HiFCS) with 10% (v/v) dimethylsulphoxide (DMSO) as 
cryopreservative. The cells were finally transferred into 1ml cryotubes (Nunc) and 
incubated overnight at -80
o
C (cooling rate 1
o
C/minute). The following morning the 
cryotubes were transferred for long term storage in liquid nitrogen until further use. 
2.4 Telomerase PCR ELISA 
 
Telomerase activity was assessed using TeloTAGGG Telomerase PCR ELISA
PLUS
 kit 
(Roche, Sussex, UK), all reagents were supplied in the kit. The manufacturers’ protocol 
was followed throughout as detailed below. 
2.4.1 Preparation of cell lysates  
 
Cells were thawed on ice, transferred to 1.5 ml polypropylene tubes and then centrifuged 
at 2000g for 10 minutes to pellet the cell-bead complexes from section 2.3.1. Supernatant 
was removed, and then the pellet was washed with 1ml of PBS and the mixture was 
centrifuged again for 10 minutes to ensure that the cell bead complexes are all collected.  
And after removing the supernatant cells were resuspended in 100µl lysis buffer from the 
TeloTAGGG Telomerase PCR ELISA
PLUS
 kit and incubated for 30 minutes on ice. Cell 
debris were removed by centrifugation (13000g for 20 minutes, at 4
o
C), and then 80-90µl 
of supernatant was removed, taking care not to transfer any cellular debris, and then 
stored at -80
o
C until analysis. 
2.4.2 Protein assay of lysates 
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The protein concentration of lysates was determined using Coomassie Plus kit (Pierce, 
Rockford, IL, USA) (Table 2.1). The contents of one BSA standard and PBS as a diluent 
were used to prepare a set of protein standards. 
 
 
 
 
 
Table 2.1: Preparation of diluted BSA standards 
Vial 
Volume of 
diluent 
Volume and source of 
BSA 
Final BSA 
concentration 
A 0 300µl of stock 2,000µg/ml 
B 125µl 375µl of stock 1,500µg/ml 
C 325µl 325µl of stock 1,000µg/ml 
D 175µl 175µl of vial B dilution 750µg/ml 
E 325µl 325µl of vial C dilution 500µg/ml 
F 325µl 325µl of vial E dilution 250µg/ml 
G 325µl 325µl of vial F dilution 125µg/ml 
H 400µl 100µl of vial G dilution 25µg/ml 
I 400µl 0 0 
 
Standards and cell lysates (10µl) were added into the appropriate microplate wells, 300µl 
of Coomassie Plus reagent was added to each well and the mixture was put on a shaker 
for 30 seconds. The plate was then incubated for 10 minutes at room temperature after 
which the absorbance at 595nm was read using a plate reader (Anthos 2010, LabTech, 
UK). A standard curve was prepared by plotting the average blank-corrected 595nm 
measurement for each BSA standard. The standard curve was used to determine the 
protein concentration of each lysate sample. See figure 2.2 for an example. 
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                        Figure 2.2: Protein standard curve example 
2.4.3 PCR condition 
 
For each sample and control template a master mix consisting of 25µl of reaction mixture 
and 5µl of internal standard were prepared per each tube. Master mix (30µl) was 
transferred into a microtitre plate per PCR reaction. Cell lysates (3µl) and 1µl of control 
template control (high and low) were added to each well. Nuclease-free water was added 
to each well to make a total volume of 50µl. Two sets of aliquots of the above were 
prepared; one was treated with heat (85
o
C for 10 minutes) in order to inactivate the 
samples for use as a negative control, and one was the test. Then the relevant tubes were 
subjected to thermal cycling (Techne Progene, UK) according to the following protocol: 
1) Primer elongation for 30 minutes at 25oC 
2) Telomerase inactivation for 5 minutes at 94oC 
3) Amplification (30 seconds at 94oC, 30 seconds at 50oC, 90 seconds at 72oC) x 30 
cycles and 10 minutes at 72
o
C 
2.4.4 Hybridization and ELISA 
 
Concentration µg/ml 
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Following PCR, two aliquots of amplification products (2.5µl) were denatured at room 
temperature for 10 minutes with 10µ denaturation reagent. The denatured hybridization 
products were then hybridized separately to one of two digoxigenin labelled detection 
probes, either specific for telomeric repeats (hybridization buffet T) or the internal 
standard (IS buffer), mixed briefly and then added to streptavidin coated microtitre plate. 
The plate was covered and incubated at 37
o
C on a shaker (300rpm) for 2 hours. 
Hybridization solutions were removed and the wells washed three times with washing 
buffer. The anti-DIG-HRP antibody (polyclonal sheep antibody against digoxigenin 
conjugated to horseradish peroxidase) conjugate working solution (100µ) was added and 
incubated with shaking at room temperature for 30 minutes. The solution was removed 
and the wells were washed five times with a solution buffer. Tetramethylbenzidine 
(TMB) substrate (100µl) was added; the plate was covered with foil and incubated on 
shaker at room temperature for 10-20 minutes (until colours developed). A 100µl of stop 
reagent that contains < 5% of sulphuric acid was added and the absorbance of samples 
measured (450nm-690nm) on an Anthos plate reader (Lab Tech, UK). The mean of the 
absorbance readings of the negative samples were subtracted from the absorbance 
readings of the test samples. Samples were regarded as positive if the difference in 
absorbance was higher than twice the background activity, as recommended by the 
manufacturer’s protocol.   
2.5.1 Preparation of PBMC  
 
PBMC were prepared and stored using the methods and materials mentioned in section 
2.3 and 2.3.1using 30 ml of venous blood.  
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2.5.2 Cell counting and viability testing 
 
Trypan blue (0.1%w/v, 10µl) was added to 10µl of PBMC suspension and the 
concentration of cells in solution determined in duplicate using a haemocytometer 
(Improved Neubauer, Weber, UK). Viable cells exclude the dye, whereas dead cells take 
it up through their disrupted membranes. A systematic method of counting was used in 
order to ensure accuracy and precision and to avoid re-counting the same cell. The 25 
large squares in the counting chamber were counted starting from left to right and then 
across and back, in a snake-like fashion. Each of the large squares, made up of 25 smaller 
squares, were counted in the same way as the large squares. A manual clicker counter 
was used to enumerate the cells. A minimum count of 100 viable cells was needed in 
order to ensure that the cells could be fixed to a concentration of 2x10
6
cells/ml. The 
concentration of cells was calculated by: number of counted cells x 10
4
 x dilution factor. 
When calculating cell numbers for subsequent assay only viable cell numbers were used 
for HLA-A2 and HLA-A3 typing. 
2.5.3 HLA-A2 and HLA-A3 typing of PBMC 
 
The HLA typing of the patients was determined by flowcytometry (FACS). PBMC were 
incubated with mouse anti-human HLA-A2 mAb, mouse anti human HLA-A3 mAb, and 
two irrelevant mouse mAb; Ig1-RPE/IgG1-FIT (as  negative controls), and CD3-
RPE/CD4-FITC (as positive control), in order to confirm the interpretation of the 
fluorescence histograms. The cells were incubated with the primary antibodies at 4
o
C, 
after which the excess antibody was washed away with 500µl of PBS-BSA-N3 solution 
(PBS with 0.25% w/v BSA, and 10mM sodium azide) and then the cells centrifuged 
(400g for 5 minutes at 4
o
C). The supernatant was discarded and 50µl/tube of secondary 
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antibodies (F(ab’)2 rabbit anti-mouse IgG:FITC, 1mg/ml stock – 1/100 dilution - 50µl 
(Serotec) was added. Two other controls were established, represented by tubes to which 
only the secondary antibody or cells only were added, respectively. The cells were then 
incubated for another 30 minutes at 4
o
C. Unbound antibody was washed from the cells as 
before with PBS-BSA-N3 and the cell pellets were finally re-suspended in 400µl of this 
buffer. 
To measure the proportion of labelled cells within a population, a flow cytometer 
(FACSCalibur, BD Biosciences) was used, and data analyzed using CELL Quest® 
software (BD Biosciences). 
Only patients who reacted positively with both anti HLA-A2 and/or HLA-A3 were 
considered to be HLA-A2
+
/A3
+
 and their PBMC was used for subsequent analysis of anti 
hTERT CD8
+
 T cells. Figure 2.3 illustrates HLA typing by flow-cytometry.  
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1)  HLA-A2/A3 negative 
2) HLA-A2 positive 
----- Negative control 1 
----- Negative control 2 
----- Positive control 
----- HLA/A +ve 
 
          
2 +ve 
----- Negative control 1 
----- Negative control 2 
----- Positive control 
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3) HLA-A3 positive 
4) HLA-A2/A3 positive 
Figure 2.3 examples of HLA typing on flow cytometry. 
----- Negative control 1 
----- Negative control 2 
----- Positive control 
----- HLA/A3 +ve 
 
          
----- Negative control 1 
----- Negative control 2 
----- Positive control 
----- HLA/A2 +ve 
----- HLA/A3 +ve 
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2.5.4. ELISpot Assay 
 
The ELISpot assay assesses CTL responses against specific peptides expressed by host 
MHC; it was performed using an IFN-γ ELISpot kit according to the manufacturer’s 
instructions (R&D systems, UK). If CTL react against the tumour-derived peptide the 
CD8 positive cells will usually release IFN-γ that can be detected with immobilised 
antibodies. The multiscreen-HA sterile 96 well filtration plate (ELISpot plate) (Millipore, 
CA, USA) used allows for a maximum of seven samples to be run on a single plate. All 
the techniques were carried out in sterile conditions, in a class II microbiological safety 
cabinet.  
2.5.4.1 Day 1 
 
For each assay, up to seven PBMC samples were selected and removed from the liquid 
nitrogen. Attention was taken to ensure that all the samples had the same HLA status so 
that they could all be put onto the same plate with the same peptides. The PBMC samples 
were thawed in a water bath at 37°C for a few minutes. Each sample was carefully mixed 
and transferred into RPMI 1640 culture medium (10ml) and centrifuged at 400g for 5 
minutes to remove freeze media. The supernatant was discarded and the pellet re-
suspended in 1ml CTL medium. The samples were incubated at 37°C until ready to be 
used. The number of viable cells present in the sample was determined by counting the 
number of viable PBMC using the method in section 2.5.2. Samples with a cell count of 
100 or more were used and samples with a significantly low number of cells were 
discarded. The samples that had between 70-99 cells were kept and if there was another 
sample stored in the liquid nitrogen, it was prepared in the same way, counted, and 
combined to increase the number of cells to make up at least 100. In the case when two 
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samples were mixed together, these were centrifuged again (400g for 3 minutes) and 
resuspended in 1ml CTL medium. If the samples could not be used, more samples were 
defrosted in the same way, prepared and counted, until there were seven different 
patients’ samples that could be used. The samples were adjusted to a concentration of 
2x10
6 
cells/ml using CTL medium. Each sample was put into a well of a 6 well plate and 
put in a 37°C incubator overnight. Any spare wells with no cells were filled with RPMI, 
in order to create a humidified environment for the growth of the cells. Capture antibody 
(100µl, IFN-γ without biotin) was pipetted into each of the wells of the ELISpot plate and 
incubated in the fridge at 4°C overnight.  
2.5.4.2 Day 2 
 
The plate was washed six times by multichannel pipetting 200µl sterile PBS into the 
wells and discarding in virkon (2% w/v). After tapping dry, 150µl of blocking medium (a 
15ml quantity of PBS-10% w/v BSA was made up and filter sterilised by passage through 
a 0.2µm filter, Sartorius AG, Goettingen, Germany) was added to each well and the plate 
incubated for two hours at 37°C. After discarding the blocking medium and tapping dry, 
100µl of each cell sample from the 6 well plates was added to the ELISpot microtitre 
plate. Appropriate hTERT peptides (10µl of 100ng/ml, ProImmune, Oxford, UK) were 
then added to the wells according the pipetting scheme layout (Figure 2.4)  
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 1 2 3 4 5 6 7 8 9 10 11 12 
A hTERT-1  
→ 
hTERT-2  
→ 
Inf-
A2 
 
→ 
hTERT-
A3 
 
→ 
Inf-
A3 
 
→ 
PMA 
 
Cells 
only 
B hTERT-1  
→ 
hTERT-2  
→ 
Inf-
A2 
 
→ 
hTERT-
A3 
 
→ 
Inf-
A3 
 
→ 
PMA Cells 
only 
C hTERT-1  
→ 
hTERT-2  
→ 
Inf-
A2 
 
→ 
hTERT-
A3 
 
→ 
Inf-
A3 
 
→ 
PMA Cells 
only 
D hTERT-1  
→ 
hTERT-2  
→ 
Inf-
A2 
 
→ 
hTERT-
A3 
 
→ 
Inf-
A3 
 
→ 
PMA Cells 
only 
E hTERT-1  
→ 
hTERT-2  
→ 
Inf-
A2 
 
→ 
hTERT-
A3 
 
→ 
Inf-
A3 
 
→ 
PMA Cells 
only 
F hTERT-1  
→ 
hTERT-2  
→ 
Inf-
A2 
 
→ 
hTERT-
A3 
 
→ 
Inf-
A3 
 
→ 
PMA Cells 
only 
G hTERT-1  
→ 
hTERT-2  
→ 
Inf-
A2 
 
→ 
hTERT-
A3 
 
→ 
Inf-
A3 
 
→ 
PMA Cells 
only 
 IFN-γ IFN-γ IFN-γ       CTL CTL CTL 
Figure 2.4: Schematic ELISpot plate layout 
 
Note: CTL denotes CTL medium (a negative control set of wells) 
Influenza peptides (10µl) and 5µl of Phorbol 12-myristate 13-acetate PMA were added to 
their respective wells. In addition, 100µl of recombinant IFN-γ (1ng/µl, Serotec, Oxford, 
UK) was added to three wells as an additional positive control. The presence of IFN-γ 
should always give a positive result. No peptides were added to some of the cells, leaving 
the cells in the well alone with the capture antibody, which will show a background level 
of IFN-γ response. Any response measured in these wells was deducted from the values 
obtained from the test peptides. CTL medium (100µl) was used as a negative control, and 
was added to three wells. The plate was incubated at 37°C overnight.  
2.5.4.3 Day 3 
 
The wells were washed six times using 200µl PBS-0.05% v/v Tween-20 (Sigma) and 
tapped dry. Mouse anti-human IgG1 IFNγ antibody (100µl) conjugated to biotin 
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(Mabtech AB, Nacka, Sweden) was added to each well, to detect bound IFNγ, and 
incubated overnight in the fridge at 4°C. 
2.5.4.4 Day 4 
 
PBS-0.05% Tween-20 (200µl) was used to wash the plate six times, as before. 100µl of 
streptavidin-alkaline phosphatase (Bio-Rad Laboratories, Hemel Hemstead, UK), diluted 
1 in 1000 with PBS, was added to the wells and left in the dark at room temperature for 
two hours. The plate was washed six times as before using PBS-0.05% v/v Tween, 
alkaline phosphatase substrate was made up from a kit (Bio-Rad) by adding 100µl of 
solution A, 100µl of solution B and 400µl of buffer to 9.6ml distilled water. Then the 
alkaline phosphatase substrate solution (100µl) was added to the plate. The plate was left, 
covered, for 15-30 minutes until visible blue spots appeared. The remaining reagent in 
the plate discarded. The plate was then washed under running tap water and left to dry.  
 
The plates were stored in a dark and dry place at room temperature until they were taken 
to be counted using the AID ELISpot automated plate reader at St James University 
Hospital, Leeds by Dr. L Madden. The analysis of the results was done using the AID 
ELISpot analysis software.     
2.6 RT-PCR of serum samples 
 
Serum samples were collected from 97 CRC patients, who underwent curative surgical 
resection. Blood samples were collected on three occasions; pre-operatively, one month 
and one year post operatively.  
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2.6.1 Serum preparation 
 
The venous blood samples were kept in the fridge (4
o
C) in an upright position for at least 
30 minutes. After that the blood samples were centrifuged (3000g, for 10 minutes, at 
4
o
C). Then serum was extracted and stored at -80
o
C until use. 
2.6.2 RNA extraction 
 
The manufacturer’s protocol was followed throughout to extract serum RNA. (SV Total 
RNA Isolation System, Promega USA).  
Serum samples were thawed on ice, and then 175µl of serum was transferred into a sterile 
1.5 ml micro-centrifuge tube using RNase-free pipettes tips to reduce the chance of 
RNase contamination. The same amount of SV RNA lysis buffer was added to each 
sample and mixed gently by pippeting. Next 175µl of the mixture was added to 350µl of 
SV RNA dilution buffer and mixed gently by inverting the tube 3- 4 times; the tubes were 
then placed in a water bath at 70
o
C for 3 minutes. Finally the tubes were centrifuged at 
13000g at 20-25
o
C to pellet cell protein debris. 
The cleared lysate solution was transferred to a fresh micro-centrifuge tube and 200µl 
ethanol (95%) was added to each tube and mixed gently by pipetting 3-4 times. The 
mixture was then transferred to spin column assembly and the mixture was centrifuged at 
13000g for one minute. After discarding the liquid from the spin basket 600µl of SV 
RNA wash solution was added to the spin column assembly, and then the columns were 
centrifuged at 13000g for one minute. 
After that a 50µl of DNase incubation mix (40µl Yellow Core Buffer, 5µl 0.09M MnCL2 
and 5µl of DNase I enzyme) was added directly to the membrane of each spin column 
assembly and incubated for 15 minutes at room temperature. After the incubation period 
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200µl of SV DNA stop solution was added to each sample and then centrifuged at 
13000g for one minute. Then 600µl of SV RNA wash solution was added and the spin 
column assembly centrifuged for a further one minute. The spin basket was then emptied 
and 250µl of SV RNA Wash Solution was added and the column was centrifuged for 2 
minutes. Then the spin basket was put in a new elution tube and 100µl of nuclease-free 
water was added directly to the membrane of the spin basket and then the tube was 
centrifuged for 2 minutes to elicit the purified RNA which if not used immediately was 
stored at -80
o
C. 
2.6.3 RT-PCR condition 
 
The QIAGEN oneStep RT-PCR protocol was followed thoroughly (QIAGEN, West 
Sussex). RNA extract, primer solutions, hTERT forward and reverse, (RL-hTERT-FOR: 
5’-CGT GGT TTC TGT GTG GTG TC-3’, RL-hTERT-REV: 5’-CCT TGT CGC CTG 
AGG AGT AG-3’) (http://frodo.wi.mit.edu/), dNTP Mix, 5x QIAGEN oneStep RT-PCR 
Buffer and RNase free water were all thawed on ice. A master mix was made according 
to Table 2.2, and 45µl dispensed into PCR tubes.  
 
Table 2.2: Master Mix concentrations 
RNase-free water 29.75µl/reaction 
RT-PCR Buffer 10.0µl/reaction 
dNTP Mix 2.0µl/reaction 
hTERT for 0.5µl/reaction 
hTERT rev 0.5µl/reaction 
RT-PCR enzyme mix 2.0µl/reaction 
RNase inhibitor 0.25µl/reaction 
Total Master Mix 45µl/reaction 
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Template RNA from patients, normal controls, or CRC cell lines (5µl) (CaCO2 & LoVo 
cell lines) and 5µl of nuclease-free water as a negative control were added to each 
individual PCR tube. The thermal cycler was pre-heated to 50
o
C before the PCR tubes 
were placed in the thermal cycler. The following PCR conditions were applied (Table 
2.3) and the PCR products were later run on an agarose gel (section 2.6.4). 
 
Table 2.3: PCR conditions 
 
 
 
 
 
 
 
 
 
2.6.4 3% agarose gel preparartion  
 
             Agarose (3g) was mixed with 100ml of 1xTBE (Tris base, boric acid and EDTA); the 
mixture was put in the autoclave to allow the 3% w/v gel to desolve. The gel solution was 
left to cool down, and after that 2µl of ethidium bromide was added to the gel. The gel 
was poured into a casting mould with a comb to form the wells and the gel was left to set. 
 
 
 
 
RT-PCR steps  Time  Temperature  
Reverse transcription 30 minutes 50
o
C 
Initial PCR activation step 15 minutes 95
o
C 
3-step cycling  (40 cycles)   
 Denaturation  1 minute 94
o
C 
Extension  1 minute 72
o
C 
Final extension  10 minutes 72
o
C 
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2.6.5 PCR products loading 
 
PCR product (10µl) were  mixed with 2µl of 6x loading dye (BlueJuice™ Gel Loading 
Buffer, Invitrogen), and then the mixture and the DNA ladder (GeneRuler
TM
 DNA 
ladder, Invitrogen) were loaded in the agarose plate and left running on electrophoresis at 
100 V for 45 minutes. The gel was photographed using a UV illuminator (Uvi Tech). 
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CHAPTER 3 
 
Detection of specific cytotoxic T lymphocytes recognising hTERT 
using the ELISpot assay 
 
In this chapter the results of the telomerase activity in peripheral blood of CRC patients 
using ELISpot assay will be discussed 
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3.1 Introduction 
 
TAA are oncogenic proteins expressed by tumour cells. Human telomerase reverse 
transcriptase (hTERT) is the catalytic subunit of telomerase and it is the rate limiting 
factor. Peptide epitopes from this molecule could be a used as universal TAA since it is 
expressed by most human tumours, plays a universal role in tumourgenesis and is 
recognized by the CD8 cytotoxic T lymphocytes (CTL) in an MHC restricted manner 
(see section 1.11.2)  
The aim of this study was to detect CTL that can recognize hTERT epitopes. 
3.2 Patient samples 
 
Out of the 105 patients that were initially recruited, 34 were HLA-A2 or HLA-A3 
positive; the remaining 71 patients were not eligible to be used in the ELISpot study. 
Some of the samples were found to be either dead or there were not enough viable cells 
(2x10
5
cells/µl) required to perform the ELISpot, therefore, only 30 of the 34 patients 
were used. Table 3.1 shows the relevant patient details of the patients that were used for 
the ELISpot assay. The median age of the patients was 69 (53-83). 
Although all of the patients had at least two samples taken: pre (sample 1) and post-
operation (sample 2), not all the samples could be analysed, due to insufficient viable 
cells. Table 3.2 shows the patient and their samples that were used. 28 pre and 13 post-
operational samples were tested, providing a cohort of 12 sample pairs that for analysis. 
A further 6 patients had more than 2 consecutive samples tested, allowing a small pilot 
study on follow-up with time. 
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Table 3.1: Patient details that were used for the ELISpot assay 
Patient 
No. 
Site of 
Cancer  
Dukes 
Stage Age 
Date of 
Death 
HLA 
Status 
21 Rectum C 57 n/a A2+ 
26 Colon C2 74 n/a A2+ 
36 Colon D 73 n/a A2+ 
37 Colon C2 83 n/a A2+ 
40 Rectum C 62 19/02/2005  A2+ 
42 Colon C 67 n/a A2+ 
43 Colon C 58 n/a A2+ 
44 Rectum C2 77 n/a A2+/A3+ 
53 Benign Benign 75 26/02/2005  A2+ 
61 Rectum C1 59 n/a A3+ 
66 Colon B 77 n/a A2+ 
67 Rectum C1 62 n/a A2+ 
69 Rectum C1 68 n/a A2+ 
71 Colon B 69 n/a A3+ 
72 Colon B 77 n/a A2+ 
73 Benign Benign 72 n/a A2+ 
75 Rectum C2 78 n/a A2+ 
76 Colon B 59 n/a A2+ 
77 Rectum C1 53 n/a A2+ 
79 Rectum A 78 n/a A2+/A3+ 
80 Colon B 80 n/a A2+ 
90 Benign Benign 80 02/05/2005  A2+ 
91 Colon D 70 n/a A3+ 
95 Rectum C2 81 06/11/2005  A2+ 
97 Rectum C 67 25/02/2006  A2+/A3+ 
98 Colon C1 63 n/a A2+/A3+ 
99 Colon A 76 n/a A2+ 
100 Benign Benign 65 n/a A2+/A3+ 
101 Rectum C1 67 n/a A2+/A3+ 
105 Rectum B 64 n/a A2+ 
Note: n/a=not applicable, as patient did not die during the course of the study 
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Table 3.2: Showing the ELISpot assays performed 
Patient 
No. 
Dukes 
Stage Sample No. 
    1 2 3 4 5 6 
21 C             
26 C2             
36 D             
37 C2             
40 C             
42 C             
43 C             
44 C2             
53 Benign             
61 C1             
66 B             
67 C1             
69 C1             
71 B             
72 B             
73 Benign             
75 C2             
76 B             
77 C1             
79 A             
80 B             
90 Benign             
91 D             
95 C2             
97 C             
98 C1             
99 A             
100 Benign             
101 C1             
105 B             
Note: Black boxes indicate that the sample was used for the ELISpot assay 
3.3 HLA status and CTL response against hTERT peptides in CRC patients 
 
From the 30 patients that were investigated, 21 (70%) were HLA-A2 positive, 3 (10%) 
were HLA-A3 positive and 6 (20%) were HLA-A2 and A3 positive. 
The immediate results from the practical work can be shown by observing the spots 
obtained on the ELISpot plates. The results obtained were variable, as Figure 3.1 shows 
that the size, intensity, and number of spots were different in each case.  The spots were 
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then counted using an AID ELISpot automated plate reader (St James Hospital, Leeds) to 
give the final results as numbers.   
a)  
      1) hTERT-1          2) hTERT-2       3) Influenza-A2         4) PMA     5) No peptide 
 
 
b) 
 
   
 
c) 
 
 
d) 
 
 
Figure 3.1 Examples of ELISpot results.  
a) Good response  
b) Good response, but high response with no peptide creates negative results 
c) Poor response, but positive PMA. 
d) Poor result due to background colouration (from prelimary work). 
 
For all the data, the numbers of spots are recorded per 2x10
5 
PBMC. The specific number 
of spots was calculated by subtracting the number of spots present in the wells with no 
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peptide (negative control well). This gives the number of spot forming cells (SFC), which 
relates directly to the exact number of cells that responded. Where the number of spots 
became a negative number, the value was changed to zero, as it is not possible to have a 
negative number of spots. This method was previously used by (Amarnath et al. 2004) 
Tables 3.3 and 3.4 show the average ELISpot results for the A2 and A3 positive patients 
respectively. The patients that are positive for A2 and A3 are recorded in both tables, and 
the results analysed independently, denoted as two samples.  
The results obtained can be looked at on an individual basis, or may be compared in 
groups to establish patterns of responses, at a certain time-point, or over time. It is mainly 
the hTERT peptide response and influenza response that will be studied. Other factors 
that come into consideration will also be noted, such as the site and stage of cancer, and 
patient death.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 84 
Table 3.3: ELISpot results for A2 positive patients 
Patient Average number of SFC per well Specific number of SFC per well 
Number Sample 
hTERT-
1 
hTERT-
2 
Inf 
A2 PMA 
No 
peptide 
hTERT-
1 
hTERT-
2 
Inf 
A2 PMA 
21 2 8 4 7 16 1 7  3  6  15  
21 2 59 69 55 171 24 35  45  31  147  
21 4 194 213 187 269 203 0 10  0  66  
21 6 88 90 87 193 81 7  9  6  112  
26 2 15 8 3 37 6 9  2  0  31  
36 2 0 1 3 1 2 0  0  1  0  
36 3 10 3 1 116 2 8  1  0  114  
37 1 56 38 45 185 42 14  0  3  143  
37 2 1 3 4 9 5 0  0  0  4  
40 1 7 0 1 12 5 2  0  0  7  
42 1 0 0 0 38 0 0  0  0  38  
42 2 9 4 11 25 1 8  3  10  24  
42 3 5 2 7 5 1 4  1  6  4  
43 1 1 2 1 69 2 0  0  0  67  
43 3 26 17 6 21 2 24  15  4  19  
43 4 1 2 1 14 1 0  1  0  13  
44 1 5 3 0 5 1 4  2  0  4  
44 3 90 100 97 329 100 0  0  0  229  
44 4 27 39 30 87 32 0  7  0  55  
53 1 5 1 2 12 1 4  0  1  11  
66 1 25 27 31 287 19 6  8  12  268  
66 2 26 29 20 153 22 4  7  0  131  
66 3 123 59 47 183 35 88  24  12  148  
67 1 186 164 174 205 120 66  44  54  85  
69 1 5 2 0 12 3 2  0  0  9  
71 1 95 101 77 148 81 14  20  0  67  
72 1 91 80 82 246 55 36  25  27  191  
72 2 12 20 18 111 21 0  0  0  90  
73 1 100 89 87 182 78 22  11  9  104  
75 1 58 50 66 305 56 2  0  10  249  
76 1 174 186 170 240 169 5  17  1  71  
77 1 242 238 233 260 204 38  34  29  56  
79 1 25 12 19 368 8 17  4  11  360  
80 1 0 1 0 65 1 0  0  0  64  
90 1 0 0 2 5 4 0  0  0  1  
95 1 3 5 11 32 13 0  0  0  19  
97 1 10 31 16 118 58 0  0  0  60  
97 2 3 3 1 12 1 2  2  0  11  
98 1 13 10 7 5 9 4  1  0  0  
98 2 13 21 17 17 3 10  18  14  14  
99 1 1 8 8 5 7 0  1  1  0  
100 1 97 112 147 166 109 0  3  38  57  
105 1 1 0 0 8 0 1  0  0  8  
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Table 3.4: ELISpot results for A3 positive patients 
Patient Average number of SFC per well Specific number of SFC per well 
Number sample hTERT A3 
Inf 
A3 PMA no peptide hTERT A3 Inf A3 PMA 
44 1 3  3  5  1  2  2  4  
44 3 72  74  329  100  0  0  230  
44 4 31  31  100  32  0  0  55  
61 1 23 29 159 32 0  0  127  
71 1 9 4 12 12 0  0  0  
71 2 99 89 116 115 0 0  1  
71 3 5 9 7 73 0  0  0  
71 4 56 38 95 86 0  0  9  
71 5 42 50 42 215 0  0  0  
79 1 16 13 368 8 8  5  360  
91 1 2 8 4 6 0  2  0  
91 2 123 59 87 90 33  0  0  
97 1 10 14 118 58 0  0  60  
97 2 5 3 12 1 4  2  11  
98 1 29 9 17 3 26  6  14  
98 2 133 121 166 109 24  12  57  
100 1 133 121 166 109 24  12  57  
101 1 18 0 1 3 15  0  0  
101 1 0 3 29 2 0  1  27  
101 2 59 69 172 77 0  0  95  
 
Twenty-eight HLA-A2 positive patient samples were stimulated with PMA of these 18 
(64%) showed recognition of the hTERT-1 peptide, 19 (68%) responded to hTERT-2 
peptide, and 16 (57%) recognised both peptides. Six of the 9 (67%) HLA-A3 positive 
samples recognised the hTERT A3 peptide. 
The pattern of response to hTERT was also investigated by examining the results for 
samples that belong to the same patient pre-operatively and post-operatively. Where CTL 
that recognized hTERT were detected in 20/28 patients (71%) pre-operatively, and 7/13 
(54%) analyzable post-operative samples showed a CTL response. Table 3.5 simplifies 
the results of tables 3.3 and 3.4.  
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Table 3.5: CTL response against hTERT in patients’ samples 
Patient 
No. 
Dukes 
Stage Sample No. 
    1 2 3 4 5 6 
21 C +  +    +    +  
26 C2   +          
36 D   - +        
37 C2  + -          
40 C  +           
42 C  - +  +        
43 C  -   +        
44 C2 + -  +        
53 Benign +           
61 C1  -           
66 B  + +  +        
67 C1  +           
69 C1  +           
71 B  + -  -  -  -    
72 B  + -          
73 Benign  +           
75 C2  +           
76 B  +           
77 C1  +           
79 A  +           
80 B -           
90 Benign -           
91 D - +          
95 C2 -           
97 C - +          
98 C1 +  +          
99 A +            
100 Benign +            
101 C1 +            
105 B + -          
+: positive CTL response 
-: negative CTL response 
 
The above pre and post operative samples provided a cohort of 12 sample pairs. In this 
cohort 3 patients had CTL response in their pre and post operative samples, five patients 
had CTL response in the pre-operative sample but not in any of the post-operative 
samples and 4 patients developed CTL response in their post-operative samples but not in 
the pre-operative samples.  
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A further 6 patients had more than 2 consecutive samples tested, allowing a small pilot 
study on follow-up with time. In this group 5 patients in their last sample had CTL 
against hTERT peptides detected and one sample was negative. Four of these patients 
were Duke’s C and 2 were Dukes’ B, these samples were collected over a period of 4 
months. 
3.4 Repeated samples 
 
In order to validate the assay, the ELISpot assay was repeated on the same samples but it 
was not possible to repeat the tests for all the samples as there was either insufficient time 
or there were insufficient cells from the patient. In the case of patient 21, sample 2, and 
patient 101, sample 1, where the only two samples that were repeated. The results are 
shown in Table 3.6 and 3.7.  
 
 
Table 3.6: ELISpot results for a HLA-A2 positive patient- patient 22, sample 2 
 
Table 3.7: ELISpot results for a HLA-A3 positive patient- patient 101, sample 1 
Patient Specific number of SFC per well Positive results 
Number Sample hTERT A3 Inf A3 PMA hTERT A3 Inf A3 PMA 
101 1 16  0  0  Y N N 
101 1 0  1  27  N Y Y 
 
Even though the magnitude of the responses was not the same in the repeat, the results 
for patient 21 and 101 showed positive for both samples. Therefore this assay’s validity is 
confirmed. 
Patient Specific number of SFC per well Positive results 
Number Sample hTERT-1 hTERT-2 Inf A2 PMA 
hTERT-
1 
hTERT-
2 
Inf 
A2 PMA 
21 2 7  4  6  16  Y Y Y Y 
21 2 35  46  31  147  Y Y Y Y 
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3.5 Averaged results  
 
The results for the final ELISpot count, given in Tables 3.2 and 3.3, are calculated 
averages between several wells. For each sample, the test for each peptide was triplicated, 
and an average taken, to look at the variability of the result and to ensure a representative 
number. Table 3.8 shows a few examples of the original number of spots in the wells, as 
well as the calculated average. In the case of patients 76 and 77, the original numbers are 
very closely associated so, therefore, the average is a true reflection of the result. 
However, there are some samples, for example patient 40, where the numbers of spots are 
not so closely associated, giving a number that may be incorrect. The variability makes 
comparisons difficult and may be overcome by repeating the assay and taking more care 
over the procedure. 
Table 3.8: Showing an example of the number of SPC counted per well and the 
average 
Patient hTERT-1 PMA No peptide 
Number Sample   Average   Average   Average 
40 1 3 16 1 7 19 4 12 0 9 5 
76 1 160 193 170 174 247 233 240 181 156 169 
77 1 256 233 238 242 257 263 260 222 186 204 
 
3.6 PMA stimulation and Influenza response 
 
PMA is a positive control, as it causes a non-specific response in all viable cells. 
However, not all the results show an effective PMA stimulation, suggesting that the cells 
may be dead. The threshold for a positive response was taken from (Titu et al. 2004) to 
be 16 and above. In his study the most appropriate method was to calculate the mean 
number of spots counted in all irrelevant wells and add three standard deviations to obtain 
the threshold above which the number of spots counted in study wells can be considered 
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as being significant. More than 99% of the spots obtained in the irrelevant wells would be 
found below this threshold, and, consequently, it can be postulated that any number of 
spots obtained in the study wells above this threshold indicates a positive response to 
peptide stimulation. As a method of further verifying the results obtained, the frequencies 
of CTL active against an HLA-A2/A3-restricted epitope of the influenza a (IA) matrix 
protein were also quantified. The influenza response gives indication of the state of the 
patient’s immune system, and because of the efficient vaccination of the human body 
against influenza it was used as a positive control for the assay in many studies 
(Scheibenbogen et al. 1997)  (Vonderheide et al. 2001). A negative influenza response 
shows that the body had no or very little immune response. Table 3.9 shows patient 
sample responses to both PMA and influenza. Out of the 51 samples, 30 (59%) showed a 
positive response to PMA. The average number of SFC in response to PMA was 65. 
Twenty-three (45%) samples out of the 51 responded to influenza, and 16 (31%) showed 
a positive response to both PMA and influenza. Seven samples were viable but had no 
immune response. The average number of SPC in response to influenza was 5. 
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Table 3.9: Patient responses to PMA stimulation and influenza: number of SFC 
obtained with PMA and Influenza. 
Patient 
No. 
Sample 
No. PMA 
Above 
Threshold Influenza Response 
21 2 81 + 18 + 
21 4 66 + 0 - 
21 6 112 + 6 + 
26 2 31 + 0 - 
36 3 114 + 0 - 
36 2 0 - 1 + 
37 1 143 + 3 + 
37 2 4 - 0 - 
40 1 7 - 0 - 
42 1 38 + 0 - 
42 2 24 + 10 + 
42 3 4 - 6 + 
43 1 67 + 0 - 
43 3 19 + 4 + 
43 4 13 - 0 - 
44 1 4 - 0 - 
44 3 229 + 0 - 
44 4 55 + 0 - 
53 1 11 - 1 + 
61 1 127 + 0 - 
66 1 268 + 12 + 
66 2 131 + 0 - 
66 3 148 + 12 + 
67 1 85 + 54 + 
69 1 9 - 0 - 
71 1 0 - 0 - 
71 2 1 - 0 - 
71 3 0 - 0 - 
71 4 9 - 0 - 
71 5 0 - 0 - 
72 1 191 + 27 + 
72 2 90 + 0 - 
73 1 104 + 9 + 
75 1 249 + 10 + 
76 1 71 + 1 + 
77 1 56 + 29 + 
79 1 360 + 13 + 
80 1 64 + 0 - 
90 1 1 - 0 - 
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Patient 
No. 
Sample 
No. PMA 
Above 
Threshold Influenza Response 
91 1 0 - 2 + 
91 2 0 - 0 - 
95 1 19 + 0 - 
97 1 60 + 0 - 
97 2 11 - 1 - 
98 1 7 - 3 + 
98 2 57 + 13 + 
99 1 0 - 1 + 
100 1 57 + 25 + 
101 1 13 - 1 + 
101 2 95 + 0 - 
105 1 8 - 0 - 
Note: Repeated results were averaged 
 
3.7 Benign tumours 
 
Four patients were found to have benign tumours. The ELISpot assay was still 
performed, as this information was revealed after the assay had been carried out, and 
provided an interesting contrast with malignant disease.  
Patients 53 and 90 did not show a positive response to PMA, so their data is not valid. 
Patient 73 showed good PMA stimulation, both hTERT peptides responded, and 
influenza caused a response. Patient 100 showed almost no response to the A2 hTERT 
peptides, but responded highly to hTERT A3 (see Table 3.3 & 3.4).  
3.8 Site and stage of cancer 
 
Out of all the patients used for the study, half originated in the colon and half in the 
rectum (excluding the 4 benign patients). Tables 3.10 and 3.11 show the results grouped 
according to their cancer origin. 
For the samples from the colon, all except for 3 samples (67%) responded to hTERT. 
About 60% of the rectal cancer patients responded to hTERT.  
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Table 3.10: Patients samples with tumours originating in the colon 
Patient Specific number of SFC per well 
Number Sample hTERT-1 hTERT-2 hTERT A3 PMA Influenza 
26 2 9 2 n/a 31 0 
36 3 8 1 n/a 114 0 
37 1 14 0 n/a 143 3 
42 1 0 0 n/a 38 0 
42 2 8 3 n/a 24 10 
43 1 0 0 n/a 67 0 
43 3 24 15 n/a 19 4 
66 1 6 8 n/a 268 12 
66 2 4 7 n/a 131 0 
66 3 88 24 n/a 148 12 
72 1 36 25 n/a 191 27 
72 2 0 0 n/a 90 0 
76 1 5 17 n/a 71 1 
80 1 0 0 n/a 64 0 
98 2 10 18 24 57 13 
 
 
Table 3.11: Patient samples with the tumour originating in the rectum 
Patient Specific number of SFC per well 
Number Sample hTERT-1 hTERT-2 hTERT A3 PMA Influenza 
21 2 21 24 n/a 81 18 
21 4 0 10 n/a 66 0 
21 6 7 9 n/a 112 6 
44 3 0 0 0 229 0 
44 4 0 7 0 55 0 
61 1 n/a n/a 0 127 0 
67 1 66 44 n/a 85 54 
75 1 2 0 n/a 249 10 
77 1 38 34 n/a 56 29 
79 1 17 4 8 360 13 
95 1 0 0 n/a 19 0 
97 1 2 2 4 60 0 
101 2 n/a n/a 0 95 0 
 
Putting the site of cancer aside, 2 (8%) patients’ had Dukes’ A cancer, 6 (23%) had 
Dukes’ B, 16 (61%) Dukes’ C (including Dukes’ C1 and C2), and 2 (8%) had Dukes’ D. 
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3.8 Deceased patients  
 
Table 3.12 shows the relevant details and results of the 5 patients who died. Two of the 
patients who died had benign tumours. Both died within 3 months of their operation. 
Their average age was 78, suggesting that that may have died due to operation stress 
rather than the tumour per se. The other three patients had CRC in the rectum. Their CRC 
were all at a fairly late stage: Dukes’ C2.  
The hTERT responses were consistently low and all the patients had no or a very low 
influenza response, indicating that the immune system was not functioning normally. 
This could have been one reason for the cause of death. A faster rate of disease 
progression than otherwise would be normal may have caused death, due to many other 
factors.  
Table 3.12: Patient details of patients who died during the course of the study 
Patient Site of Dukes Age Specific number of SFC per well 
Number Cancer Stage  hTERT-1 hTERT-2 hTERT A3 PMA Influenza 
40 Rectum C 62 2 0 n/a 7 0 
53 Benign Benign 75 4 0 n/a 11 1 
90 Benign  Benign 80 0 0 n/a 1 0 
95 Rectum  C2 81 0 0 n/a 19 0 
97 Rectum  C 67 2 2 2 35 0 
 
3.9 Conclusion 
 
In this thesis 2 peptides were used that react to CTL in an HLA-A2 and HLA-A3 
restricted manner. 
Thirty patients in this study were HLA-A2/A3 positive and were having chemotherapy 
and hence were studied for CTL reaction. Twenty eight pre-operative samples and 
thirteen post-operative samples were analysable, 71% of pre-operative samples and 54% 
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post-operative samples had CTL reaction towards hTERT peptides whether in an HLA-
A2, HLA-A3 or HLA2/A3 restricted manner.  
The results of this thesis seems to be higher than Titu et al results, who studied the T-cell 
response against two HLA-A2 specific peptides of hTERT (I540 and P865) in 37 CRC 
patients and 12 normal controls (Titu et al. 2004). The results of their study demonstrate 
that CTL active against hTERT are present in only 20% of CRC patients. The 
discrepancy in the results of both studies could be due to the fact that in our study 
samples were considered positive only if the value SFC was ≥ 1. Whereas in Titu et al 
study the samples were considered positive only when the number of the spots with 
peptides were ≥ 16 spots which is the threshold level from the cells with no peptides. 
Furthermore in our study we added another hTERT which have contributed for the higher 
results. 
The results in this thesis were closer to Amarnath et al (Amarnath et al. 2004) results who 
investigated CTL response in breast cancer patients. The same methods and peptides 
were used in their study and CTL recognized HLA-A2 P540 and P865 peptides in 76% 
and 47% respectively, CTL recognized both HLA-A2 peptides in 47%, CTL recognized 
HLA-A3 K973 peptides in 71% patients.  
In this study the responses to both PMA and influenza were analysed. Out of the 51 
samples, 30 (59%) showed a positive response to PMA. The average number of SFC in 
response to PMA was 65.   
Twenty three (45%) samples out of the 51 responded to influenza, and 16 (31%) showed 
a positive response to both PMA and influenza. 7 samples were viable but had no 
immune response. The average number of SPC in response to influenza was 5. These 
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results were more or less similar to results of many studies (Vonderheide et al. 2001) 
(Titu et al. 2004)  (Amarnath et al. 2004) (Scheibenbogen et al. 1997)  studies. 
Although the experimental methods in this chapter were used by other authors and they 
produced reliable generic methodology for the study of the CTL immune response 
against any peptide antigens, in our study there was variability in the results were the 
size, intensity, and number of spots were different in each case as shown in figure 3.1, 
which could be due to contamination making our results unreliable.  
So far all studies conducted agree that CTL precursors capable of recognizing hTERT 
peptides can be found or expanded in vitro in cancer patients but none of them have 
studied the effect of these CTL cells on tumours’ development and progression. 
 
 
 
 
 
 
 
 
 
 
 
 
 96 
CHAPTER 4 
Detection of hTERT mRNA in serum samples of CRC patients 
In this chapter the results of the hTERT mRNA detection serum samples of CRC patients 
using RT-PCR will be discussed 
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4.1 Introduction 
 
The expression of hTERT in blood, reported in only five previous studies, has been 
detected in: 90% (70/78) of serum samples of patients with hepatocellular carcinoma 
(Miura, N. et al. 2003), 25 % (4/16) of serum samples of patients with breast cancer 
(Chen et al. 2000) using RT-PCR, 46% (30/65) of the peripheral blood of patients with 
gastric cancer using red blood cell lysis followed by RT-PCR (Shin et al. 2002), and in 
53% (29/55) of patients with hepatocellular carcinoma using immunomagnetic separation 
technique to isolate CTC followed by RT-PCR (Waguri et al. 2003). 
Finally hTERT mRNA has been detected in the plasma samples of CRC patients (Lledo 
et al. 2004) with  82% (41/50) of these patients having hTERT mRNA expression values 
higher than the maximum values of normal control using real time PCR. 
In this study the aim was to detect the expression of hTERT mRNA in serum samples of 
CRC patients who underwent curative resection and to determine the correlation between 
hTERT expression, disease stage and patient prognosis.  
4.2 Detection of serum hTERT mRNA  
 
Ninety seven patients were recruited prospectively and serum blood samples were 
collected pre-surgery, one month and one year post operatively. The serum samples were 
aliquoted and stored at -80
O
C until use. The mean age for the patients was 71 (43-90 
years). Forty six percent of the patients were Duke’s C, 26% Duke’s B, 20% Duke’s A 
and 7% were Duke’s D. The mortality rate in this study was 17%. The demographic 
features of the patients recruited are shown in Appendix 4.1. 
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4.2.1 Preliminary work  
 
In the first experiment of serum hTERT mRNA expression, 5 patients’ samples were 
used to extract RNA. Purified water (ddH2O) and a sample from a normal volunteer were 
used as negative controls. The RT-PCR reaction was prepared using the following 
primers: (http://frodo.wi.mit.edu/), with TERT PCR product size of 4015 bp. 
1) RL-hTERT-FOR: 5’-CGT GGT TTC TGT GTG GTG TC-3’ 
2) RL-hTERT-REV: 5’-CCT TGT CGC CTG AGG AGT AG-3’ 
3) GAPDH-FOR: 5’-ACC ACA GTC CAT GCC ATC AC-3’ 
4) GAPDH-REV: 5’-TCC ACC ACC CTG TTG CTG TA-3’   
The RT-PCR reaction steps were followed as detailed in section 2.6.3 in the methods 
chapter, but initially 35 steps were used for denaturation and extension. In this reaction 
hTERT and GAPDH expression should show bands of 214 bp and 450 bp respectively. 
The results of this experiment were all negative even using the GAPDH primers (Figure 
4.1). The same experiment was repeated 3 times using the same samples and all were 
negative. 
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Figure 4.1 A 1.2% w/v agarose loading gel showing no PCR bands in any tube. 
N.B. 100 bp ladder was used (GeneRuler
TM
 DNA ladder, Invitrogen) 
Tube 1: ddH2O + GAPDH primers (negative control) 
Tube 2: normal volunteer + GAPDH primers 
Tube 3: normal volunteer + RL-hTERT primers  
Tube 4: ddH2O + RL-hTERT primers (negative control) 
Tube 5: normal volunteer + RL-hTERT primers (negative control) 
Tube 6: Sample 92a + RL-hTERT primers 
Tube 7: Sample 90a + RL-hTERT primers 
Tube 8: Sample 87a + RL-hTERT primers 
Tube 9:  Sample 50c + RL-hTERT primers 
Note:  a: pre- operative sample, b: 1 month post operative sample and c: one year post operative sample. 
 
4.2.2 RT-PCR verification  
 
As a consequence of the negative results in the GAPDH controls it was decided to use an 
additional house keeping gene and two cancer cell lines that are known to express hTERT 
mRNA (positive controls) in order to check the integrity of the RT-PCR reaction. The 
two cancer cell lines were CACO2 (colon cancer cell line) and MCF-7 (breast cancer cell 
line). 
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Initially the integrity of the cancer cell lines was checked by measuring the RNA 
concentration by measuring the absorbance of each sample at 260 nm by 
spectrophotometry. RNA preparations from CACO2 and MCF-7 cancer cell line showed 
sufficient RNA concentrations (10 ng/µl and 70 ng/µl respectively), that subsequently 
produce a positive RT-PCR reaction since the QIAGEN RT-PCR kit provides highly 
efficient sensitive reverse transcriptase of any RNA quantity from 1pg to 2 µg.  
In this experiment the RT-PCR was optimised to allow the detection of the control genes 
using both cancer cell lines (Figure 4.2). This experiment was repeated again and the 
same positive results were obtained.  
 
 
Figure 4.2 The bright bands at approximately 450 bp demonstrate the positive 
expression of the cancer cell lines of GAPDH and ß-actin genes. 
Tube 1: CACO2 + GAPDH 
Tube 2: CACO2 + ß-actin 
Tube 3: MCF-7 + GAPDH 
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4.2.3 RT-PCR for patient samples 
 
Having demonstrated that the cell lines obtain sufficient mRNA and the RT-PCR reaction 
can detect both control genes, these samples together with a number of patients’ samples 
were tested for house keeping genes and hTERT expression.  
The RNA concentration and purity for patients’ samples were measured to check the 
samples integrity using the spectrophotometer where the purity ratio, according to the 
manufacturer protocol, should be within the following range (1.9-2.1 in 10 mM Tris.CL, 
pH 7.5). Then their concentration and purity were compared to CACO2 cell line RNA 
concentration and purity that had positive results for GAPDH and ß-actin. The results are 
shown in Table 4.1: 
Table 4.1: RNA concentration and purity 
Sample no. Conc. ng/µl Purity ratio 
50c 7 1.19 
87a 93 0.8 
87b 14 1.2 
90a 14 1.2 
92a 15 1.18 
Normal control 11 1.18 
CACO2 cell line 32 1.05 
 
 
The above table shows that RNA concentration are lower than the CACO2 cell line 
except sample 87a, and shows that the patients samples and the CACO2 cell line all have 
low RNA purity. Although the above shows low RNA concentrations and purity it was 
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decided to use the same samples for the next RT-PCR using the same conditions as 
previously used successfully.  
In this experiment the 1.2 % w/v agarose gel demonstrated faint bands in samples 8 (87a) 
and 9 (50c)  at approximately 215 bp which is the correct-sized band for hTERT mRNA 
expression which could be explained by the insufficient RNA concentration in patients’ 
samples, its low purity or a combination of both factors (Figure 4.3). 
 
Figure 4.3: 1.2% w/v agarose loading gel showing faint PCR bands in tubes 8 & 9 
Tube 1: ddH2O + GAPDH primers 
Tube 2:  normal volunteer + GAPDH primers 
Tube 3: ddH2O + LR-hTERT primers 
Tube 4:  normal volunteer + LR-hTERT primers 
Tube 5: Sample 92a + LR-hTERT primers 
Tube 6: Sample 90a + LR-hTERT primers  
Tube 7: Sample 87b + LR-hTERT primers   
Tube 8: Sample 87a + LR-hTERT primers   
Tube 9: Sample 50c + LR-hTERT primers    
  
   
As the RNA concentration and purity in the samples used were low, it was decided to 
increase the number of RT-PCR cycles in this experiment from 35 to 40 cycles in order to 
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get a higher yield of RT-PCR products. The previous experiment was repeated using the 
same samples as two of these samples demonstrated positive hTERT bands, in addition 
GAPDH primers and CACO2 cell line were used (Figure 4.4). 
 
Figure 4.4 RT-PCR increased to 40 cycles to get a higher yield of RT-PCR products 
Tube 1: Sample 50c + LR-hTERT primers 
Tube 2: Sample 50c + GAPDH primers 
Tube 3: Sample 87a + LR-hTERT primers 
Tube 4: Sample 87a + GAPDH primers 
Tube 5: Sample 87b + LR-hTERT primers 
Tube 6: Sample 87b + GAPDH primers 
Tube 7: Sample 90a + LR-hTERT primers 
Tube 8: Sample 90a + GAPDH primers 
Tube 9: Sample 92a + LR-hTERT primers 
Tube 10: Sample 92a + GAPDH primers 
Tube 11: normal control + LR-hTERT primers 
Tube 12: normal control + GAPDH primers 
Tube 13: CACO2 + LR-hTERT primers 
Tube 14: CACO2 + GAPDH primers 
 
Figure 4.4 showed that samples 2, 8 and 14 had expression of RT-PCR products when 
GAPDH primers were used in two patients samples and CACO2 cell line (at band 450 
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bp), but none of the samples expressed hTERT mRNA which could be due to the 
insufficient mRNA concentration in the samples. 
As the result of the above it was decided to extract RNA from new patients’ serum 
samples and use them as fresh in order to avoid any RNA degradation and use new LR-
hTERT primers and hTERT primers that were used in Chen et al and Lledo et al studies 
(Chen et al. 2000) (Lledo et al. 2004) in order to compare them to the LR-hTERT 
primers, these new hTERT are:  
CHEN-hTERT FOR: 5’-TGA CAC CTC ACC TCA CCC-3’ 
CHEN-hTERT REV: 5’-CAC TG CTT CCG CAA GTT CAC-3’ 
LLEDO-hTERT FOR: 5’-ACC GTC TGC GTG AGG AGA TC-3’ 
LLEDO-hTERT REV: 5’-CCG GTA GAA AAA AGA GCC TGT TC -3’ 
Furthermore new ddH2O and GAPDH primers were used to avoid contamination. 
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Figure 4.5 There are two faint bands at around 450 bp in columns 22 and 25. 
Tube 1: Sample 9a + LR-hTERT primers  Tube 13: 19b+ GAPDH primers 
Tube 2: Sample 9b + LR-hTERT primers  Tube 14: ddH2O + GAPDH primer 
Tube 3: Sample 11a + LR-hTERT primers   Tube 15: 9a + CHEN-hTERT primers 
Tube 4: Sample 11b + LR-hTERT primers  Tube 16: 9b + CHEN-hTERT primers 
Tube 5: Sample 19a + LR-hTERT primers  Tube 17: 9a + LLEDO-hTERT primers 
Tube 6: Sample 19b+ LR-hTERT primers   Tube 18: 9b + LLEDO-hTERT primers 
Tube 7: ddH2O + LR-hTERT primers  Tube 19: 9a + ß-actin primers 
Tube 8: 9a + GAPDH primers   Tube 20: 9b + ß-actin primers 
Tube 9: 9b + GAPDH primers   Tube 21: CACO2 + LR-hTERT primers 
Tube 10: 11a + GAPDH primers   Tube 22: CACO2 + GAPDH primers 
Tube 11: 11b + GAPDH primers   Tube 23: CACO2 + CHEN-hTERT primers 
Tube 12: 19a + GAPDH primers   Tube 24: CACO2 + LLEDO-hTERT primers 
       Tube 25: CACO2 + ß-actin primers 
 
 
This experiment again has failed to demonstrate hTERT expression. There were 2 
samples, only positive with ß-actin and GAPDH primers used (samples 22 and 25). 
Furthermore the gel was difficult to analyse, as it was difficult to differentiate between 
the bands that were created by hTERT expression or the bands of the starting template, in 
order to over come this obstacle 3% w/v agarose gel was used instead of the 1.2% w/v 
agarose. The 3% w/v gel has the ability to give wider spaces between bands of a small 
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size and hence can differentiate between the bands created by hTERT expression or the 
starting template. 
The following RT-PCR (Figure 4.6) was performed using two colon cancer cell lines 
with the available hTERT primers and 3% w/v agarose gel used for electrophoresis.  
 
 
 
Figure 4.6 Demonstrates bright bands at 450 bp and 214 bp 
Tube 1: ddH2O + LR-hTERT primers 
Tube 2: ddH2O + GAPDH primers 
Tube 3: CACO2 + LR-hTERT primers 
Tube 4: LoVo + ß-actin primers 
Tube 5: LoVo + GAPDH primers 
Tube 6: LoVo + LLEDO-hTERT primers 
Tube 7: LoVo + CHEN-hTERT primers 
Tube 8: LoVo + LR-hTERT primers 
 
From this experiment it was concluded that Both LoVo and CACO2 have expressed 
hTERT mRNA (band 214 bp) when the LR-hTERT primers were used but not CHEN-
hTERT and LLEDO-hTERT primers, and both LoVo and CACO2 produced a bright 
band at around 450 bp when the ß-actin and GAPDH primers were used. This experiment 
was repeated on two occasions and was successful. 
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Having succeeded in detecting hTERT mRNA using the appropriate cancer cell lines and 
hTERT primers, the experiment was repeated applying the same conditions using 
patients’ serum samples from which the RNA was freshly extracted (Figure 4.7).  
 
Figure 4.7 RT-PCR using patients’ serum samples 
Tube 1: LoVo 10% + LR-hTERT primers      Tube 13: Sample 79a + LR-hTERT primers 
Tube 2: LoVo + LR-hTERT primers   Tube 14: Sample 78a + LR-hTERT primers 
Tube 3: ddH2O + LR-hTERT primers   Tube 15: Sample 77a + LR-hTERT primers 
Tube 4: normal control + LR-hTERT primers  Tube 16: Sample 76b + LR-hTERT primers 
Tube 5: Sample 85b + LR-hTERT primers   Tube 17: Sample 76a + LR-hTERT primers 
Tube 6: Sample 84a + LR-hTERT primers   Tube 18: Sample 75b + LR-hTERT primers 
Tube 7: Sample 83a + LR-hTERT primers   Tube 19: Sample 74a + LR-hTERT primers 
Tube 8: Sample 82 a + LR-hTERT primers   Tube 20: Sample 73b + LR-hTERT primers 
Tube 9: Sample 81b + LR-hTERT primers   Tube 21: Sample 72b+ LR-hTERT primers 
Tube 10: Sample 81a + LR-hTERT primers   Tube 22: Sample 72a + LR-hTERT primers 
Tube 11: Sample 80b + LR-hTERT primers   Tube 23: Sample 71b + LR-hTERT primers 
Tube 12: Sample 80a + LR-hTERT primers   Tube 24: Sample 71a + LR-hTERT primers 
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The results (Figure 4.7) of this experiment were very encouraging, as LoVo cancer cell 
line expressed hTERT mRNA and Samples 19,20,22,23, and 13 may have expressed 
hTERT mRNA. 
In order to check the integrity of the results the experiment was repeated on the positive 
samples (Figure 4.8). 
 
Figure 4.8 All patients’ samples expressed hTERT mRNA  
Tube 1: CACO2 + LR-hTERT 
Tube 2: LoVo + LR-hTERT primers 
Tube 3: ddH2O + LR-hTERT primers 
Tube 4: Sample 72a + LR-hTERT primers 
Tube 5: Sample 73b + LR-hTERT primers 
Tube 6: Sample 74a + LR-hTERT primers  
Tube 7: Sample 75b + LR-hTERT primers 
Tube 8: Sample 76b + LR-hTERT primers 
Tube 9: Sample 79a + LR-hTERT primers 
 
Based upon the encouraging results above, RNA was extracted from 42 new samples of 
patients’ serum and using the same RT-PCR conditions it could not give any positive 
results, in fact the products were smeared on the 3% w/v agarose gel with no obvious 
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explanation (Figure 4.9), the only possibility was water contamination, the water was 
replaced with a new one but still the results were negative, the experiment was repeated 
many time on the new samples but never managed to get positive results again. As a 
result of continuous inconsistency of the experiment and lack of positive RT-PCR on 
serum samples it was decided not to pursue this approach.  
 
 
Figure 4.9 3% w/v agarose gel with smeared products 
 
4.3 Conclusion  
 
This study failed to find a standard reliable technique that could detect hTERT mRNA in 
serum samples of CRC as hTERT mRNA was only detected in 6 samples out of all other 
samples. Such approach has been reported previously and the discrepancy could be for a 
number of reasons;  
1)  The first reason could be the source of samples, where in this study serum samples of 
CRC patients were used. Two studies used RT-PCR on serum samples, the first on breast 
cancer patients (Chen et al. 2000) and the other using hepatocellular cancer (Miura, N. et 
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al. 2003), both studies managed to produce positive results using the same methods as 
applied in this thesis, but both studies have not commented on the duration of sample 
storage, hTERT expression was also detected intracellularly in the peripheral blood in  
46% of patients with gastric cancer using red blood cell (RBC) lysis followed by RT-
PCR (Shin et al. 2002), and detected in 29/55 (53 percent) patients with hepatocellular 
carcinoma using immunomagnetic separation technique to isolate CTC followed by RT-
PCR (Waguri et al. 2003). 
Furthermore hTERT mRNA has been detected in the plasma samples of CRC 
patients.(Lledo et al. 2004)  peripheral blood samples of 50 patients using real time PCR, 
it was found that 82% of CRC patients had hTERT mRNA expression values higher than 
the maximum values of normal control and the sensitivity and the specificity of the assay 
were 98% and 64% respectively. The fact that plasma samples alone were used in this 
study, without an attempt to first isolate tumour cells by means of immunomagnetic 
separation, could explain the high level of detection of hTERT expression, as 
transcription of telomerase from non-tumour sources such as activated lymphocytes 
would have been possible. 
In 2007 Uen et al used a (Uen et al. 2007) Membrane-arrays consisting of a panel of 
mRNA markers that included hTERT, CK19, CK20, and CEA mRNA were used to 
detect CTCs in the peripheral blood of 194 stage II CRC patients who underwent 
potentially curative resection. Digoxigenin (DIG)-labelled cDNA were amplified by RT-
PCR from the peripheral blood samples, which were then hybridized to the membrane-
array. All patients were followed up regularly, and their outcomes were investigated 
completely. Fifty-three of 194 (27.3%) stage II patients were detected with the expression 
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of all 4 mRNA markers using the membrane-array method. After a median follow up of 
40 months, 56 of 194 (28.9%) developed recurrence/metastases postoperatively. 
Univariately, postoperative relapse was significantly correlated with the depth of invasion 
(P < 0.001), the presence of vascular invasion (P < 0.001), the presence of perineural 
invasion (P = 0.048), the expression of all 4 mRNA markers (P < 0.001), and the number 
of examined lymph nodes (P = 0.031). Meanwhile, using a multivariate logistic 
regression analysis, T4 depth of tumour invasion (P = 0.013), the presence of vascular 
invasion (P = 0.032), and the expression of all 4 mRNA markers (P < 0.001) were 
demonstrated to be independent predictors for postoperative relapse. Combination of the 
depth of tumour invasion, vascular invasion, and all 4 mRNA markers as predictors of 
postoperative relapse showed that patients with any 1 positive predictor had a hazard 
ratio of about 27-fold to develop postoperative relapse (P < 0.001; 95% CI = 11.42-
64.40). The interval between the detection of all 4 positive molecular markers and 
subsequently developed postoperative relapse ranged from 4 to 10 months (median: 7 
months). Furthermore, the expression of all 4 mRNA markers in all stage II CRC 
patients, or either stage II colon or rectal cancer patients were strongly correlated with 
poorer relapse-free survival rates by survival analyses (all P < 0.001). This study 
concluded that  the constructed membrane-array method for the detection of CTCs is a 
potential auxiliary tool to conventional clinicopathological variables for the prediction of 
postoperative relapse in stage II CRC patients who have undergone curative resection. 
This study is the first one to study the prognostic value of hTERT mRNA as a tumour 
marker as the patients were followed up over a period of 40 months. 
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2)  The second explanation is the duration of storage; the samples in this study were 
stored at a temperature of -80
C 
for a period ranging between few days to few months; the 
long duration of the samples could have degraded the RNA present in the samples. 
The third explanation for the discrepancy in the results, are the conditions of RT-PCR; 
i.e. single or multiplex, number of PCR cycles and if the PCR is standard, nested or real 
time.  RT-PCR is a very sensitive technique that could give variable results depending on 
the conditions applied, the previous studies used different condition, hence the 
discrepancy in their results, although it is hard to compare between their results as each 
study dealt with cancers of different origins.  
 
At the end of this chapter it is recommended that there is an urgent need to define a 
standard technique, not requiring excessive time and labour input, which can be utilised 
by different groups to undertake large, well-controlled, randomized studies on the 
markers with most promise. 
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CHAPTER 5 
 
Detection of circulating tumour cells in the peripheral blood of 
CRC patients 
 
 
This chapter describes the use of the TeloTAGGG PCR-ELISA to identify circulating 
colorectal tumour cells 
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5.1 Introduction  
 
Nearly half of all CRC patients who undergo curative resection relapse as a result of 
occult metastases (the presence of CTC). In 1869 Ashworth  as cited in Ghossein and 
Bhattacharya (Ghossein and Bhattacharya 2000) was the first to describe CTC. CTC are a 
potential cause of metastases and subsequently disease relapse particularly following 
surgery; therefore the presence or absence of CTC could be an important prognostic 
factor, and an indicator for the decision concerning adjuvant treatment and follow-
up.(Hardingham et al. 1995)   
Telomerase has been used as a diagnostic marker to detect CTC in tissue, bone marrow 
and blood samples (section 1.6). It has the advantage of being both highly cancer specific 
and an indicator for the detection of viable tumour cells. 
The aims of this study were to:  
1) Determine the prognostic value of telomerase activity in CTC in a previous cohort 
of patients with CRC. 
2) Assess the validity of using the TeloTAGGGTM Telomerase PCR ELISA to 
identify CTC. 
5.2 Prognostic value of telomerase activity in CTC  
 
A previous retrospective study was undertaken on a cohort of 34 patients who underwent 
curative resection for CRC in Hull.  Peripheral blood samples were taken pre- and 1 week 
post operatively from all patients and from 10 healthy normal controls with the same age 
and sex-match. A mononuclear cell preparation was made by density centrifugation, 
epithelial tumour cells were isolated using Dynabeads coupled with Ber-EP4 and 
telomerase activity was assessed using TeloTAGGG PCR-ELISA assay as mentioned in 
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the methods and material chapter section 2.3 and 2.4. The study was carried out by Dr R 
Loveday (University of Hull) (Loveday et al. 2004) in order to detect the presence of 
CTC via telomerase activity in the pre and post operative samples and to determine its 
diagnostic value. 
In this thesis the same patients were followed up over a period of time and the mortality 
and recurrence rates of those patients were correlated with presence of CTC as assessed 
by telomerase activity. 
5.2.1 Results 
 
Thirty four patients underwent a surgical resection for CRC. The clinicopathological data 
and telomerase status are shown in Table 5.1. 
In this study there were 22 males (65%) and 12 (35%) females, the mean age was 64 
(range 30-81). Half of the tumours were located in the rectum and the remaining cases 
were distributed throughout the colon. In this study 15% of the tumours were Dukes A, 
35% Dukes B, 29% Dukes C and 21% Dukes D. The mean time from diagnosis to last 
follow up was 47.5 months. Telomerase activity was detected in 32% of the pre-operative 
samples and 56% of the post-operative samples and was not detected in any of the 
healthy control samples. CTC presence did not correlate to the tumour site or Dukes 
stage. Seventeen (50%) patients developed recurrence or metastases with a mean time of 
18.2 months. Three patients out of 11 (27%) were positive for CTC in their pre-operative 
sample, and 8 out of 19 (42%) with positive CTC in their post-operative samples died as 
a result of metastases. 
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Table 5.1: Patients’ clinicopathological data 
Patient 
No. Tumour Site Dukes Follow up Recurrence Pre-op CTC Post-op CTC 
1 Rectum A 58 No Positive Positive 
2 Rectum A 48 Yes Negative Negative 
3 Rectum A 68 No Positive Negative 
4 Sigmoid A 50 No Negative Positive 
5 Rectum A 50 Yes Negative Positive 
6 Rectum B 57 Yes Positive Positive 
7 Transverse colon B 55 No Negative Negative 
8 Rectum B 15 Yes Positive Positive 
9 Sigmoid B 42 Yes Positive Negative 
10 Descending colon B 50 No Positive Positive 
11 Sigmoid B 51 Yes Negative Positive 
12 Rectum B 53 No Negative Negative 
13 Sigmoid B 53 No Negative Negative 
14 Sigmoid B 54 No Negative Positive 
15 Sigmoid B 53 No Negative Negative 
16 Sigmoid B 50 No Negative Negative 
17 Sigmoid B 49 No Positive Positive 
18 Rectum C 58 No Positive Positive 
19 Sigmoid C 58 No Negative Positive 
20 Rectum C 67 No Positive Positive 
21 Rectum C 47 Yes Negative Negative 
22 Sigmoid C 53 Yes Positive Negative 
23 Sigmoid C 59 No Negative Positive 
24 Rectum C 56 Yes Negative Positive 
25 Rectum C 48 No Negative Positive 
26 Rectum C 57 Yes Negative Negative 
27 Rectum C 53 No Negative Positive 
28 Rectum D 56 Yes Negative Positive 
29 Rectum D 31 Yes Negative Negative 
30 Sigmoid D 29 Yes Negative Negative 
31 Sigmoid D 21 Yes Negative Negative 
32 Rectum D 6 Yes Negative Negative 
33 Transverse colon D 8 Yes Negative Positive 
34 Sigmoid D 53 Yes Positive Positive 
M: male, F: female (Loveday et al. 2004) 
 
Five out of 11 patients (45%) with positive CTC in their pre-operative samples and 8 out 
of 19 patients (42%) with positive CTC in their post operative samples developed 
recurrence or metastases. Eight (23.5%) patients had CTC detected in both pre and pos-
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operative samples; 3 of which developed recurrence or metastases and 2 died of 
metastatic disease. 
The above results showed no significant statistical correlation between the presence of 
CTC in peripheral blood and recurrence or mortality rates. 
5.2.2 Conclusion 
 
This study has demonstrated that the use of immunomagnetic separation of the tumour 
cells from the PBMC, and the use of the TeloTAGGG PCR-ELISA assay for the 
detection of CTC and telomerase activity in the peripheral blood of CRC patients to be 
specific where 32% of pre-operative samples and 56% post-operative samples were 
positive. However this small cohort study has failed to demonstrate any correlation 
between the presence of CTC and the disease stage. The presence of CTC in peripheral 
blood was shown to have no prognostic value after a median follow up of 47.5 months. 
Based on the result of this small cohort study it was decided to perform a prospective 
study on a larger scale in order to confirm the findings. 
5.3 Detection of Telomerase activity in circulating epithelial cells by Telomerase 
PCR ELISA 
5.3.1 Methods 
 
A prospective study was undertaken on a cohort of 98 patients who underwent curative 
resection for CRC. Peripheral blood samples were taken pre- and 4-6 weeks post 
operatively and if the patients were receiving chemotherapy further blood samples were 
obtained on a monthly interval. Methods and materials described in section 2.3 and 2.4 
were used for cell isolation and telomerase activation. 
 
 118 
5.3.2 The conception of TeloTAGGG Telomerase PCR ELISA 
 
 1) Telomeric Repeat Amplification Protocol assay (TRAP) 
A biotin-labelled synthetic P1-TS-primer and a 216 bp internal standard (IS) are provided 
in the kit. The IS is an internal amplification control that allows detection of Taq DNA 
polymerase inhibitors. It has been reported that some tissue samples contain inhibitors of 
Taq DNA polymerase (Wright et al. 1995), thus giving false-negative results when 
analysed for telomerase activity. Therefore an IS has been used in order to identify false 
negative tumour samples. 
In this first step if telomerase is present in patients’ samples the enzyme will add 
telomeric repeats (TTAGGG) to the 3’-end of the biotin-labeled synthetic P1-TS-primer. 
The elongation products as well as the IS are subsequently amplified by PCR using the 
primers P1-TS and the anchor-primer P2 to allow highly sensitive detection of telomerase 
activity.  
To confirm the specificity of product formation in the TRAP assay, samples were split 
into two groups. One group was treated with heat for 10 min at 85°C to inactivate 
telomerase protein prior to the TRAP assay. 
2) ELISA (Enzyme Linked Immuno-Sorbent Assay) (see section 2.4): 
Briefly the PCR products were denatured and hybridized separately to digoxigenin-
(DIG)-labeled detection probes, specific for the telomeric repeats (P3-T) and for the (IS) 
(P3-Std), respectively. The resulting products were then immobilized via the biotin label 
to a streptavidin-coated microplate, and subsequently detected with an antibody against 
digoxigenin that is conjugated to horseradish peroxidase (Anti-DIG-HRP). A peroxidase 
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substrate TMB (3,3’,5,5’-tetramethylbenzidine)is then added to the plate which induces a 
colour change that can be measured on a plate reader A450nm-A690nm. 
5.3.3 Data analysis 
 
Negative Control 
Controls should be considered as negative only when their values are less than 0.1A450nm-
A690nm units when analyzed with the telomerase specific detection probe (P3-T). If the 
telomerase-specific values are higher than that, the entire experiment —including the 
TRAP reaction— should be repeated with prolonged heat. 
Positive Control 
The values for low and high controls should be in the range of 0.2–0.5 and 2.0–4.0 
absorbance unit (after 10 min substrate reaction) respectively as set by the manufacturer 
protocol. 
Samples 
Samples are to be considered as telomerase-positive if the difference in absorbance (ΔA) 
between the negative controls and samples is higher than the twofold background activity 
(background activity = value of negative control or heat-treated sample). 
5.3.4 Results  
 
The full details of the patients’ clinicopathological status were shown previously in 
chapter 4 (Table 4.1 chapter 4). 
The patients’ samples, positive and negative controls were arranged in the ELISA plate in 
the following order as shown in Figure 5.1 
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Figure 5.1 Samples distribution on ELISA plate 
H: High positive control TB: Telomerase buffer  IS: Internal standard 
L: Low positive control S: heat treated samples                  
LB: Lysis buffer  S: None heat treated samples  
 
In the experiment PBMC lysates were extracted from patients’ samples, and were kept 
frozen before they were used for the TeloTAGGG assay. The protein concentration was 
determined using Coomassie Plus kit (section 2.4.2).  
The study protocol set the level of protein content in the sample lysates to be 0.2µg/µl 
hence the samples were then standardised to 0.2µg/µl by dilution with lysis buffer. The 
manufacturer’s recommendation for the TeloTAGGG assay is 0.5-10µg total protein per 
tube. Table 5.2 shows that some samples had sufficient protein concentration for 
TeloTAGGG assay with exception of samples highlighted in red. The low protein 
concentration in some samples could be due to its relatively low cell numbers in the CTC 
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preparation during storage in liquid nitrogen before extracting the cell lysates and/or due 
to the fact that the cell lysates were frozen for more than 4-6 weeks before using them for 
TeloTAGGG assay and hence some protein may have been lost. 
Table 5.2: Protein concentration of cell lysates 
Sample number Sample Concentration µg/µl 
19#5 4.2 
19#6 0.1 
21#5 0.1 
21#6 3.1 
28#2 2.8 
31#2 3.6 
34#2 3.5 
36#3 2 
39#2 0.3 
41#2 3.2 
44#2 0.1 
45#2 0.6 
53#1 3 
54#2 0.1 
56#1 4 
57#3 0.1 
62#1 0.2 
63#1 2.6 
N.B. The first number indicates the patient number and the #x indicates the number of 
sample, for an example 19#6 means; blood sample number 6 from patient number 19  
 
Table 5.3 shows the results of the TeloTAGGG assay, where the high and low controls 
were positive when telomerase and internal standard (TB, IS) buffers were used in fact 
both were higher than expected as the values for low and high controls should be in the 
range of 0.2–0.5 and 2.0–4.0 respectively as set by the manufacturer protocol. 
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Furthermore the lysis buffer tube was negative indicating that there was no 
contamination.  
Looking at the samples inactivated with heat (negative controls) most of them had 
negative results with the exception of the samples highlighted in red; this could be as a 
result of insufficient inactivation with heat or could represent some sort of contamination 
hence the associated results should be considered carefully. Most of the IS (the positive 
controls) were significantly positive and were 2 fold higher than that of the negative 
controls (lysis buffer and heat treated samples) with the exception of the samples 
highlighted in gray, this could be due to the presence of telomerase inhibitors in these 
samples.  In the TB samples only sample 19#5 was positive where it was 2 fold higher 
than the negative control. 
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Table 5.3: An example TeloTAGGG assay 
  C+ IS C + TB Sample no. HT + TB NHT + TB NHT + IS 
H 2.599 2.93 19#5 0.046 0.222 2.577 
L 1.657 1.893 19#6 0.066 0.036 2.682 
LS 0.04 0.056 21#5 0.075 0.052 3.039 
   21#6 0.074 0.049 2.52 
   28#2 0.045 0.051 0.054 
   31#2 0.49 0.041 0.048 
   34#2 0.065 0.067 1.832 
   36#3 0.083 0.058 2.344 
   39#2 0.139 0.059 2.702 
   41#2 0.046 0.045 0.055 
   44#2 0.081 0.059 2.951 
   45#2 0.114 0.045 2.82 
   53#1 0.08 0.07 2.325 
   54#2 0.086 0.059 2.814 
   56#1 0.124 0.083 2.179 
   57#3 0.143 0.057 3.11 
   62#1 0.051 0.055 2.837 
   63#1 0.05 0.064 2.828 
H: High 
L: Low 
LS: Lysis buffer   
C: Control  
IS: Internal standard 
HT: Heat treated   
TB: Telomerase buffer    
NHT: None heat treated 
 
The same experiment was repeated using another set of 18 samples, where the cell lysates 
were more than 4-6 weeks old. Some samples had a very low protein concentration with 
the exception of few samples highlighted in pink which meant that the samples were used 
undiluted for the PCR reaction. Tables 5.4 and 5.5 demonstrate the results of these 
experiments. 
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Table 5.4: Protein concentrations 
Sample number Sample Concentration µg/µl 
19#4 0.16 
21#2 0.1 
21#4 0.07 
23#2 0.16 
24#2 0.09 
35#1 0.18 
35#2 3.4 
35#3 0.3 
36#1 0.7 
36#2 0.7 
36#3 3.4 
41#3 2.8 
46#1 0.08 
46#2 3.1 
46#3 0.1 
47#1 0.3 
47#2 0.8 
47#3 0.25 
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Table 5.5: TeloTAGGG assay 
  C + IS C + TB Sample no. HT + TB NHT + TB NHT + IS 
H  1.35 0.3 19#4 0.038 0.04 2.85 
L 1.12 0.08 21#2 0.062 0.056 3.13 
LB 0.9 0.04 21#4 0.042 0.04 4.95 
   23#2 0.041 0.043 2.52 
   24#2 0.04 0.047 3.12 
   35#1 0.034 0.037 0.7 
   35#2 0.035 0.041 0.045 
   35#3 0.036 0.032 1.91 
   36#1 0.036 0.039 0.399 
   36#2 0.028 0.041 0.157 
   36#3 0.037 0.041 0.587 
   41#3 0.033 0.043 0.033 
   46#1 0.039 0.042 2.39 
   46#2 0.04 0.042 0.042 
   46#3 0.035 0.039 1.61 
   47#1 0.039 0.042 1 
   47#2 0.039 0.036 0.503 
   47#3 0.038 0.062 0.037 
H: High 
L: Low 
LS: Lysis buffer   
C: Control  
IS: Internal standard 
HT: Heat treated   
TB: Telomerase buffer    
NHT: None heat treated 
 
Table 5.5 demonstrates that the standard positive high and low controls were positive, 
again the low control is higher than it should be according to the manufacturer’s 
instructions, which could be due to contamination. All of the samples cell lysates used 
with TB were negative and some of the cell lysates when used with the IS showed 
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negative results. In this experiment increasing the protein content of the sample lysates 
did not increase the ability of detecting CTC using the TeloTAGGG assay. 
In the next step it was decided to extract the cell lysates and use them for TeloTAGGG 
assay immediately without any storage period in order to prevent any potential protein 
degradation.  
Table 5.6: TeloTAGGG assay 
  C + IS C + TB Sample no. HT + TB NHT + TB NHT + IS 
H  3.330 2.8 44#1 0.091 0.052 2.156 
L 2.835 1.58 67#1 0.085 0.078 1.797 
LB 0.04 0.032 67#2 0.061 0.072 1.952 
   68#1 0.065 0.055 2.134 
   68#2 0.083 0.048 2.133 
   69#1 0.132 0.047 2.695 
   69#2 0.154 0.043 2.498 
   70#1 0.138 0.039 2.309 
   71#1 0.077 0.059 1.141 
   72#1 0.083 0.044 1.367 
   73#1 0.068 0.043 1.511 
   74#1 0.066 0.481 1.64 
   75#1 0.073 0.418 1.402 
   76#1 0.12 0.318 2.528 
   77#1 0.108 0.254 1.741 
   78#1 0.176 0.169 1.477 
   79#1 0.147 0.181 1.633 
   80#1 0.056 0.062 0.674 
H: High 
L: Low 
LS: Lysis buffer   
C: Control  
IS: Internal standard 
HT: Heat treated   
TB: Telomerase buffer    
NHT: None heat treated 
Four patients’ samples with acceptable protein concentrations, according to the protocol, 
when used with TB, showed positive results. 
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 Two samples were higher than their negative controls by 2 folds (blue colour) and the 
remaining (highlighted in red) where only 2-3 times higher than there negative controls 
(0.318/0.120), (0.254/0.108) (Table 5.6). 
To verify the results 2 further TeloTAGGG assay were undertaken using freshly 
extracted cell lysates: 4 samples out of 35 were telomerase positive. The positive and 
negative controls on the plates all gave the appropriate values. After these two 
experiments 3 further TeloTAGGG kits were used on freshly extracted cell lysates from 
46 samples, all of the 3 assays failed to detect any telomerase activity. When the positive 
standard controls and the cell lysates used with IS buffers were studied none of them 
showed any positive results which raise up the suspicion of a technical failure of the kit 
and and as a result the experiment was ended.  
Although the aim of this experiment was to correlate the telomerase activity in the CTC 
samples, stage of the disease and its prognosis. It was difficult in this study to make any 
correlation as there were only few positive results and not possible to analyse all samples 
as a result of the faulty batches used later in the experiments. The majority of the patients 
analysed were in the Dukes’ C stage and only one patient has Dukes’ A Table 5.7 shows 
the clinicopathological status of the patients with the positive results. 
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Table 5.7: Patients with positive telomerase activity 
NO SEX AGE DUKE METS DEATH 
14 M 80 A N N 
16 F 72 C N N 
19 M 64 C N N 
23 F 53 D  N N 
24 F 59 D LIVER N 
71 M 47 C N N 
74 F 64 C N N 
75 M 56 D N N 
76 M 61 B N N 
77 M 72 D LIVER N 
79 F 78 B N N 
84 M 68 C N N 
92 F 72 B N N 
93 F 69 C N N 
 
5.4 Summary  
 
In this chapter the aim was to detect telomerase activity using TeloTAGGG assay, in total 
assays were performed on independent 132 samples, fourteen samples showed positive 
telomerase activity (11%). In this study 36 samples, in which the cell lysates had been 
stored for ≥ 4-6 weeks before use, were assayed with only one positive result (3%). A 
further 71 samples were analysed immediately after cell lysing and 9 (13%) were found 
to be positive for telomerase activity. One of these assays was performed in collaboration 
with a colleague (Mr. D Beral) working in the same laboratory, where telomerase activity 
was detected in 4 out of 25 samples tested, the cell lysates used in this assay were stored 
for less than 4 weeks and when the assay was repeated 2 and 4 weeks after the first 
experiment the same samples gave negative results. In fact in this study it was not 
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possible to get positive results on repeated samples, which strongly suggests that storage 
leads to the loss of telomerase activity.  
5.5 Conclusions and recommendations 
 
In this experiment telomerase activity was detected in CTC however some difficulties 
were encountered using the above kit, and this experiment has raised a number of 
questions.  
5.5.1 The validity of IMS technique 
 
The efficiency of IMS technique in isolating CTC from PBMC has been checked by a 
colleague (Mr. D. Beral) who clearly demonstrated the ability of Dynabeads covered with 
BerEP4 antibody to isolate BerEP4 expressing cells. Cancer cell that express BerEP4 and 
others that do not express BerEP4 were mixed with Dynabeads covered with BerEP4 
antibody and this was observed under the microscope. The pictures showed that the cell 
lines that express BerEP4 were attached to the Dynabeads coated with the relevant 
antibody (Figure 5.2 & 5.3)  
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Figure 5.2 BerEP4-Dynabeads with no cells attached after mixing with BerEP4-
negative cell line (CaCO-2) and extraction with magnet. Provided by D. Beral 
 
 
Figure 5.3 BerEP4-Dynabeads attached to cells after mixing with a BerEP4-positive 
cell line (MCF-7) and extraction using the magnet. Provided by D. Beral 
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5.5.2 Protein concentrations of cell lysates used in TeloTAGGG assay 
 
The study protocol set the level of protein content in the sample lysates to 0.2µg/µl using 
the modified Bradford assay. The manufacturer’s recommendation for the TeloTAGGG 
assay was 0.5-10µg total protein per tube, therefore with 3µl per reaction tube there was 
0.6µg total protein per tube.  This level was deliberately chosen to be at the lower end of 
the recommended range in order to reduce the risk of false positive results and had been 
used previously within this laboratory (Loveday et al. 2004). After initial assays on study 
cohort samples it became apparent that very few samples were giving positive results.  It 
was hypothesised that the protein content may have been set too low.  To test this, 
undiluted samples were used in order to increase the protein content in the lysates but 
none of the samples gave positive results for telomerase thus not supporting the 
hypothesis that the protein content was set too low. 
5.5.3 The duration of samples storage 
 
In this experiment 36 samples in which the cell lysates had been stored for ≥ 4-6 weeks 
before use were assayed with only one positive result (3%). A further 71 samples were 
analysed immediately after cell lysing and 9 (13%) were found to be positive for 
telomerase activity. In a previous experiments performed by Mr. Beral the 4/25 positive 
samples failed to reproduce positive results after storage for an additional 2 and 4 weeks. 
Together these experiments strongly suggest that the fresher the cell lysates the more 
likely they are to produce positive results. As it seems that there is a degree of protein 
degradation during the period of cell lysates storage. This conclusion is supported when 
the data was compared to Loveday study (Loveday et al. 2004), as in this study the 
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isolated CTC were lysed only few days after storage and TRAP assay was performed on 
the samples within 2-4 weeks of storing the cell lysates.  
Furthermore it was hypothesised that the longer the CTC are frozen in liquid nitrogen the 
higher the chance of protein degradation, hence the lesser the chance of telomerase 
detection. To investigate this hypothesis the samples were divided into two groups. The 
first group contained the patients with positive telomerase results and the second group 
was the one with negative results. The time between CTC isolation and their lysis was 
determined for each group. It was shown that the samples with the positive telomerase 
were stored for an average period of 28 days (range 2-60) whereas the negative 
telomerase group was stored for an average of 73 days (range 1-275), fully supporting the 
above hypothesis. Furthermore the results of Gauthier et al  study support this hypothesis  
(Gauthier et al. 2001) where 8/11 (72%) of Duke’s A patients were telomerase positive, 
in this study the samples were lysed and stored without a period of storage to the isolated 
epithelial cells.  
5.5.4 The validity of the TeloTAGGG kits 
 
The manufacturers were contacted for advice regarding the persistently negative results 
in the last batch to see if any systematic error in performing the assay could be identified, 
despite having followed the manufacturers’ instructions.  No such error was able to be 
identified, however it was noted that the kit was subsequently withdrawn from the 
market, with no explanation. 
In conclusion isolated CTC should be stored in liquid nitrogen for only a short period of 
time before extracting cell lysates and the cell lysates should be prepared for assay 
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immediately before performing the assay as long as there is no faulty technique with the 
assay used.  
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CHAPTER 6 
Discussion  
In this chapter the wider implications of the work reported in this thesis will be discussed 
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6.1 CTL response against tumour cells  
 
The catalytic subunit of telomerase (hTERT) has been widely considered to be a 
universal tumour antigen and has the potential to be a major factor in future cancer 
immunotherapy since it is expressed by most human tumours but is absent in the majority 
of normal tissues. It also plays a universal role in tumourgenesis, and its peptide 
sequences have been recognized by the T cell repertoire in an MHC restricted manner. 
Seven synthetic peptides derived from hTERT that induce specific CTL response have 
been investigated to date; four of these peptides react with CTL in an HLA-A2 restricted 
manner (Vonderheide et al. 1999) (Scardino et al. 2002); a fifth peptide acts in an HLA-
A3 restricted manner (Vonderheide et al. 2001) and the final two peptides bind in an 
HLA-A24 restricted manner (Arai et al. 2001).  
In this thesis 2 peptides were used [hTERT (I540 and P865)] that react with CTL in an 
HLA-A2 restricted manner and hTERT (K973) that acts in an HLA-A3 restricted 
manner. 
Thirty patients with CRC were studied for CTL reaction. The results showed that 70% of 
the patients were HLA-A2 positive, 10% HLA-A3 positive and 20% were HLA2/A3 
positive. Twenty eight pre-operative samples and thirteen post-operative samples were 
analysable, 71% of pre-operative samples and 61% post-operative samples had CTL 
reaction towards hTERT peptides whether in an HLA-A2, HLA-A3 or HLA2/A3 
restricted manner.  
On analysis the results appear to be higher than the results obtained by Titu et al who 
studied the T-cell response against the same two HLA-A2 specific peptides of hTERT 
(I540 and P865) in 37 CRC patients and 12 normal controls (Titu et al. 2004). Their 
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results demonstrate that CTL active against hTERT are present in only 20% of CRC 
patients. There are two explanations for the discrepancy in the results of both studies; the 
first explanation is that in our study the specific number of spots was calculated by 
subtracting the number of cells present in the well with no peptide (negative control well) 
from the number of cells present with peptides, and samples were considered positive 
only if the value was ≥ 1. Whereas in the study of Titu and colleagues the samples were 
considered positive only when the number of the spots with peptides were ≥ 16 spots 
which is the threshold level calculated from the cells with no peptides. In his study the 
mean and the standard deviation was calculated for the number of spots in the control 
wells with no peptides, and a threshold level was set by adding 3 standard deviations to 
the mean, his method was previously used by Pittet et al. (Pittet et al. 1999). The second 
explanation is that in this study another hTERT peptide was added which might have 
contributed for the higher results. 
Our results were more similar to Amarnath et al (Amarnath et al. 2004) results who 
investigated the specific CD8
+
 CTL response in primary breast cancer patients. In her 
study of 45 patients using the same methods and peptides as utilised in this thesis, CTL 
recognized HLA-A2 P540 and P865 peptides in 76% and 47% respectively, CTL 
recognized both HLA-A2 peptides in 47% of patients and CTL recognized HLA-A3 
K973 peptides in 71% patients.  
Furthermore our results appear to contradict those of Vonderheide et al. (Vonderheide et 
al. 2001) who were unable to detect a CTL response against hTERT-P540 peptide in 
freshly isolated PBMC from either cancer or normal controls. This could be due to a 
number of reasons; firstly in their experiments they analysed samples from 8 patients 
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only which make it possible to have missed the ones with circulating CTL; secondly the 
patients analysed were of various histologies ( multiple myeloma, melanoma, lymphoma 
and prostate cancer) and none of them had CRC which, makes it difficult to compare 
directly between the two studies; and finally in their study only one hTERT peptide was 
used compared with 3 peptides in the present work.  
6.1.1 Clinical trials of hTERT immunotherapy and future work 
 
Multiple phase 1 clinical trials of hTERT immunotherapy have already been conducted in 
patients with advanced cancer, each of which test the hypothesis that hTERT-specific 
vaccination can overcome immunological tolerance and trigger anti-tumour T cell 
responses in vivo. Main findings include the induction of hTERT-specific T cells in the 
absence of toxicity. Objective clinical responses have been rarely reported, but no study 
yet has been statistically powered to measure this endpoint adequately. 
Vonderheide and colleagues in 2004 has taken the first step into applying the above 
laboratory results into clinical practice when they performed a Phase I clinical trial to 
evaluate the clinical and immunological impact of vaccinating 5 patients with hormone 
refractory metastatic prostate cancer and 2 patients with metastatic chemotherapy 
resistant breast cancer with the HLA-A2-restricted hTERT I540 peptide presented with 
dendritic cells (Vonderheide et al. 2004). hTERT-specific T lymphocytes were induced in 
4 of 7 patients with both cancers after vaccination with dendritic cells pulsed with hTERT 
peptide. Tetramer-guided high-speed sorting and polyclonal expansion achieved highly 
enriched populations of hTERT-specific cells that killed tumour cells in an MHC- 
restricted fashion. Partial tumour regression in 1 patient was associated with the induction 
of CD8+ tumour infiltrating lymphocytes. These results demonstrate the immunological 
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feasibility of vaccinating patients against telomerase and provide rationale for targeting 
self-antigens with critical roles in oncogenesis.  
In another clinical trial, 19 HLA-A2 positive women with metastatic breast cancer were 
vaccinated subcutaneously with hTERT I540 peptide emulsified in Montanide adjuvant 
and administered with granulocyte macrophage colony stimulating factor (GM-CSF) up 
to eight times (Domchek et al. 2006). Based on in vitro analyses performed on peripheral 
blood obtained before and after treatment, 68% of patients were found to have responded 
immunologically. Tumour-infiltrating lymphocytes (TIL) were evident after, but not 
before vaccination, with 4-13% of post-vaccine CD8+ TIL specific for hTERT I540. 
Induction of TIL manifested clinically with tumour-site pain and pruritis and 
pathologically with marked tumour necrosis. Peripheral blood hTERT-specific CD8+ T 
cells were also induced and shown in vitro to proliferate, produce IFN-γ, and lyse 
tumours. An exploratory landmark analysis revealed an association between an hTERT-
specific CD8+ T cell immune response and overall survival in these patients. 
Interestingly, these clinical and immunological findings were not observed in an earlier 
study where 14 patients with metastatic cancers (melanoma, renal, colon cancers) and 
were injected with hTERT I540 in Montanide without GMCSF. Although induction of 
I540-specific CTL was observed in 50% of patients without toxicity, CTL isolated ex 
vivo failed to lyse tumours endogenously expressed telomerase and no clinical benefit 
was observed (Parkhurst et al. 2004). With the goal of inducing both CD4 and CD8 T 
cells responses in patients, another trial enrolled 26 patients with non-small cell lung 
cancer who were repeatedly injected with 2 hTERT peptides; I540 (HLA-A2 peptide) and 
E611 (DR, DP and DQ peptide) and GM-CSF (Brunsvig et al. 2006). Treatment was well 
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tolerated and immune responses against E611 were detected in 46% of evaluable patients. 
A complete tumour response was observed in one patient who developed an immune 
response following treatment. In a second trial at the same institution, patients with non-
resectable pancreatic cancer were immunised with E611 peptide alone, with GM-CSF, 
with specificT cell responses detected in 63% of patients (Bernhardt et al. 2006.) Median 
survival for immune responders was significantly higher than that for non-responders. 
To test the immunogenicity of low-affinity hTERT peptides, two trials enrolled HLA-A2 
positive patients. Patients were given subcutaneous injections of 572Y modified peptide 
in Montanide adjuvant. Nineteen patients with chemotherapy refractory and progressing 
malignant tumours advanced were treated in a phase I trial (Mavroudis et al. 2006), and 
22 patients with advanced non-small cell lung cancer were treated in a follow up 
expanded safety trial Peptide specific T cell responses were observed in the majority of 
patients without toxicity. In the second trial, estimated overall survival was 30 months for 
immunological responders vs. 4 months for non-responders (Bolonaki et al. 2007). 
Another trial testing both I540 and 572Y peptides loaded onto autologous B cells as a 
vaccine was tested in 15 patients with advanced prostate cancer. Again, immune 
responses were observed without toxicity (Cortez-Gonzalez and Zanetti 2007). 
Finally, in the first clinical trial evaluating immunotherapy with full-length hTERT (Su et 
al. 2005), 20 patients with metastatic prostate cancer were administered autologous 
dendritic cells transfected with mRNA encoding hTERT with or without the inclusion of 
a chimeric construct of lysosome-associated membrane protein-1 (LAMP). Induction of 
hTERT-specific CD8 T cells was observed in all but one patient, with up to 1.8% of 
CD8+ T cells exhibiting hTERT specificity. Antigen-specific immune measurements 
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were higher in patients immunised with chimeric LAMP hTERT. Treatment was 
associated with an increase in the prostate-specific antigen doubling time and molecular 
clearance of circulating micrometastases. 
The above published reports of hTERT vaccination offer preliminary evidence to support 
the notion that hTERT can function as a TAA target for novel vaccines. If, in further 
studies with second-generation vaccines, optimal immunity can be successfully elicited in 
cancer patients without the induction of severe autoimmunity, hTERT clearly becomes a 
prime candidate for a widely applicable cancer vaccine.  
6.2 Telomerase and CTC 
 
Despite the modest improvements in patient survival from CRC in the last few decades, 
the overall five-year survival rate remains at 40-45 %.  Surgical resection is the mainstay 
of treatment for CRC, but nearly half of all patients who undergo a potentially curative 
resection will relapse because of undetected micrometastases.  The fact that the overall 
survival rate remains poor, strongly suggests that the dissemination of these cells occurs 
early in the disease process and emphasizes the need for finding feasible diagnostic 
methods with sufficient sensitivity and specificity.  
In this thesis two well described techniques in the literature were used to detect CTC in 
the peripheral blood of CRC patients utilising telomerase activity and its catalytic 
subunit. In the first experiment peripheral blood samples were collected from 105 
patients with curative CRC before and after surgery and CTC were isolated from the 
PBMC using the immunomagnetic separation technique and a TeloTAGGG Telomerase 
PCR ELISA
PLUS
 assay was done on the isolated cell lysates in order to detect telomerase 
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activity. In the second experiment serum samples of CRC patients were used to detect the 
expression of hTERT mRNA utilising RT-PCR technique. 
In the first telomerase assay performed only 14 samples demonstrated telomerase 
activity, these 14 samples were either freshly prepared or frozen for less than 4 weeks 
compared with the remaining negative samples. It was concluded that the longer the 
samples are kept frozen the higher the chance of protein degradation. In this experiment a 
correlation between the disease stage and the presence of telomerase activity or its 
prognostic value could not be studied as the reliability of the test could not be confirmed. 
Furthermore, it was not possible to find a standard reliable technique which could detect 
hTERT mRNA in serum samples of CRC patients as hTERT mRNA was only detected in 
6 samples out of all other samples. This could be again as a result of the long duration of 
samples storage.   
The expression of hTERT in peripheral blood samples was  reported in previous studies, 
where it has been detected in blood samples of patients with hepatocellular carcinoma 
(Miura, N. et al. 2003) (Waguri et al. 2003), breast cancer (Chen et al. 2000), gastric 
cancer (Shin et al. 2002), and CRC patients (Lledo et al. 2004) . 
Furthermore recently (Uen et al. 2007) was the first to report the prognostic value of 
hTERT mRNA as a tumour marker where the patients were followed up over a period of 
40 months. A Membrane-arrays technique was used consisting of a panel of mRNA 
markers that included hTERT, CK19, CK20, and CEA mRNA to detect CTCs in the 
peripheral blood of 194 stage II CRC patients who underwent potentially curative 
resection. Fifty-three of 194 (27.3%) stage II patients were detected with the expression 
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of all 4 mRNA markers. After a median follow up of 40 months, 56 of 194 (28.9%) 
developed recurrence/metastases postoperatively.  
6.3 Conclusion 
6.3.1 Technical issues in CTC detection  
 
CTC detection is all about rare event detection. In metastatic cancer patients, CTC in the 
peripheral circulation occur at an estimated number of one CTC per 1X10
5–7 
peripheral 
blood mononuclear cells. Therefore, most assays apply an enrichment step to increase the 
sensitivity. 
 Another major problem in the routine and automated detection of CTC arises from the 
illegitimate expression of the epithelial cell-related markers and the lack of tumour cell 
specific markers. As the detection of mRNA markers is especially difficult due to the 
sensitivity of mRNA to preparation procedures, the exploration of new marker or markers 
is required.  
Furthermore, tumour cells may lose epithelial features during dissemination through a 
process called epithelial-to-mesenchymal transition (EMT). EMT renders tumour cells to 
become less rigid and more motile thereby facilitating their invasion of stromal tissue. 
(Willipinski-Stapelfeldt et al. 2005) (Yang et al. 2006).  This process is characterised by 
the loss of cell-to-cell adhesion, increased expression of mesenchymal markers, and loss 
of several epithelial markers. Since the epithelial markers that get lost during EMT may 
include markers used for CTC detection, underestimation of the actual CTC number may 
occur. 
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6.3.2 Clinical application of CTC detection in cancer prognosis and treatment  
 
The detection of CTC for CRC in early diagnosis, staging and prognosis is a long term 
dream of researchers and clinicians. As the molecular biology tools became widely 
applicable in the last 15 years, significant achievements were observed. 
Initial results obtained from clinical studies strongly suggest that CTC detection and 
enumeration has indeed prognostic value and can serve as an early marker to assess anti-
tumour activity of cancer treatment. 
A recent study in patients with CRC identified CTC by RT-PCR positivity for both CK-
20 and CEA mRNA. A Hundred and ninety-six patients with curative CRC undergoing 
primary tumour resection were observed over a median follow-up of 1393 days, they 
concluded that the presence of CTC within 24 hours after resection was predictive for 
relapse, in particular when combined with lymph node status (Allen-Mersh et al. 2007). 
Concerning metastatic disease, all studies published so far in which CTC were identified 
through PCR-based methods included numbers of patients too small to draw firm 
conclusions. By contrast, data from studies recruiting large numbers of metastatic 
patients are available using the CellSearch TM Epithelial Cell Kit/CellSpotter TM 
Analyzer. In this method, CTC were isolated from whole blood by IMS using ferrofluids 
coated with epithelial cell adhesion molecule (EpCam) specific antibodies. Subsequently, 
the isolated cells were stained with fluorescent monoclonal antibodies for epithelial cells 
(CK 8, 18, 19), leucocytes (CD45) and a nuclear staining dye, and thereafter enumerated 
using a semi-automated fluorescence microscope. CTC were defined as nuclear cells, 
expressing CK and lacking CD45 expression (Allard et al. 2004). With this procedure it 
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was demonstrated that only one out of 344 (0.3%) healthy and non-malignant subjects 
had ≥2 CTC per 7.5 ml whole blood, while approximately 60–70% of metastatic breast 
cancer patients have ≥2 CTC (Riethdorf et al. 2007) (Cristofanilli et al. 2004). In a 
prospective, multicentre study including 177 metastatic breast cancer patients, a high 
CTC number at baseline, defined as ≥5 CTC per 7.5 ml whole blood, was an independent 
predictor for a poor outcome in terms of progression-free (2.7 versus 7.0 months) and 
overall survival (10.1 versus >18 months) (Cristofanilli et al. 2004). Also, at each 
examined time point after treatment initiation, from 3 weeks onwards, a high CTC count 
was able to distinguish patients with an unfavourable clinical outcome. In addition, 
patients who initially had an increased number of CTC but a low number after the first 
administration of systemic treatment had a better outcome in terms of progression-free 
survival and overall survival compared with patients in whom the number of CTC 
remained elevated (Cristofanilli et al. 2005) (Hayes et al. 2006). This strongly suggests 
that CTC enumeration can serve as an early surrogate marker for response assessment. 
The feasibility of CTC enumeration to guide treatment was further supported by the 
observation that in patients without progression at radiological assessment those patients 
with a high CTC count had a poorer overall survival than patients with a low count. 
Additionally, the inter-reader variability for determining a response on the basis of CTC 
enumeration was smaller than when using radiological imaging (Budd et al. 2006), which 
suggests that CTC enumeration outperforms radiological assessments for response 
evaluation. 
Using the assay mentioned earlier, similar results were recently presented in a multi-
centre study comprising 413 patients with metastatic colorectal carcinoma (Meropol et al. 
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2007). Patients with ≥3 CTC per 7.5 ml blood at base-line fared more poorly than 
patients with less CTC in terms of median progression-free and overall survival; 4.5 
versus 7.9 months and 9.4 versus 18.5 months, respectively. Additionally, a decrease in 
CTC levels 3–5 weeks following treatment initiation was associated with improved 
progression-free and overall survival compared to those patients who remained at high 
CTC levels. 
Also, in patients with hormone-refractory prostate cancer showing prostate specific 
antigen (PSA)-progression and who started chemotherapy, CTC enumeration showed 
encouraging results (Moreno et al. 2007). Using a cut-off level of ≥5 CTC per 7.5 ml 
blood, patients with a low level at base line (43% of the 240 patients) had a better median 
overall survival of 21.4 months compared to patients with an elevated count (10.7 
months). Similar to the studies performed in breast and CRC, a CTC decrease to low 
levels at all time-points assessed was predictive for improved survival, from 2 to 5 weeks 
after starting therapy onwards. 
6.3.3 Future work 
 
Determination of the significance of micrometastatic cell in the peripheral blood of 
Dukes stage B under chemotherapy is still missing. Currently, there are several methods 
available for CTC detection, some of which in clinical studies have been shown to be 
associated with clinical outcome. However, confirmation of the results, which look 
promising at first glance indeed, is required prior to widespread use and having clinical 
impact. In particular, the observation that CTC levels during treatment may serve as 
marker for early assessment of anti-tumour activity is intriguing, but whether this should 
have therapeutic consequences is currently unknown. To solve this question, randomised 
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studies would be required in which patients exhibiting a high CTC count after starting a 
certain treatment are randomly allocated to receive an alternative treatment directly or to 
continue the same systemic therapy and only after radiological progression to be switched 
to the alternative therapy. Such a study can determine whether early switching to another 
type of therapy on the basis of CTC enumeration yields a better outcome. 
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Appendix 4.1: Patients’ data 
No. Sex Age Duke Site Operation Complications Met 
1 M 80 C Rectum APR N N 
2 M 59 C Rectum AR  N N 
3 M 74 A Rt colon AR N N 
4 M 71 B Rt colon Rt hemicolectomy N N 
5 M 73 B Sigmoid AR N N 
6 M 89 A Sigmoid AR N N 
7 M 84 A Rectum AR Wound infection N 
8 F 49 B Lt colon Total colectomy N N 
9 F 85 B Rectum AR N N 
10 M 71 A Sigmoid AR Wound infection N 
11 M 60 C Rectum AR N N 
12 F 75 C Rectum AR N N 
13 M 86 D Rectum AR N Lung 
14 M 80 A Rectum AR N N 
15 F 68 C Rectum Total colectomy N N 
16 F 72 C Rectum APR N N 
17 M 66 B Sigmoid AR N N 
18 M 43 C Rectum APR Small bowel obstruction N 
19 M 64 C Sigmoid Lt hemicolectomy N N 
20 M 79 C Rectum Hartmanns N N 
21 M 70 C Rectum Lt hemicolectomy N N 
22 M 74 C Sigmoid AR N N 
23 F 53 D Sigmoid AR N Liver 
24 F 59 D Rectum AR N Liver 
25 M 62 A Sigmoid AR N N 
26 F 75 C Sigmoid Total colectomy N N 
27 F 78 C Caecum Rt hemicolectomy N N 
28 M 78 C Lt colon AR N N 
29 F 67 B Rectum APR N N 
30 F 71 B Rectum AR N N 
31 M 87 C Rt colon Rt hemicolectomy N N 
32 M 83 B Rt colon Rt hemicolectomy N N 
33 M 79 B Rectum AR N N 
34 F 83 A Sigmoid AR N N 
35 F 88 A Rectum AR AL N 
36 M 75 D Sigmoid AR N N 
37 M 81 C Rectum Colostomy  N N 
38 F 90 B Rectum APR N N 
39 F 54 C A colon Rt hemicolectomy N N 
40 F 81 C Rectum APR Pancreatitis N 
41 F 56 B Caecum Rt hemicolectomy N N 
42 M 78 B Rectum Total colectomy N N 
43 M 87 C Rt colon Rt hemicolectomy N N 
44 M 64 B Rectum Hartmanns Wound infection N 
45 F 68 C Rectum AR N N 
46 F 72 A Rectum AR N N 
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No. Sex Age Duke Site Operation Complications Met 
47 F 69 C Sigmoid Sigmoid colectomy N N 
48 F 71 C Caecum Total colectomy N Liver 
49 F 81 C Rectum Hartmanns N N 
50 F 60 C Lt colon Lt hemicolectomy N N 
51 F 85 C Rt colon Lt hemicolectomy N N 
52 M 83 C Caecum Rt hemicolectomy N N 
53 M 55 C Rectum AR N N 
54 M 60 B Rt colon Lt hemicolectomy N N 
55 F 77 A Sigmoid AR N N 
56 F 62 C Rectum APR N N 
57 M 64 C Rectum AR + LI N N 
58 M 76 C Sigmoid AR Colocutanous fistula  N 
59 M 74 A Rectum AR N N 
60 F 56 C Sigmoid   N N 
     LT colectomy and    
     liver resection   
61 F 74 A Rectum AR N N 
62 F 82 A Rectum AR N N 
63 F 71 B Sigmoid AR N N 
64 F 73 D Rectum AR N N 
65 F 51 C Rectum AR N N 
66 M 70 C Rectum AR N N 
67 M 82 D Rectum AR Fluid collection Liver 
68 F 84 B Sigmoid Sigmoid colectomy N N 
69 F 75 C Sigmoid AR AL  N 
70 F 63 A Sigmoid AR N N 
71 M 47 C T colon Subtotal colectomy N N 
72 M 57 A Rectum AR AL  N 
73 M 52 C Rectum AR N N 
74 F 64 C Rectum AR N N 
75 M 56 D Sigmoid Total colectomy N N 
76 M 61 B Caecum Total colectomy Stenosis  N 
77 M 72 D Rt colon Rt hemicolectomy N N 
78 M 79 B Caecum Rt hemicolectomy N N 
79 F 78 B Rt colon Rt hemicolectomy N N 
80 M 60 A Rectum AR N N 
81 M 76 B Rectum AR Pneumonia N 
82 M 82 C Rectum AR N N 
83 M 71 C T Colon 
Extended Rt 
hemicolectomy N N 
84 M 68 C Rectum AR N N 
85 M 70 B T colon AR N N 
86 F 69 A Rt colon Rt hemicolectomy N N 
87 F 73 B Rectum AR N N 
88 M 64 C Rectum AR N Liver 
89 F 66 A Rt colon Rt hemicolectomy N N 
90 F 53 C Rectum AR N N 
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91 M 79 C Rectum AR N N 
92 F 72 B Sigmoid AR N N 
93 F 69 C Sigmoid AR N N 
94 M 77 B Sigmoid AR N N 
95 M 85 C T colon Lt hemicolectomy N N 
96 F 78 B Rt colon Rt hemicolectomy N N 
97 F 73 A Lt colon 
Extended Rt  
hemicolectomy N N 
F: Female     M: Male 
Lt: Left        Rt: Right 
T: Transverse      A: Ascending  
AR: Anterior resection     LI: Loop ileostomy 
APR: Abdomino-perineal resection  AL: Anastomotic leak 
Met: Metastases  
 
